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A B S T R A C T
Background
Despite its proven efficacy in improving symptoms and reducing exacerbations, many patients with asthma are not fully adherent to
their steroid inhaler. Suboptimal adherence leads to poorer clinical outcomes and increased health service utilisation, and has been
identified as a contributing factor to a third of asthma deaths in the UK. Reasons for non-adherence vary, and a variety of interventions
have been proposed to help people improve treatment adherence.
Objectives
To assess the efficacy and safety of interventions intended to improve adherence to inhaled corticosteroids among people with asthma.
Search methods
We identified trials from the Cochrane Airways Trials Register, which contains studies identified through multiple electronic searches
and handsearches of other sources. We also searched trial registries and reference lists of primary studies. We conducted the most recent
searches on 18 November 2016.
Selection criteria
We included parallel and cluster randomised controlled trials of any duration conducted in any setting. We included studies reported
as full-text articles, those published as abstracts only and unpublished data. We included trials of adults and children with asthma and a
current prescription for an inhaled corticosteroid (ICS) (as monotherapy or in combination with a long-acting beta2-agonist (LABA)).
Eligible trials compared an intervention primarily aimed at improving adherence to ICS versus usual care or an alternative intervention.
Data collection and analysis
Two review authors screened the searches, extracted study characteristics and outcome data from included studies and assessed risk of
bias. Primary outcomes were adherence to ICS, exacerbations requiring at least oral corticosteroids and asthma control. We graded
results and presented evidence in ’Summary of findings’ tables for each comparison.
We analysed dichotomous data as odds ratios, and continuous data as mean differences or standardised mean differences, all using a
random-effects model. We described skewed data narratively. We made no a priori assumptions about how trials would be categorised
but conducted meta-analyses only if treatments, participants and the underlying clinical question were similar enough for pooling to
make sense.
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Main results
We included 39 parallel randomised controlled trials (RCTs) involving adults and children with asthma, 28 of which (n = 16,303)
contributed data to at least one meta-analysis. Follow-up ranged from two months to two years (median six months), and trials were
conducted mainly in high-income countries. Most studies reported some measure of adherence to ICS and a variety of other outcomes
such as quality of life and asthma control. Studies generally were at low or unclear risk of selection bias and at high risk of biases
associated with blinding. We considered around half the studies to be at high risk for attrition bias and selective outcome reporting.
We classified studies into four comparisons: adherence education versus control (20 studies); electronic trackers or reminders versus
control (11 studies); simplified drug regimens versus usual drug regimens (four studies); and school-based directly observed therapy
(three studies). Two studies are described separately.
All pooled results for adherence education, electronic trackers or reminders and simplified regimens showed better adherence than
controls. Analyses limited to studies using objective measures revealed that adherence education showed a benefit of 20 percentage
points over control (95% confidence interval (CI) 7.52 to 32.74; five studies; low-quality evidence); electronic trackers or reminders led
to better adherence of 19 percentage points (95% CI 14.47 to 25.26; six studies; moderate-quality evidence); and simplified regimens
led to better adherence of 4 percentage points (95% CI 1.88 to 6.16; three studies; moderate-quality evidence). Our confidence in the
evidence was reduced by risk of bias and inconsistency.
Improvements in adherence were not consistently translated into observable benefit for clinical outcomes in our pooled analyses. None
of the intervention types showed clear benefit for our primary clinical outcomes - exacerbations requiring an oral corticosteroid (OCS)
(evidence of very low to low quality) and asthma control (evidence of low to moderate quality); nor for our secondary outcomes -
unscheduled visits (evidence of very low to moderate quality) and quality of life (evidence of low to moderate quality). However, some
individual studies reported observed benefits for OCS and use of healthcare services. Most school or work absence data were skewed
and were difficult to interpret (evidence of low quality, when graded), and most studies did not specifically measure or report adverse
events.
Studies investigating the possible benefit of administering ICS at school did not measure adherence, exacerbations requiring OCS,
asthma control or adverse events. One study showed fewer unscheduled visits, and another found no differences; data could not be
combined.
Authors’ conclusions
Pooled results suggest that a variety of interventions can improve adherence. The clinical relevance of this improvement, highlighted by
uncertain and inconsistent impact on clinical outcomes such as quality of life and asthma control, is less clear. We have low to moderate
confidence in these findings owing to concerns about risk of bias and inconsistency. Future studies would benefit from predefining
an evidence-based ’cut-off ’ for acceptable adherence and using objective adherence measures and validated tools and questionnaires.
When possible, covert monitoring and some form of blinding or active control may help disentangle effects of the intervention from
effects of inclusion in an adherence trial.
P L A I N L A N G U A G E S U M M A R Y
Strategies to help people with asthma take their steroid inhaler as prescribed
Background to the question
Inhalers containing steroids improve asthma-related symptoms and reduce asthma attacks when taken regularly. But many people with
asthma do not take them as prescribed. This leads to more symptoms and flare-ups, which have been linked to a third of asthma deaths
in the UK.
Missing doses is sometimes called ’non-adherence’. Reasons for missing doses vary from person to person. For example, people often
forget to take their inhaler or have a busy and unpredictable lifestyle that makes it difficult to fit this in. Some people do not appreciate
the need for taking inhalers as prescribed. Some people choose to reduce or discontinue taking steroids. This can happen for many
reasons, including side effects, fear of side effects or a perception that benefits do not outweigh disadvantages.
The aim of this review was to find out whether strategies to help people with asthma take their steroid inhaler really work, and whether
improved adherence leads to other benefits.
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Study characteristics
We found 39 studies including more than 16,000 adults and children with asthma who were taking a steroid inhaler. Most studies
collected data at six months, so we can really apply the messages in this review only over six months - we cannot say whether these
methods are effective in a few years time, for example. We searched multiple sources for relevant studies. This review is current as of
November 2016.
Different studies tried different ways to help people take their inhaler more regularly. We grouped studies according to four ways of
helping people take their inhaler: providing education about adherence (20 studies); using electronic monitoring or reminders to take
the inhaler (11 studies); making the drug easier to take (e.g. once instead of twice a day, one inhaler instead of two) (four studies); and
giving the inhaler during school hours (three studies).
We mainly looked for whether strategies helped people to take their inhaler as prescribed, and whether people had fewer asthma attacks
and better asthma control.
Key results
People who were given education were better at taking their inhaler than controls; 20% more people took their treatment (likely to
be somewhere between 8% and 33% more). Those given trackers or electronic reminders were 19% better at using their inhaler than
controls (14% and 25%). People who were given an easier way of taking their inhaler (e.g. fewer times a day) were only 4% better than
those who carried on as usual (2% and 6%).
Unfortunately, these efforts to help people take their inhaler as prescribed generally did not lead to obvious benefit for things like
asthma control and number of attacks, but in most cases, we could not tell either way. We also did not see a difference for quality of
life or time people needed off school or work, but the evidence was often uncertain.
Studies investigating the possible benefit of giving children their inhaler during school hours did not actually measure how often they
missed doses.
Quality of the evidence
It’s difficult to tell whether these different strategies are worth using because studies were quite different from one other. This variation
means that we cannot be sure what the real benefit is, beyond improving adherence. Sometimes we did not find enough studies to detect
a difference between groups. The fact that most people knew which group they were in also reduced our confidence in the findings
because this can affect things like how positively people respond to questionnaires. We had concerns about how many people dropped
out of about half the studies, and we are uncertain whether studies reported everything they measured.
Key message
The studies we found suggest that various strategies can help people with asthma take their inhaler better, compared with “control”
(e.g. usual asthma care). However, many of these studies were quite different from one another, and we are not certain about whether
people will find that their asthma is improved as a result of this approach.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Adherence education compared with controls for asthma
Patient or population: asthma
Setting: community
Intervention: adherence educat ion
Comparison: control group (no educat ion)
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of partici-
pants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Risk with controls Risk with adherence
education
% Adherence
WMD of follow-up
71.7 weeks (all stud-
ies)
Objective measures Mean adherence in
the control group
was 46.7%
Mean adherence
with adherence edu-
cat ion was 20.13%
higher (7.52 higher
to 32.74 higher)
- 280
(5 RCTs)
⊕⊕©©
LOWa,b,c
Only studies in
which adherence
was measured with
an electronic moni-
tor
All measures Mean adherence in
the control group
was 57.1%
Mean adherence
with adherence edu-
cat ion was 11.59%
higher (3.72 higher
to 19.46 higher)
- 1693
(10 RCTs)
⊕⊕©©
LOWa,b,c
Exacerbations requiring OCS
(people with 1 or more)
WMD of follow-up 30.8 weeks
149 per 1000 242 per 1000
(148 to 370)
OR 1.82
(0.99 to 3.36)
349
(3 RCTs)
⊕⊕©©
LOWa,d
Asthma control (ACQ)
WMD of follow-up 28.5 weeks
Mean ACQ score
was 1.52
Mean score with ad-
herence educat ion
was 0.03 better (0.
49 better to 0.43
worse)
- 455
(4 RCTs)
⊕⊕⊕©
M ODERATEa,e
Lower score indi-
cates better control.
Scale 0 to 6. MCID
0.5
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Asthma control (ACT)
WMD of follow-up 29.5 weeks
Mean ACT score
was 18.88
Mean score with ad-
herence educat ion
was 0.30 better
(1.43 better to 0.82
worse)
- 333
(3 RCTs)
⊕⊕⊕©
M ODERATEa,e
Higher score indi-
cates better control.
Scale 5 to 25. MCID
3
Unsheduled visits to a healthcare provider
(people with 1 or more)
WMD of follow-up 67.2 weeks
159 per 1000 83 per 1000
(35 to 184)
OR 0.48
(0.19 to 1.19)
688
(4 RCTs)
⊕©©©
VERY LOWa,b,d,f
Includes visits to ED,
GP, hospital for any
cause
Absenteeism
WMD of follow-up 63.3 weeks
We did not perform an analysis of ab-
sences because the data were heavily
skewed
- 109
(2 RCTs)
Not graded
Quality of life (AQLQ)
WMD of follow-up 27.4 weeks
Mean AQLQ score
was 5
Mean score with ad-
herence educat ion
was 0.01 better (0.
20 worse to 0.23 bet-
ter)
- 734
(6 RCTs)
⊕⊕⊕©
M ODERATEa,e
Higher score indi-
cates better QOL.
Scale 1 to 7. MCID
0.5
* The risk in the intervention group (and its 95% conf idence interval) is based on assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%
CI)
ACQ: Asthma Control Quest ionnaire; ACT: Asthma Control Test; AQLQ: Asthma Quality of Life Quest ionnaire; CI: conf idence interval; ED: emergency department; GP: general
pract it ioner; MCID: minimal clinically important dif f erence; OCS: oral cort icosteroid; OR: odds rat io; QOL: quality of lif e; RCT: randomised controlled trial; WMD: weighted mean
durat ion
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to the est imate of ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of ef fect but may be substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded once primarily owing to risk of bias f rom open-label trials and some concerns regarding attrit ion bias, select ive
report ing and select ion bias (-1 risk of bias)
bDowngraded once owing to inconsistency between study results (-1 inconsistency)
cFunnel plot examined; no clear evidence of publicat ion bias (no downgrade for publicat ion bias)
dConf idence intervals include no dif ference and/ or potent ial important harm or benef it of the intervent ion (-1 imprecision)5
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eConf idence intervals fall within the established MCID for this scale (no downgrade for imprecision)
f Studies contribut ing to this analysis reported dif ferent types of unscheduled visits and some recorded visits for any cause
rather than asthma alone (-1 indirectness)
gUnclear how absenteeism was def ined or reported, and dif ferent part icipants may have dif ferent thresholds for m issing work
or school. One study was conducted in children and the other in adults. Combined, this makes the outcome hard to interpret
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Asthma is a chronic breathing condition that affectsmore than 300
million adults and children worldwide (Global Asthma Report
2014). Asthma can cause shortness of breath, chest tightness and
cough and typically presents with wheezing. Many people with
asthma experience intermittent worsening of their asthma symp-
toms, known as ’exacerbations’, ’flare-ups’ or ’attacks’ (GINA
2016). Approximately 20% of people with asthma have at some
point been admitted to hospital or attended an emergency de-
partment for asthma treatment (Rodrigo 2004). Attacks can be
triggered by common irritants and allergens such as pollution, to-
bacco smoke, pollen and house dust mites (CDC 2016). Asthma
is under-diagnosed and under-treated worldwide. Most asthma-
related deaths occur in middle-income and low-income countries.
Poorly controlled asthma places a huge burden on individuals,
their families and society (WHO 2013).
The mainstay of asthma treatment for all but the mildest cases
consists of inhaled corticosteroids (ICSs) (Barnes 1993), which
are also known as ’preventer’ or ’controller’ medications (i.e. the
intention is that they are used once or twice daily (depending on
the preparation), even when well, to maintain control over symp-
toms). Inhaled corticosteroids, which are delivered directly to a
patient’s airways via an inhaler or a nebuliser, work by suppress-
ing the multiple inflammatory cascades that are activated in the
airways of a person with asthma. Inflammation leads to increased
mucus production and airway constriction, which in turn con-
tribute to symptoms of asthma. Reduction in underlying inflam-
mation through sustained use of an ICS can result in symptom
improvement and reduced asthma-related morbidity and mortal-
ity (Barnes 2003; Bårnes 2015).
Inhaled corticosteroids commonly used today include budesonide,
beclomethasone, fluticasone (propionate and furoate), mometa-
sone and ciclesonide. They can be given alone or in combination
with other preventer medications such as long-acting beta2-ago-
nists (LABAs) or leukotriene receptor antagonists (LTRAs) (BNF).
Description of the intervention
Despite its proven efficacy, many patients are not fully adherent to
their prescribed ICS (Bårnes 2015). Adherence is described by the
World Health Organization (WHO) as “the degree to which use
of medication by the patient corresponds with the prescribed reg-
imen”; WHO emphasises the “diversity and complexity of adher-
ence behaviour”. In addition, patients with asthma may be fully
adherent to preventer medication when symptomatic but poorly
adherent when well (WHO Report 2003). This may reflect the
fact that, unlike rescue medication, which gives immediate relief
of symptoms (i.e. a ’reliever’ or ’rescue’ inhaler containing a short-
acting beta2-agonist (SABA) such as salbutamol), an ICS given for
airway inflammation may take several weeks to provide maximal
benefit.
Reasons for non-adherence to asthma therapies, including ICSs,
vary among individuals. Commonly cited reasons include com-
plexity of the treatment regimen; cost; administration route; and
patient beliefs about therapy, including safety, necessity and risk of
dependence. Lower socioeconomic status, inclusion in a minority
ethnic group and fewer years of education have also been associ-
ated with reduced adherence (Bårnes 2015; Bender 2005; Clark
1999; Cochrane 1999).
Understanding the underlying reasons for non-adherence is essen-
tial for tackling the problem. The WHOReport 2003 has subcat-
egorised these reasons as follows.
• ’Erratic non-adherence’ - perhaps most common and largely
the result of forgetfulness or a busy, unpredictable lifestyle.
• ’Unwitting non-adherence’ - usually the result of failure to
appreciate the specifics of regimens or the need for adherence.
• ’Intelligent non-adherence’ - the result of a purposeful
choice to reduce or discontinue ICS use for many reasons,
including side effects, fear of side effects or a perception that the
benefits do not outweigh the disadvantages.
Similarly, Horne 2002, which reported a cross-sectional survey
of people with asthma who completed validated questionnaires,
identified that adherence was primarily associated with doubts
about the necessity for the medication and concerns about the
side effects of treatment. This study reported that a more negative
perception of the consequences of illness is associated with poorer
adherence to preventer medication. A possible explanation for this
unexpected finding is that those who are already poorly adherent
may be more likely to experience poorer asthma control and thus
may rate the consequences of illness more negatively.
Interventions to improve adherence to ICS may take many forms,
including audiovisual reminders (Charles 2007), electronic moni-
toring of dosing with clinician feedback (Onyirimba 2003), inter-
active voice response system via mobile phone (Mulvaney 2013),
text message reminders (Johnson 2015) and more comprehensive
patient or parent education (Bender 2002).
How the intervention might work
How the intervention works will be directly related to the type of
non-adherence targeted and the type of intervention offered. The
simplest interventions proposed to tackle ’erratic non-adherence’
mightwork by providing a very basic prompt to patients to remem-
ber to use their inhaler. Multi-faceted interventions that involve
tackling ’unwitting’ or ’intelligent’ non-adherencemight comprise
patient education and partnership building between healthcare
professionals and patients and are likely to work through more
complex psychological and behavioural pathways.
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A recently updated Cochrane Review assessing the evidence for
interventions to improve adherence across the whole spectrum of
health care identified 109 randomised controlled trials (RCTs) for
inclusion. Review authors concluded that a small number of tri-
als, which implemented complex interventions, demonstrated im-
provement in adherence and clinical outcomes, suggesting that the
more rudimentary interventions generally have little impact. This
may reflect the likelihood that any individual under treatment for
asthma will likely have a combination of reasons for non-adher-
ence, possibly both intentional and unintentional (Horne 2002).
However, the highly complex nature of the interventions imple-
mented in these ’successful’ trials casts doubts on their feasibility
in a real-life setting (Nieuwlaat 2014).
Medication adherence is recognised to deteriorate often during
adolescence (Dinwiddie 2002). Patients in this age group might
be particularly receptive to newer technologies for assisting with
adherence, for example, Internet-based care and text message re-
minders. However, the authors of Nieuwlaat 2014 concluded that
evidence is currently insufficient to show with certainty whether
these newer methods of improving adherence are effective.
Lower levels of adherence in minority communities and among
those from lower socioeconomic groups suggest that even when
access to health care and prescription coverage is equal (Krishnan
2001), cultural tailoring of interventions may be required for suc-
cessful treatment.
Why it is important to do this review
Suboptimal adherence leads to poorer clinical outcomes and in-
creased health service utilisation. Although difficult to quantify,
studies report that up to, and possibly in excess of, 50% of
participants are non-adherent to their prescribed ICS (Bårnes
2015; Bender 2004;Mahkinova 2015;Murphy 2012; Rand 1994;
Williams 2003). Failure to take appropriate medication was found
to be a potentially avoidable factor contributing to approximately
one-third of asthma deaths in the UK over the course of a year
(NRAD 2014). Mahkinova 2015 demonstrated that patients who
are adherent to their preventer medication make fewer claims for
oral corticosteroid prescriptions, reflecting a lower rate of exacerba-
tion. Williams 2003 identified an association between hospitalisa-
tions and emergency department visits and non-adherence to ICS.
Murphy 2012 found that non-adherence was an independent pre-
dictor of the need for ventilation therapy in acute severe asthma, as
well as lower forced expiratory volume in one second (FEV1) and
higher sputum eosinophils, both of which are markers of poorly
controlled asthma. A 2015 review of ICS adherence in asthma
found that 24% of exacerbations and 60% of asthma-related hos-
pitalisations could be attributed to poor adherence (Bårnes 2015).
In addition, it is well recognised that uncontrolled asthma places
a greater financial burden on an economy than is incurred by con-
trolled asthma (Barnes 1996; Global Asthma Report 2014).
Evidence shows thatmany people with asthma benefit greatly from
regular use of an ICS. However, ways that healthcare professionals
can best assist patients in maintaining adherence remain unclear.
We are conducting this review to explore this topic.
O B J E C T I V E S
To assess the efficacy and safety of interventions intended to im-
prove adherence to inhaled corticosteroids among people with
asthma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel and cluster RCTs of any duration conducted
in any setting. If we identified cross-over trials, we included only
data from the first part of the study because of the potential for
carry-over effects of the intervention.
We included studies reported as full-text articles, those published
as abstracts only and unpublished data.
Types of participants
We included adults and children of any age with a diagnosis of
asthma, according to international or national guidelines or as di-
agnosed by a healthcare professional, and currently prescribed an
ICS alone or in combination with a LABA. We excluded partic-
ipants with other respiratory comorbidities such as chronic ob-
structive pulmonary disease (COPD) or bronchiectasis. If we iden-
tified trials in which only a subset of participants had received a
diagnosis of asthma, we included these participants if we could ob-
tain disaggregated data. If we identified trials targeting improved
adherence to asthma therapies generally, and at least 80% of par-
ticipants were using an ICS at baseline, we included these trials in
the review. We also included trials in which the intervention was
targeted at a healthcare professional (the trial “participant”), who
in turn would deliver the adherence intervention to patients with
asthma.
Types of interventions
We included trials that compared an intervention primarily aimed
at improving adherence to ICS (± LABA) versus:
• usual care/no additional intervention;
• an alternative intervention that does not primarily aim to
increase adherence; or
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• an alternative intervention of a different type or intensity,
also aimed at improving adherence.
Interventions may range from simple automated reminders to
more complex behavioural, psychological and motivational inter-
ventions. Interventions may be delivered to the participant or to
the parent/career by any healthcare professional or trained peer.
Interventions may also be delivered to a healthcare professional.
We allowed other co-interventions in the management of asthma
provided they were provided in the same way for intervention
and comparison groups, for example, a personalised asthma action
plan (PAAP) + adherence prompt versus PAAP alone.
Types of outcome measures
Primary outcomes
• Adherence to ICS (as reported by trialists; e.g. self-report
via diary or questionnaire, electronic monitoring, prescription
monitoring/pharmacy claims data).
• Exacerbations requiring at least oral corticosteroids.
• Asthma control (ideally measured on a validated scale such
as the Asthma Control Test (ACT)).
Secondary outcomes
• Unscheduled visits to a healthcare provider.
• Absenteeism from work/school.
• Quality of life (ideally measured on a validated scale such as
the Asthma Quality of Life Questionnaire (AQLQ)).
• All adverse events*.
We chose adherence as a primary outcome, as studies will be aim-
ing to improve this outcome. However, we believe it is important
to assess whether improvement in adherence translates into im-
proved clinical outcomes; thus, we have included exacerbations
and asthma control as primary outcomes in the belief that these are
important to patients. Outcomes of adverse events, absenteeism
and quality of life are also important to patients. Unscheduled
visits to a healthcare provider are important to patients as well and
serve as a marker of usage of healthcare services.
If outcomes were reported at multiple time points, we extracted
and included the latest reported time point. If studies reported
post-intervention follow-up, we extracted this information and
presented it narratively.
Reporting one or more of the outcomes listed here was not a
criterion for inclusion of trials in this review.
*If we identified serious adverse events reported as ’asthma’, we
described these narratively, as they are likely to represent a severe
exacerbation requiring at least hospitalisation.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
The Cochrane Airways Trials Register contains studies identified
from several sources.
• Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (crso.cochrane.org/).
• Weekly searches of MEDLINE Ovid SP 1946 to date.
• Weekly searches of Embase Ovid SP 1974 to date.
• Monthly searches of PsycINFO Ovid SP.
• Monthly searches of the Cumulative Index to Nursing and
Allied Health Literature (CINAHL) EBSCO.
• Monthly searches of the Allied and Complementary
Medicine Database (AMED) EBSCO.
• Handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference pro-
ceedings, are provided in Appendix 1. See Appendix 2 for search
terms used to identify studies for this review. We conducted the
primary search on 20 May 2016, and updated the search on 18
November 2016.
We conducted additional searches of the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL) (all years to 18 Novem-
ber 2016) and MEDLINE Ovid (1946 to 18 November 2016)
to identify adherence trials targeting mixed populations including
people with asthma (Appendix 2).
We searched the following trials registries on 20 May 2016 and
18 November 2016.
1. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov).
2. World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch/).
We did not apply any restrictions on the language of publication.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. We searched relevant manufac-
turer websites for trial information.
We searched on 23 November 2016 for errata or retractions
from included studies published in full text on PubMed (
www.ncbi.nlm.nih.gov/pubmed).
Data collection and analysis
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Selection of studies
We used the Rayyan Web app (Elmagarmid 2014) to indepen-
dently screen titles and abstracts of all studies identified by the
search for possible inclusion, and we coded each study as ’include’
(eligible or potentially eligible/unclear) or ’exclude’. KK screened
all titles and abstracts, and RN and ES each screened one-half. We
retrieved full-text study reports/publications, and two review au-
thors (RN and KK) independently screened them to identify stud-
ies for inclusion, and to identify and record reasons for exclusion
of ineligible studies. We resolved disagreements through discus-
sion, or, if required, we consulted the third review author (ES).We
identified and excluded duplicates and collatedmultiple reports of
the same study, so that each study rather than each report was the
unit of interest in the review. We recorded the selection process
in sufficient detail to complete a PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) flow diagram
and Characteristics of excluded studies table (Moher 2009).
Data extraction and management
We planned to use Covidence 2015 to extract study characteristics
andoutcomedata, butwe found it too time consuming and instead
used an Excel data extraction form that we each piloted on at
least one study. We planned that one review author (RN) would
extract the following study characteristics from included studies,
but instead we shared the studies equally between all three review
authors (RN, ES and KK).
• Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
setting, withdrawals and date of study.
• Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
• Interventions: intervention, comparison, concomitant
medications and excluded medications.
• Outcomes: primary and secondary outcomes specified and
collected and time points reported.
• Notes: funding for trial and notable conflicts of interest of
trial authors.
Each review author extracted outcome data independently from
two-thirds of the studies so that data from each study were ex-
tracted twice. We noted in the Characteristics of included studies
table if outcome data were not reported in a useable way. We
resolved disagreements by reaching consensus or by involving a
third review author (RN, KK or ES). One review author (RN)
transferred data to the Review Manager (RevMan 2014) file. We
double-checked that data had been entered correctly by compar-
ing data presented in the systematic review against study reports.
A second review author (KK or ES) spot-checked study character-
istics for accuracy against the trial report.
Assessment of risk of bias in included studies
As for numerical data extraction, each review author indepen-
dently assessed risk of bias for two-thirds of the included studies,
so that each study was assessed twice.We used the criteria outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We resolved disagreements by discussion or by
consultation with the third review author who had not already
assessed the study (RN, KK or ES). We assessed risk of bias ac-
cording to the following domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
We graded each potential source of bias as high, low or unclear and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We summarised
risk of bias judgements across different studies for each of the
domains listed. We considered blinding separately for different
key outcomes when necessary (e.g. for an unblinded outcome
assessment, risk of bias for all-causemortalitymay be very different
than for a patient-reported pain scale). When information on risk
of bias relates to unpublisheddata or correspondencewith a trialist,
we noted this in the ’Risk of bias’ table.
When considering a treatment effect, we took into account the
risk of bias for studies that contributed to that outcome.
Assesment of bias in conducting the systematic
review
We conducted the review according to this published protocol and
reported deviations from it in the Differences between protocol
and review section of the systematic review.
Measures of treatment effect
We analysed dichotomous data usingMantel-Haenzsel odds ratios
(ORs) with a random-effects model and 95% confidence intervals
(CIs). When rare events were reported, we used Peto ORs. When
data were reported as rates or times-to-events (e.g. exacerbations),
we analysed them as time-to-event or rate ratios. We transformed
reported rate ratios into log-rate ratios and analysed them using
a random-effects model and generic inverse variance (GIV) in
Review Manager 5 (RevMan 2014). We entered data presented as
a scale with a consistent direction of effect.
We analysed continuous outcomes (e.g. ACT, AQLQ) as mean
differences (MDs) or as standardised mean differences (SMDs)
using a random-effects model and 95%CIs.We used change from
baseline scores when available.
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Weundertookmeta-analyses only when this wasmeaningful (i.e. if
treatments, participants and the underlying clinical question were
similar enough for pooling to make sense).
We narratively described skewed data reported as medians and
interquartile ranges.
When multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms. If two comparisons (e.g. interven-
tion A vs usual care, intervention B vs usual care) were combined
in the same meta-analysis, we halved the control group to avoid
double-counting.
If both change from baseline and endpoint scores were available
for continuous data, we used change from baseline unless most
studies reported endpoint scores. Similarly, we preferred adjusted
data examined by analysis of variance (ANOVA) to account for
baseline differences when available.
When both per-protocol/completer and intention-to-treat (ITT)
analyses were provided in a single report, we used the latter.
Unit of analysis issues
We analysed dichotomous data using participants (rather than
events) as the unit of analysis. However, if exacerbations were re-
ported as rate ratios, we analysed them on this basis. We meta-
analysed data from cluster RCTs only if available data had been,
or could be, adjusted to account for clustering. We adjusted data
from Foster 2014 for meta-analysis using an intracluster correla-
tion coefficient (ICC) of 0.037 (based on the ACT score, kindly
supplied by the study author team). However, this adjustment had
very little impact on the meta-analyses, and so we have used the
raw unadjusted data.
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and to request missing numerical outcome data
when possible (e.g. when a study is identified as abstract only).
When this was not possible, and missing data were thought to
introduce serious bias, we considered this in the GRADE rating
for the affected outcome.
Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the tri-
als in each analysis. If we identified substantial heterogeneity, we
reported this and explored possible causes through prespecified
subgroup analyses.
Assessment of reporting biases
When we were able to pool more than 10 studies, we created
and examined a funnel plot to explore possible small study and
publication biases.
Data synthesis
We used a random-effects model and performed a sensitivity anal-
ysis using a fixed-effect model.
’Summary of findings’ table
We created four ’Summary of findings’ tables, one for each of the
comparisons, using the following outcomes: adherence to ICS; ex-
acerbations requiring at least an oral corticosteroid (OCS); asthma
control; quality of life; unscheduled visits to a healthcare provider;
absenteeism from work/school; and adverse events. We used the
five GRADE (Grades of Recommendation, Assessment, Develop-
ment and Evaluation Working Group) considerations (study lim-
itations, consistency of effect, imprecision, indirectness and pub-
lication bias) to assess the quality of a body of evidence as it relates
to studies that contributed data to the prespecified outcomes. We
used methods and recommendations described in Section 8.5 and
Chapter 12 of the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011) andGRADEpro software (GRADEpro
GDT). We justified all decisions to downgrade or upgrade the
quality of studies by using footnotes, and we made comments to
aid readers’ understanding of the review when necessary.
Subgroup analysis and investigation of heterogeneity
We planned the following subgroup analyses.
• Type of intervention: interventions meeting the definition
of a complex intervention* versus simpler interventions.
• Age of participants: adults versus adolescents versus
children.
• To whom the intervention is delivered: participant/parent/
career versus healthcare professional.
We constructed an additional table to present other potential fac-
tors across studies that may alter the treatment effect (e.g. type,
delivery, dose and schedule of ICS; whether treatment was given in
a combination inhaler with a LABA; baseline severity of asthma).
We used the following outcomes in subgroup analyses.
• Adherence to ICS.
• Exacerbations requiring at least an OCS.
• Asthma control.
We used the formal test for subgroup interactions provided in
RevMan 2014.
*Complex interventions are conventionally described as those in-
cluding ’several interacting components’ (Campbell 2000). From
a public health point of view, complex interventions, which are
likely to involve a substantial educational element, and popula-
tion-based interventions, which may include cluster RCTs, are
thought to have greater overall impact on patient behaviour. Sim-
pler interventions, such as cue reminders, will not address themore
complex issues of adherence, and effects may be less likely to per-
sist beyond removal of the intervention. Thus, we considered this
an important subgroup analysis for inclusion.
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Sensitivity analysis
We planned the following sensitivity analyses.
• Excluding unpublished data.
• Excluding trials considered at high risk of selection bias.
• Excluding trials in which not all participants were
prescribed ICS at baseline.
• Excluding trials in which adherence was measured via non-
objective methods (e.g. diary, self-report). In a post hoc change
to our analysis plan, we have presented studies using objective
measures (i.e. electronic inhaler monitors) as the primary analysis
for % adherence, as we deemed this to be a more useful analysis.
An analysis including studies using all measures then follows.
R E S U L T S
Description of studies
Results of the search
Through database searches, we retrieved 2707 references. Our
searches of other resources, including trials registries, revealed 127
additional records. Once duplicates had been removed, we had a
total of 1725 records left to screen. We excluded 1575 records on
the basis of titles and abstracts. We obtained the full text of the
remaining 150 records. We excluded 45 studies (51 references),
added five studies to Studies awaiting classification and listed 13
studies as ongoing (15 records). We included 39 studies (79 refer-
ences). For further details of our screening process, see the study
flow diagram (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Thirty-nine studies met our inclusion criteria, and 28 of these
contributed data to at least one meta-analysis. These studies in-
cluded a total of 16,303 participants who were randomly assigned
to comparisons of interest in this review. The largest study was a
pragmatic trial that included 9603 pre-existing users of ICS, and
the smallest included 12. Themedian total number of participants
was 102. Investigators reported three trials as conference abstracts
only (Black 2008; Hart 2002; NCT02451709), one on the clin-
icaltrials.gov website (NCT02413528) and one as a pharmaceu-
tical company report (ADERE PEDIATRIC 1). The remainder
were full-text peer-reviewed journal articles. We present a sum-
mary of the characteristics of included studies in Table 1.
Methods
As per our protocol, all included trials were RCTs with parallel
design that compared an intervention to improve adherence to in-
haled corticosteroids versus usual care or an alternative interven-
tion not specifically designed to improve adherence, or of a lower
intensity. Two studies used a cluster randomised design (Foster
2014; NCT00459368); the remainder were randomised at an in-
dividual participant level. One study included four relevant arms
(personalised adherence discussion (PAD); inhaler reminders and
feedback (IRF); PAD + IRF; and usual care; Foster 2014). Two
studies included three relevant arms: NCT00233181 randomised
participants to adherence monitoring and education, education
or usual care; and NCT00166582 randomised participants to a
team work intervention, an asthma education intervention (not
deemed relevant to this review) or usual care. The remainder were
two-arm parallel-group trials.
Intevention length varied, and follow-up continued from two
months to two years. The median duration of follow-up
was 24 weeks. Several studies reported a previous run-in pe-
riod during which participants were stabilised on an asthma
treatment regimen. Outcome data were extracted at the last
time point reported to assess enduring effects of the interven-
tion. Trials were conducted in a variety of mainly high-in-
come countries worldwide. Most were carried out in the USA
(Bender 2010; Gerald 2009; Halterman 2004; Kamps 2008;
Mann 1992; NCT00115323; NCT00149487; NCT00166582;
NCT00233181; NCT00414817; NCT00459368;
NCT00958932; NCT01169883;
NCT01175434; NCT01714141; NCT02413528; Onyirimba
2003), the UK (Bosley 1994; Hart 2002; Koufopoulos 2016;
NCT01064869; NCT02451709; Price 2010), New Zealand
(ACTRN12606000508572; Black 2008; Chan 2015; Charles
2007) and Australia (ACTRN12607000489493; Burgess 2007;
Foster 2014). The remainder were carried out in Brazil (ADERE
PEDIATRIC 1;Chatkin 2006),Norway (Gallefoss 1999), Sweden
(NCT00516633), TheNetherlands (Vasbinder 2015 E-MATIC),
Canada (NCT01132430), Belgium (Mehuys 2008), Denmark
(Strandbygaard 2010) and Denmark and Switzerland (Ulrik
2009).
Participants
We included studies involving both children and adults. Eighteen
studies included only children, 20 studies included adults and/or
adolescents only and one study recruited both adults and children.
Most studies did not specify the ethnicity of participants.
All studies included participants with a diagnosis of asthma. Al-
most all studies required participants to be using ICS at baseline,
although in two studies (Strandbygaard 2010; Ulrik 2009), some
participants were commenced on ICS during the run-in period.
Asthma severity at baseline was inconsistently reported, so it is not
possible to characterise the population in this review as a whole.
When available, we extracted information about baseline severity
and reported this in the Characteristics of included studies tables.
Interventions
Studies included a variety of comparisons, which we classified into
four broad groups. Some studies appear in more than one com-
parison, as they included three or more arms. Most studies did not
specify which additional medications were allowed or disallowed,
so we assume that most participants continued their usual asthma
medication regimen.We have outlined below the four broad com-
parisons.
Adherence education versus control (Table 1)
We included the following studies in this group: Bender 2010;
Chatkin 2006; Foster 2014; NCT00115323; NCT00149487;
NCT00166582; NCT00958932 (PAD and PAD + IRF groups vs
IRF and control groups); ADERE PEDIATRIC 1;Gallefoss 1999;
Hart 2002; Kamps 2008; Mehuys 2008; NCT00233181 (adher-
ence monitoring and education vs control and education alone
vs control); NCT00516633; NCT01064869; NCT01132430;
NCT01169883;Onyirimba 2003 (adherence education andusual
care arms); and Ulrik 2009; and NCT00414817. As per our pro-
tocol, we further classified these studies into those delivering a
complex intervention versus those not delivering a complex inter-
vention. We performed subgroup analysis when possible accord-
ing to this classification.
Included studies tested a wide range of educational interventions,
including one-to-one and group face-to-face adherence education
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sessions; motivational interviewing; family-based problem-solv-
ing interventions; team work interventions; nurse-led psychoed-
ucation; telephone interventions; and interactive voice recogni-
tion systems. Full details can be found under Characteristics of
included studies and are summarised in Table 1.
We classified most of the education interventions as complex
(i.e. they involved multiple interacting components and were tai-
lored to the individual). However, we classified as non-complex
three studies using voice recognition software to deliver adher-
ence education and reminders (Bender 2010; NCT00414817;
NCT00958932). Participants in Chatkin 2006 received a maxi-
mum 10-minute phone call from a trained nursing student to pro-
mote adherence; we judged this intervention to be non-complex,
although we lacked detail about the contents of the call. Another
study, which deviated from protocol and for which we do not
have results, stated that participants received telephone ’medical
guidance’; we classified this intervention as non-complex (ADERE
PEDIATRIC 1).
Electronic trackers or reminders versus control (Table 2)
Studies that used electronic adherence trackers plus feedback
to participants included ACTRN12607000489493; Foster
2014 (IRF and IRF + PAD groups vs PAD and control
groups); NCT00233181 (adherence education and monitor-
ing vs education alone); NCT01714141; NCT02451709; and
NCT00459368.
Studies that used electronic reminders alone, without an adherence
feedback discussion, included Black 2008; Chan 2015; Charles
2007; Strandbygaard 2010; and Vasbinder 2015 E-MATIC.
We classified studies in this group as non-complex if they tested
automated reminders such as text messages or an inhaler device
with an audible or visual alarm system. However, if participants
received tailored feedback from a healthcare professional based on
adherence data acquired through electronic monitoring, we clas-
sified this intervention as complex (ACTRN12607000489493;
Foster 2014; NCT00233181; NCT00459368; NCT02451709).
Full details can be found under Characteristics of included studies
and are summarised in Table 2.
Simplified drug regimen versus usual drug regimen (Table 3)
Studies that aimed to improve adherence by randomising
participants to a simplified therapeutic regimen included
ACTRN12606000508572; Bosley 1994; Mann 1992; and Price
2010. We classified all four studies as providing a non-complex
intervention.Full details can be found under Characteristics of
included studies and are summarised in Table 3.
School-based directly observed therapy (Table 4)
Gerald 2009, Halterman 2004 and NCT01175434 randomised
children to receive their ICS at school or usual care. Gerald 2009
and Halterman 2004 were classified as non-complex, as the inter-
vention was largely limited to providing school-based ICS ther-
apy. NCT01175434 was classified as complex, as participants also
underwent web-based screening to assess children’s asthma, which
generated a report that was sent to their primary care provider
and was used to adjust the medication regimen. Full details can
be found under Characteristics of included studies and are sum-
marised in Table 4.
Finally, we were unable to classify several studies according to
the above categories. Burgess 2007 used an “incentive” inhaler
device (the “Funhaler”) to encourage children to adhere to their
inhaled medication. Koufopoulos 2016 trialled use on an online
community of people with asthma (“AsthmaVillage”) to improve
adherence.
We have provided additional details of these studies under
Characteristics of included studies.
Outcomes
Outcomes reported were not consistent across reviews, and inves-
tigators did not always use validated scales. Almost all included
studies reported some measure of adherence, usually as a per-
centage, with 100% showing complete adherence, but the way in
which this was captured and calculated varied between studies.
When possible, we extracted and presented this information in
Characteristics of included studies and Table 1. The three stud-
ies in which the intervention consisted of supervised ICS therapy
at school did not report adherence as an outcome (Gerald 2009;
Halterman 2004; NCT01175434).
Many included studies used an objective measure of adher-
ence; this was often an electronic inhaler monitoring de-
vice. Named devices used included the “SmartInhaler” (
ACTRN12606000508572; Burgess 2007; Charles 2007;
NCT02451709); the “SmartTrack” device (Chan 2015; Foster
2014); the “MDILog or MDILog-II (Bender 2010; Kamps 2008;
NCT00149487; NCT00166582); the ”Doser Clinical Trials“
(Doser-CT) device (Bender 2010; NCT01169883); the ”E-haler/
Adhaler“ (Vasbinder 2015 E-MATIC); the ”Tubuhaler Inhalation
Computer (TIC)“ (Bosley 1994); the ”Diskus Adherence Moni-
tor“ (Bender 2010); the ”MDI Chorololog“ (Onyirimba 2003);
and the ”Nebuliser Chronolog“ (Mann 1992). Hart 2002 and
NCT00115323 report using dose-counting devices but do not
name the specific product used. ADERE PEDIATRIC 1, Chatkin
2006, Price 2010, Strandbygaard 2010 and Ulrik 2009 report
counting the doses actuated/remaining on the returned inhaler
but do not describe use of a monitoring device.
With the exception of the MDILog-II, these devices record the
time and date of inhaler actuation, and most disregard multiple
actuations in a short space of time (”dose-dumping“). The MDI-
Log-II also includes a measure of whether the drug was inhaled via
a ”temperature sensitive thermistor“. Data can be uploaded onto a
computer (for review and discussion in some studies) but in most
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cases were not visible to the participant day-to-day. In Vasbinder
2015 E-MATIC, the device sent data back to the study database
via the mobile phone network, which allowed real-time tailoring
of adherence reminder text messages for participants. Some of
the devices described above (e.g. the SmartInhaler) are capable of
producing audiovisual inhaler reminders; studies investigating this
as an intervention disabled this function in control groups (see
comparison 2).
Remaining studies used canister weight (Bender 2010;
NCT00516633) or a combination of pharmacy data and
self-report (Gallefoss 1999; Mehuys 2008; NCT00233181;
NCT00414817; NCT00459368;
NCT00958932; NCT01064869; NCT01132430). Two studies
relied on self-report (Koufopoulos 2016; NCT01714141).
The three studies that investigated school-based therapy (Gerald
2009; Halterman 2004; NCT01175434) did not measure or re-
port adherence.
Included studies reported the following outcomes: lung function
(e.g. FEV1, peak expiratory flow rate (PEFR)) (n = 15); quality
of life (e.g. AQLQ) (n = 13); rescue medication use (n = 11);
asthma control (e.g. ACT, AsthmaControlQuestionnaire (ACQ))
(n = 10); hospitalisations (n = 9); exacerbations (n = 8); asthma
symptoms (n = 8); absences from school/work (n = 7); emergency
department (ED) visits (n = 7); OCS use (n = 4); participant
satisfaction (n = 4); use of healthcare services (n = 5); beliefs about
medication (n = 3); costs (n = 3); primary care/general practitioner
(GP) visits (n = 3); adverse events (n = 3); unscheduled visits to
a healthcare provider (n = 3); self-efficacy (n = 2); anxiety and
depression (e.g. Hospital Anxiety and Depression Scale (HADS))
(n = 2); asthma knowledge (n = 2); fractional exhaled nitrous oxide
(n = 2); asthma morbidity (n = 1); parent and adolescent conflict
(n = 1); functional severity index (n = 1); episodes of poor asthma
control (n = 1); inhaler technique (n = 1); feasibility (n = 1); activity
limitation (n = 1); parent sleep interruption (n = 1); and change
in family plans due to the child’s asthma (n = 1).
We extracted and reported only our prespecified outcomes of in-
terest.
Excluded studies
After full-text review, we excluded 52 records, which were related
to 45 unique studies. The most common reason for exclusion (n
= 20) was that adherence to ICS was not the primary focus of
the intervention, for example, the study involved multi-faceted
asthma education or shared decision making. The second most
common reason (n = 12) was that the study was a trial of different
ICS types, regimens or inhaler devices, in which adherence was
observed and reported but improved adherence was not the main
intention of the intervention. Nine studies were not of appropriate
design for inclusion, one study recruited a mixed disease popula-
tion, one recruited participants among whom less than 50% were
using ICS and one study aimed to improve treatment adherence
generally in asthma, rather than ICS specifically, and did not re-
port the proportion using ICS. A final study aimed to investigate
if Symbicort Maintenance and Reliever Therapy (SMART) could
improve adherence, but our outcomes of interested would have
been confounded by the different drugs and doses used in each
arm; therefore, we excluded this study.
Risk of bias in included studies
As planned, we assessed each trial according to the Cochrane ’Risk
of bias’ tool (Figure 2). In some cases, we assessed blinding, or lack
or blinding, as associated with a different level of risk, depending
on the outcome in question. We have noted in the Characteristics
of included studies tables when this was the case, and we factored
this into our GRADE decisions for these outcomes (e.g. a study
at high risk of detection bias for patient-reported outcomes, such
as quality of life, might be at lower risk for other, more objective
outcomes, such as electronically monitored adherence).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We considered all included studies to be at low (n = 23)
or unclear (n = 16) risk of bias for the random sequence
generation domain. We considered the following studies to
be at low risk because study authors described an accepted
method of generating a random sequence (e.g. using a com-
puter-generated random sequence): ACTRN12606000508572;
Bender 2010; Burgess 2007; Chan 2015; Foster 2014;
Gallefoss 1999; Gerald 2009; Halterman 2004; Kamps
2008; Koufopoulos 2016; Mehuys 2008; NCT00115323;
NCT00166582; NCT00233181; NCT00459368;
NCT01132430; NCT01169883; NCT01175434;
NCT01714141;NCT02451709; Strandbygaard 2010;Vasbinder
2015 E-MATIC. We were unable to make a judgement on
the following studies considered at unclear risk because in-
vestigators described them as ’randomised’ but provided no
other details: ACTRN12607000489493; ADERE PEDIATRIC
1; Black 2008; Bosley 1994; Chatkin 2006; Hart 2002;
Mann 1992; NCT00149487; NCT00414817; NCT00516633;
NCT00958932; NCT01064869; NCT02413528; Onyirimba
2003; Price 2010; Ulrik 2009.
Only 14 included studies
(ACTRN12606000508572; ACTRN12607000489493; Chan
2015; Charles 2007; Gerald 2009; Halterman 2004; Mehuys
2008; NCT00233181; NCT00459368; NCT01132430;
NCT01175434; NCT01714141; NCT02451709; Vasbinder
2015 E-MATIC) described the method of allocation conceal-
ment adequately to be considered at low risk of bias in this
domain. Accepted methods included use of sequentially num-
bered, sealed, opaque envelopes. We considered one study
(NCT00166582) to be at high risk because the sequence
was available to the research assistant who recruited partici-
pants. We judged the remaining 24 studies to be at unclear
risk, as investigators did not describe methods used to con-
ceal allocation (ADERE PEDIATRIC 1; Bender 2010; Black
2008; Bosley 1994; Burgess 2007; Chatkin 2006; Foster 2014;
Gallefoss 1999; Hart 2002; Kamps 2008; Koufopoulos 2016;
Mann 1992; NCT00115323; NCT00149487; NCT00414817;
NCT00516633; NCT00958932; NCT01064869;
NCT01169883; NCT02413528; Onyirimba 2003; Price 2010;
Strandbygaard 2010; Ulrik 2009).
Blinding
Owing to the nature of the intervention, blinding of participants
and personnel was not possible in most trials, and we judged 34
of the 39 included studies to be to be at overall high risk of perfor-
mance bias.We judged two studies (Bosley 1994;Chatkin 2006) to
be at low risk of performance bias. Bosley 1994measured only out-
comes of lung function and electronically monitored adherence,
which are more objective outcomes and therefore are less likely
to be susceptible to performance bias. In addition, participants
were unaware that they were being monitored. Similarly, Chatkin
2006 did not describe blinding but reported only the outcome
of electronically monitored adherence. We assessed three studies
(ACTRN12606000508572; Mann 1992; NCT00459368) to be
at unclear risk of performance bias. Mann 1992 did not describe
procedures used to mask participants or personnel, and although
some outcomes were more objective and were less prone to bias,
others, including asthma symptoms, were more at risk. There-
fore, we judged this study to be at unclear risk overall. Similarly,
for ACTRN12606000508572, participants were unaware that the
main outcome of interest was adherence and they were monitored
covertly, but other outcomes, such as ACQ, were at greater risk of
bias. Finally, NCT00459368 randomised healthcare practitioners
rather than individuals. Practitioners were aware of their group
allocation, and it is unclear how this knowledge may have influ-
enced adherence of their patients in ways unintended by the in-
tervention itself.
Many of the outcomes of interest in this review are patient
reported (e.g. asthma control, quality of life), and the un-
blinded participant is often the outcome assessor. We therefore
judged 29 of the included studies to be at high risk of bias
in the outcome assessment domain. We judged six studies to
be at low risk (Bosley 1994; Chatkin 2006; NCT00414817;
NCT00459368;NCT00958932;NCT01169883).Wemade this
judgement because the outcomes measured were objective and
were unlikely to be influenced by outcome assessors’ knowledge
of group allocation (e.g. usage of healthcare services from med-
ical records, data from electronic monitoring devices), and for
some specific measures, studies described masking outcome as-
sessors to group allocation. We judged the remaining four stud-
ies (ACTRN12606000508572; Mann 1992; NCT01132430;
NCT02413528) to be at unclear risk of bias. NCT01132430 in-
cluded a mixture of outcomes objectively assessed by a blinded
outcome assessor and patient-reported outcomes, so overall we
judged this study to be at unclear risk. Similarly, Mann 1992
and ACTRN12606000508572 included a mix of objective out-
comes and patient-reported outcomes. NCT02413528 reported
very minimal details, so we could not make a judgement.
Incomplete outcome data
We judged 18 studies to be at low risk of attrition bias;
drop-out was low and balanced, and withdrawn partici-
pants were adequately described (ACTRN12606000508572;
ACTRN12607000489493; Bender 2010; Burgess 2007;
Chan 2015; Halterman 2004; Mann 1992; NCT00166582;
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NCT00233181; NCT00459368; NCT00516633;
NCT00958932; NCT01132430; NCT01169883;
NCT01175434; NCT01714141; NCT02451709; Price 2010).
We judged 11 studies to be at high risk, usually owing to
high and/or unbalanced drop-out from study arms (ADERE
PEDIATRIC 1; Bosley 1994; Foster 2014; Gerald 2009;
Kamps 2008; Koufopoulos 2016;Mehuys 2008; NCT00149487;
NCT01064869; Onyirimba 2003; Vasbinder 2015 E-MATIC).
We judged another 10 studies to be at unclear risk, usually be-
cause drop-outs were not adequately described to allow a judge-
ment (Black 2008; Charles 2007; Chatkin 2006; Gallefoss 1999;
Hart 2002; NCT00115323; NCT00414817; NCT02413528;
Strandbygaard 2010; Ulrik 2009).
Selective reporting
We judged five trials to be at low risk of reporting bias. We were
able to identify a prepublished protocol or prospective trial regis-
tration and found that all stated outcomes of interest were appro-
priately reported (Chan 2015; NCT00115323; NCT00459368;
NCT00958932; Vasbinder 2015 E-MATIC).We judged 15 stud-
ies to be at high risk of selective reporting. Reasons included that
the study was identified only as a conference abstract withminimal
details, that key outcomes were reported only narratively or in a
way that prevented meta-analysis or that we noted an important
deviation between protocol/registration and published results (
ACTRN12606000508572; ADERE PEDIATRIC 1; Black 2008;
Chatkin 2006; Gallefoss 1999; Gerald 2009; Hart 2002; Kamps
2008; Koufopoulos 2016; NCT00149487; NCT00233181;
NCT00414817; NCT00516633; NCT02451709; Ulrik 2009).
We judged the remaining 18 studies to be at unclear risk, primar-
ily because we were unable to identify a prepublished protocol or
prospective trial registration.
Other potential sources of bias
We did not note any additional potential sources of bias in any
included studies.
Effects of interventions
See: Summary of findings for the main comparison Adherence
education compared with controls for asthma; Summary of
findings 2Electronic trackers or reminders (± feedback) compared
with controls for asthma; Summary of findings 3 Simplified
compared with usual regimens for asthma; Summary of findings
4 School-based ICS therapy compared with home therapy for
asthma
Comparison 1. Adherence education versus controls
Adherence
Our primary analysis of adherence included only studies that used
an objective electronic monitor to measure adherence. Mean ad-
herence for those receiving adherence education was 20% better
than for those in the control group (Analysis 1.1; mean difference
(MD) 20.13, 95% confidence interval (CI) 7.52 to 32.74; 280
participants; five studies; low-quality evidence). A benefit favour-
ing adherence education is seen when studies using both objective
and subjective measures are included, but the effect is attenuated
(Analysis 1.2; MD 11.59, 95% CI 3.72 to 19.46; 1693 partici-
pants; 10 studies; low-quality evidence).
We noted great variation between individual study results in both
analyses (I2 = 81% and 88%, respectively), and concerns about
effects of performance bias and selection bias reduced our confi-
dence in the results. We created a funnel plot to look for evidence
of publication bias (Figure 3) and found none.
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Figure 3. Funnel plot of comparison: 1 Adherence education vs controls, outcome: 1.2 % Adherence (all
measures).
One larger study (Chatkin 2006) dichotomised participants into
those who achieved greater than 85% adherence and those who
did not; results showed benefit of the educational intervention
(Analysis 1.3; odds ratio (OR) 2.68, 95% CI 1.61 to 4.46; 271
participants; one study).
A test for subgroup differences between interventions judged to
be ’complex’ (i.e. multi-faceted) and interventions offering sim-
pler forms of education detected no differences between the two
types of interventions (I2 = 0%), but it should be noted that we
classified as ’simple’ only one study using objective measures. Test-
ing suggested no important differences between studies of adults,
studies of adults and adolescents and studies of children (Analysis
5.1) when all measures of adherence were considered. If the same
subgroup analysis is performed only on studies using objective
measures, only one study in the child subgroup remains; although
this analysis suggests that the intervention is more effective in chil-
dren, we interpret this finding with extreme caution. We planned
a subgroup analysis based on the recipient of the intervention, but
this was not necessary, as all interventions were delivered to adults
or children with asthma or their parents.
Exacerbations requiring OCS
It was not possible to discern with certainly whether education
had an effect on the odds that a patient would need oral steroids
for an exacerbation (OR 1.82, 95% CI 0.99 to 3.36; 349 partic-
ipants; three studies; I2 = 10%; low-quality evidence). The point
estimate lay in favour of control, but confidence intervals around
the pooled estimate showed no differences between groups (Anal-
ysis 1.4). We downgraded the evidence for risk of bias and for
imprecision. We did not perform subgroup analyses on this pri-
mary outcome because we identified too few studies and we did
not observe significant heterogeneity in the analysis.
Three
other studies (NCT00233181; NCT00958932; NCT01064869)
reported the mean number of exacerbations per person over six or
12 months, but the data were skewed so we did not pool the re-
sults. NCT00233181 reported a significant reduction in OCS use
(incident rate ratio 0.83; 95% CI 0.73 to 0.95; P = 0.008) when
both intervention groups were compared with the control group.
Conversely, NCT00958932 reported increased oral steroid use in
the intervention group over the 24 months of the study (mean
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(standard error (SE)) oral steroid bursts per person per year 0.21
(0.18) in the control group and 0.27 (0.23) in the intervention
group; P = 0.05). NCT01064869 reported a small reduction in
courses of oral steroids at 12-month follow-up in the intervention
group compared with the control group, but this finding was not
significant (mean (standard deviation (SD)) 1.7 (1.1) in the inter-
vention group and 2.0 (1.4) in the control group; P = 0.41).
Asthma control
Studies used the Asthma Control Questionnaire (Bender
2010; NCT00115323; NCT01064869; NCT01132430) and
the Asthma Control Test (Foster 2014; Mehuys 2008;
NCT01132430) as validated measures of asthma control (Analy-
sis 1.5) and reported no differences between adherence education
and control on the ACQ (MD -0.03, 95% CI -0.49 to 0.43; 455
participants; four studies; I2 = 38%; moderate-quality evidence)
nor on the ACT (MD 0.30, 95% CI -0.82 to 1.43; 333 partic-
ipants; three studies; I2 = 40%; moderate-quality evidence). We
noted some variation in study results, but our confidence in these
results was mainly reduced by risk of performance and detection
bias. Upper and lower confidence limits for both estimates fell
within the minimal clinically important differences (MCIDs) for
the scales (0.5 point for the ACQ and 3 points for the ACT), so
we did not consider the evidence imprecise. It was not possible
to perform subgroup analyses on this primary outcome because
we identified too few studies and we did not observe substantial
heterogeneity in the analysis.
Unscheduled visits
Studies reported unscheduled visits inconsistently as hospital visits,
ED visits or GP visits, and this made the estimate difficult to
interpret (Analysis 1.6). The pooled estimate lay predominantly
in favour of adherence education, but the effect was imprecise
and the upper confidence limit crossed the line of no difference
(OR 0.48, 95% CI 0.19 to 1.19; 688 participants; four studies; I
2 = 59%). We considered evidence for this outcome to be of very
low quality owing to risk of bias, inconsistency between study
results, imprecision and variation in the way unscheduled visits
were defined. Also, effects presented separately suggest possible
benefit of adherence education for ED and GP visits, but we did
not set out to assess these outcomes separately, so this must be
interpreted with caution.
Three other studies (Gallefoss 1999; NCT00233181;
NCT00958932) reported the mean number of unscheduled visits
per person, but the data were skewed so we have not presented a
mean difference. Gallefoss 1999 reported a reduction in the mean
(SD) number of GP consultations in the intervention group com-
pared with the control group: 0.7 (2.0) versus 2.6 (3.6); P < 0.001.
NCT00233181 also reported a significant reduction in the num-
ber of ED visits in the intervention group (incident rate ratio 0.88;
95%CI 0.78 to 0.99; P = 0.03), NCT00958932 reported ED and
after-hours visits but did not detect a significant between-group
difference for either outcome (P = 0.23 and P = 0.12, respectively).
Absence from work/school
Two studies reported rates of absenteeism per person over 12
months (Gallefoss 1999) or 18 months (NCT00516633). The
mean number of absence days per person in Gallefoss 1999 was
eight in the adherence education group (n = 25) and 26 in the
control group (n = 24), but standard deviations were 32 and 70
days, respectively, suggesting that the data were heavily skewed.
Consequently, we did not consider it appropriate or useful to anal-
yse the data for a mean difference. The other study reporting this
outcome (NCT00516633) observed a mean of 2.1 days in the
adherence education group (n = 32) and 3.9 days in the control
group (n = 28); the P value for this difference as reported in the
paper was 0.08.
Quality of life
Results showed no difference between adherence education and
control on the Asthma Quality of Life Questionnaire (Analysis
1.7;MD0.01, 95%CI -0.20 to 0.23; 734 participants; six studies;
I2 = 34%; moderate-quality). Upper and lower confidence limits
fell within the 0.5 MCID for the scale, so we did not downgrade
for imprecision. We had concerns regarding performance and de-
tection bias because the scale is self-rated.
All adverse events
No studies measured or reported adverse events other than the
need for oral steroids or unscheduled visits, which have already
been considered.
Comparison 1 sensitivity analyses
No unpublished data were included in the analyses, so we found
that this sensitivity analysis was not necessary.
Only one study in the objective % adherence outcome was rated
at high risk for either of the selection bias domains, and results
without this study showed a slightly smaller pooled effect than
was evident in the main analysis (MD 16.23, 95% CI 3.86 to
28.60).No studies in the ’Exacerbation requiringOCS’ or ’Asthma
control’ analyses were at high risk in either of the selection bias
domains.
Mehuys 2008 and Gallefoss 1999 were the only Comparison 1
studies in which not all participants were taking an ICS at base-
line (although proportions were between 89.5% and 97% in each
group). Mehuys 2008 did not contribute to the objective % ad-
herence outcome, as researchers did not measure adherence using
an electronic monitor. Both studies contributed to ’Exacerbations
requiring OCS’ and their exclusion left just the two Foster 2014
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comparisons (PAD vs control and IRF + PAD vs IRF) in the anal-
ysis. The point estimate favours control over education (OR 3.44,
95% CI 1.35 to 8.81; 131 participants; one study), but results
were reported by a single small study and should be interpreted
with caution. Mehuys 2008 contributed to the ACT analysis, but
our conclusions did not change when we excluded this study (MD
0.72, 95% CI -0.58 to 2.02).
As described previously, instead of excluding studies that did not
measure adherence objectively in a sensitivity analysis, we have
presented this as our main analysis (Analysis 1.1).
Comparison 2. Electronic trackers or reminders
versus controls
Adherence
As for Comparison 1, our primary analysis of adherence included
only studies that used an objective electronic monitor to mea-
sure adherence. Mean adherence of those using electronic track-
ers or reminders was 20% better than mean adherence of those
in the control group (Analysis 2.1; MD 19.86, 95% CI 14.47 to
25.26; 555 participants; six studies; I2 = 34%; moderate-quality
evidence). As with Comparison 1, our confidence in the estimate
was reduced by possible performance and selection bias. Pooling
studies using any measure of adherence had little impact on the
estimate, but greater inconsistency was evident (MD 18.41, 95%
CI 11.82 to 25.00; 762 participants; eight studies; I2 = 66%; low-
quality evidence).
Subgroup analyses for the objectively measured adherence out-
come provides weak evidence that inhaler reminders combined
with individual feedback may be more effective than inhaler re-
minders alone (test for subgroup difference: I2= 65.2%; P = 0.09;
Analysis 2.1). The test for subgroup differences between interven-
tions judged to be ’complex’ (i.e. multi-faceted) and simpler inter-
ventions also provides weak evidence that complex interventions
may be more effective, but this effect was seen only when the anal-
ysis was limited to studies using objective measures of adherence
(I2 = 65.2%; P = 0.09; Analysis 5.2). Testing also suggested no im-
portant differences between studies of adults (or adults and adoles-
cents) and children (I2 = 0%; Analysis 5.3). As with Comparison
1, the subgroup analysis based on the recipient of the intervention
was not necessary, as all interventions were delivered to adults or
children with asthma or their parents.
Three other studies reported data about adherence that could not
be pooled with data from studies reporting % adherence. Data
from Chan 2015 were skewed and were reported as medians; this
study showed large benefit of an audiovisual inhaler reminder, with
an interventionmedian adherence of 84% (10th to 90th percentile
54 to 96; N = 110) compared with a control median adherence of
30% (10th to 90th percentile 8 to 68; N = 110). NCT00459368,
a large cluster study, reported adherence as a refill rate and showed
similar results between groups (21.3 in the feedback group (SE
2.5), 23.2 in the control group (SE2,2)).NCT01714141 collected
adherence data in several ways from a self-report questionnaire,
none of which were comparable with those of other studies; scores
generally favoured the treatment group.
Exacerbations requiring OCS
It was not possible to say with certainty whether electronic trackers
or reminders improved the odds of needing oral steroids for an
exacerbation (OR 0.72, 95% CI 0.37 to 1.39; 3063 participants;
four studies; I2 = 60%; very low-quality evidence). Confidence
limits included important benefit in one direction and important
harm in the other (Analysis 2.3). We downgraded the evidence
further for risk of bias and inconsistency.
Again, as with the first comparison, we did not perform subgroup
analyses on this primary outcome because we identified too few
studies. Similarly, some studies (NCT00233181;NCT00459368;
NCT02451709; Vasbinder 2015 E-MATIC) reported the mean
number of exacerbations per person over a period of time and
the data were skewed, so we did not consider a mean difference
to be a valid measure for comparison. NCT00233181 reported
no difference between the adherence monitoring with feedback
group and the asthma education group for oral steroid use (P
= 0.32). Similarly, NCT00459368 reported oral steroid use and
found no clear benefit of adherence feedback over usual care (P
= 0.277). Vasbinder 2015 E-MATIC reported exacerbations as
requiring OCS, an ED visit or hospitalisation and reported no
advantage of the text messaging intervention over control (P =
0.432). Finally, NCT02451709 adjusted the analysis to account
for the skew and found that children receiving adherence feedback
had fewer exacerbations per 100 days compared with controls (rate
ratio 0.23, 95% CI 0.08 to 0.64).
Asthma control
Studies used the AsthmaControl Questionnaire (NCT02451709;
Strandbygaard 2010) or the Asthma Control Test (Chan 2015;
Foster 2014; NCT01714141; Vasbinder 2015 E-MATIC) as val-
idated measures of asthma control (Analysis 2.4). Results did not
show an important difference between reminders/trackers and
controls on the ACQ (MD 0.24, 95% CI -0.29 to 0.78; 109 par-
ticipants; two studies; I2 = 0%; low-quality evidence) nor on the
ACT (MD 0.74, 95% CI -0.20 to 1.69; 596 participants; four
studies; I2 = 47%; low-quality evidence). The upper limit for the
ACQ estimate includes the MCID for the scale (0.5), so trackers
and reminders could have an important effect on this measure of
asthma control; we downgraded the evidence for imprecision for
this reason. We noted some variation between ACT results, but
confidence limits fell below the 3 point MCID for the scale, so we
did not consider the estimate imprecise.
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It was not possible to perform subgroup analyses on this primary
outcome because we identified too few studies and we did not
observe significant heterogeneity in the analysis.
Unscheduled visits
Some studies reported unscheduled visits as ED visits and some
as hospital visits (Analysis 2.5); we did not pool the two because
NCT00459368 reported both. It was not possible to say with cer-
tainly whether electronic trackers or reminders reduced the odds
of unscheduled visits to the ED (OR 1.14, 95% CI 0.88 to 1.47;
2918 participants; two studies; I2 = 0%; moderate-quality evi-
dence) or to the hospital (OR 0.97, 95% CI 0.53 to 1.78; 2865
participants; two studies; I2 = 0%; not graded), as the estimates
were imprecise.
NCT02451709 reported data that could be analysed as rate ratios
(Analysis 2.6) and showed a reduction in hospital visits (rate ratio
4.38, 95% CI 1.46 to 13.14) but not in GP or ED visits (rate ratio
1.15, 95% CI 0.83 to 1.59).
Absence from work/school
Chan 2015 reported that the number of parents taking at least
one absence favoured controls but results were imprecise (Analysis
2.7; OR 1.42, 95% CI 0.82 to 2.47; low-quality evidence). We
considered evidence for the outcome to be of low quality owing to
imprecision and risk of bias. NCT02451709 reported absences per
100 child days that favoured reminders, but results were imprecise
(Analysis 2.8; rate ratio 1.16, 95% CI 0.97 to 1.39; evidence
quality not graded).
Quality of life
Studies reported no difference between electronic trackers or re-
minders and controls on the AsthmaQuality of LifeQuestionnaire
(MD -0.03, 95% CI -0.20 to 0.13; 369 participants; four studies;
I2 = 0%; moderate-quality evidence). Upper and lower confidence
limits lay well within the 0.5 point MCID for the scale, so we
did not consider the effect imprecise, although we had the usual
concerns related to risk of bias.
All adverse events
Only Vasbinder 2015 E-MATIC measured and reported adverse
events; this study reported serious adverse events of any cause and
observed none in either group.
Comparison 2 sensitivity analyses
No unpublished data contributed to any of the three primary
outcomes, so this sensitivity analysis was not necessary. Similarly,
we rated no contributing studies at high risk of selection bias, so
this was also not necessary.
Before the study commenced, not all participants in Strandbygaard
2010 were taking an ICS (59%), but all were taking an ICS at
the start of the study. Excluding this study made little difference
in the objective % adherence analysis (MD 20.62, 95% CI 14.30
to 26.95) but greatly decreased the precision of the ACQ analysis
(MD 0.19, 95% CI -1.37 to 1.75). This study did not contribute
to exacerbations requiring oral steroids.
As for Comparison 1, instead of excluding studies that did not
measure adherence objectively in a sensitivity analysis, we have
presented this as our main analysis (Analysis 2.1).
Comparison 3. Simplified versus usual drug regimens
Adherence
All three studies contributing to this outcome assessed adherence
using an objective measure. Adherence was 4% better with simpli-
fied drug regimens than with usual drug regimens (Analysis 1.1;
MD 4.02, 95% CI 1.88 to 6.16; 1310 participants; three studies;
I2 = 0%). We downgraded the evidence only for risk of bias and
rated it as moderate quality. The effect is difficult to interpret as
two studies compared combined versus separate inhalers (Bosley
1994; ACTRN12606000508572), andone study compared once-
daily versus twice-daily dosing (Price 2010).
Adherence data in Mann 1992 could not be combined with those
from other studies. Twice-daily and four-times-daily groups in
Mann 1992 took a similar mean number of correct daily inhala-
tions. Data from the same study showing the percentage of days
with missed inhalations favoured twice daily but were skewed
(twice daily 36.8%, SD 48.3; four times daily 57.1%, SD 49.6).
Exacerbations requiring OCS
It was not possible to tell whether simplifying drug regimens had
an effect on exacerbations, as only one study of 16 people reported
this outcome (Analysis 3.2; OR 2.33, 95% CI 0.17 to 32.58;
low-quality evidence). This study compared twice-daily treatment
versus treatment given four times daily (Mann 1992).
Asthma control
One study (ACTRN12606000508572) comparing combined in-
halers (simplified regimen) versus separate inhalers showed no dif-
ference between regimens on the ACQ (MD -0.03, 95% CI -0.34
to 0.28; 103 participants; one study). Both confidence limits fell
within the 0.5 MCID for the ACQ, so we did not downgrade
for imprecision. We had the usual concerns regarding risk of bias
through lack of blinding, so we rated the evidence as moderate
quality.
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Unscheduled visits
Price 2010 did not show benefit of once-daily dosing (simplified
regimen) versus twice-daily dosing for unscheduled visits (Analysis
3.4; OR 1.17, 95%CI 0.72 to 1.90; 1037 participants; one study;
low-quality evidence). The effect lay close to no difference, and
confidence limits showed important benefit in one direction and
important harm in the other; we downgraded the evidence for this
imprecision and for risk of bias.
Absence from work/school
On the basis of data from one study (Price 2010), it was, again,
not possible to tell whether once-daily dosing (simplified regi-
men) showed benefit for this outcome compared with twice-daily
dosing; only one study reported this, and confidence intervals in-
cluded important benefit and harm (Analysis 3.5; OR 0.93, 95%
CI 0.37 to 2.30; low-quality evidence).
Quality of life
One study comparing once-daily dosing (simplified) versus twice-
daily dosing (Price 2010) reported quality of life on the Thera-
peutics Group Asthma Short Form (Analysis 3.6); the lower con-
fidence limit crossed the line of no effect, so we were not confident
in the estimate (MD 6.00, 95% CI -0.76 to 12.76; 1037 partici-
pants; low-quality evidence). The scale ranges from 1 to 100, and
we could find no information on an agreed MCID.
All adverse events
Price 2010 reported adverse events and observed fewer in the sim-
plified regimens group (once-daily dose) than in the control group
(twice-daily dose), but confidence intervals included no difference
(OR 0.76, 95%CI 0.56 to 1.04; low-quality evidence).We down-
graded the evidence for imprecision and for risk of performance
bias.
Comparison 3 subgroup and sensitivity analyses
We did not perform any subgroup analyses for this comparison
as we included no more than three studies in any single analysis.
None of the sensitivity analyses were necessary because we located
no unpublished data, no contributing studies were at high risk of
selection bias and all used objective measures of adherence.
Comparison 4. School-based ICS therapy versus
control
The three studies performing this comparison provided no data
for adherence, exacerbations requiring OCS, asthma control or
adverse events. Gerald 2009 reported a composite measure of
episodes of poor asthma control (EPAC), which we could not
combine with any other measures. We identified too few studies
to consider any of the planned subgroup or sensitivity analyses,
but we have presented below data that could be analysed.
Unscheduled visits
Two studies reported unscheduled visits, but the data could not be
combined. Halterman 2004 reported that 18 of 89 children in the
intervention group and 26 of 91 in the control group had three or
more visits over 10 months. NCT01175434 reported that 9 of 48
children in the intervention group and 11 51 in the control group
had one or more unscheduled visits over six to eight months.
Both studies reported the number of people who had one or more
hospitalisations for any cause during the study; confidence inter-
vals showed an important benefit in either direction, so it was not
possible to say whether school-based ICS has a beneficial effect
(OR 0.58, 95% CI 0.16 to 2.05; 279 participants; two studies; I
2 = 0%; low-quality evidence).
Absence from work/school
Halterman 2004 reported mean absences per child over the 10-
month study: 6.8 absences (SD9.5) for the intervention group and
8.8 days (SD 8.8) for the control group. NCT01175434 reported
a mean of 0.37 absences (SD 0.7) in the intervention group over
two weeks and 0.85 (SD 1.3) in the control group. Both sets of
data were skewed and were not suitable for combination in a mean
difference analysis.
Quality of life
The same two studies reported results of the Paediatric Asthma
Quality of Life Questionnaire (PAQLQ). A statistically significant
effect favoured giving ICS at school, but the upper end of the
confidence limit lay under the 0.5 MCID for the scale, so the
difference is unlikely to be clinically important (MD 0.25, 95%
CI 0.01 to 0.49; 279 participants; two studies; I2 = 0%; moderate-
quality evidence).
Adverse events
NCT01175434 reported that no one in the intervention group (n
= 48) and no one in the control group (n = 51) had any adverse
events.
Unclassified studies
We were unable to classify Koufopoulos 2016 and Burgess 2007,
as both tested interventions that did not fit into any of our four
main categories.
Burgess 2007 reported that a novel spacer device, the ’Funhaler’,
did not improve adherence to ICS in children over the 12-week
study period. Endof follow-upmedian adherence (range)was 46%
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(2% to 100%) in the intervention group and 53% (0 to 100%)
in the control (Aerochamber) group. Investigators measured ad-
herence with a SmartInhaler. Study authors reported the number
of children experiencing an exacerbation requiring an OCS: 11 of
24 in the intervention group and 6 of 20 in the control group.
Koufopoulos 2016 investigated whether an online asthma com-
munity (”AsthmaVillage“) can improve self-reported adherence,
measured on the SimplifiedMedication Adherence Questionnaire
(SMAQ). Results show that the control group reported better ad-
herence to ICS during the study period and control group partic-
ipants were more likely to use the online diary than those in the
AsthmaVillage group.
25Interventions to improve adherence to inhaled steroids for asthma (Review)
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Electronic trackers or reminders (±feedback) compared with controls for asthma
Patient or population: asthma
Setting: community
Intervention: electronic trackers or reminders (± feedback)
Comparison: control group
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of partici-
pants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Risk with controls Risk with elec-
tronic trackers or
reminders (± feed-
back)
% Adherence
WMD of follow-up
47.6 weeks
Objective measures
only
Mean adherence in
the control group
was 53.27%
Mean adherence
was 19.86% higher
(14.47 higher to 25.
26 higher)
- 555
(6 RCTs)
⊕⊕⊕©
M ODERATEa
Only studies in
which adherence
was measured with
an electronic moni-
tor
All measures Mean adherence in
the control group
was 56.06%
Mean adher-
ence with trackers
was 18.41% higher
(11.82 higher to 25.
00 higher)
- 762
(8 RCTs)
⊕⊕©©
LOWa,b
Exacerbations requiring OCS
(people with at least 1)
WMD of follow-up 48.6 weeks
218 per 1000 169 per 1000
(94 to 280)
OR 0.72
(0.37 to 1.39)
3063
(4 RCTs)
⊕©©©
VERY LOWa,b,c
Asthma control (ACQ)
WMD of follow-up 43.0 weeks
Mean ACQ score in
the control group
was 0.89
Mean score with
trackers or re-
m inders was 0.24
better (0.29 worse
to 0.78 better)
- 109
(2 RCTs)
⊕⊕©©
LOWa,c
Lower score indi-
cates better control.
Scale 0 to 6. MCID
0.5
2
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Asthma control (ACT)
WMD of follow-up 34.0 weeks
Mean ACT score in
the control group
was 20.04
Mean score with
trackers or re-
m inders was 0.74
better (0.20 worse
to 1.69 better)
- 596
(4 RCTs)
⊕⊕©©
LOWa,b,d
Higher score indi-
cates better control.
Scale 5 to 25. MCID
3
Unscheduled healthcare visits to a health-
care provider (ED)
WMD of follow-up 50.0 weeks
84 per 1000 95 per 1000
(75 to 119)
OR 1.14
(0.88 to 1.47)
2918
(2 RCTs)
⊕⊕⊕©
M ODERATEc
Two studies (n =
2865) also reported
hospitalisat ions. OR
0.97 (0.53 to 1.78)
Absenteeism
(people with at least 1 absence)
Follow-up 26 weeks
327 per 1000 409 per 1000
(285 to 546)
OR 1.42
(0.82 to 2.47)
220
(1 RCT)
⊕⊕©©
LOWc,e
Quality of life (AQLQ)
WMD of follow-up 36.8 weeks
Mean AQLQ score
in the control group
was 5.15
Mean score with
trackers or re-
m inders was 0.03
worse (0.13 better
to 0.20 worse)
- 369
(4 RCTs)
⊕⊕⊕©
M ODERATEa,d
Higher score indi-
cated better QOL.
Scale 1 to 7. MCID
0.5
* The risk in the intervention group (and its 95% conf idence interval) is based on assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%
CI).
ACQ: Asthma Control Quest ionnaire; ACT: Asthma Control Test; AQLQ: Asthma Quality of Life Quest ionnaire; CI: conf idence interval; ED: emergency department; MCID: minimal
clinically important dif f erence; OCS: oral cort icosteroid; OR: odds rat io; QOL: quality of lif e; RCT: randomised controlled trial; WMD: weighted mean durat ion
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to the est imate of ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of ef fect but may be substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded once primarily owing to risk of bias f rom open-label trials and some concerns regarding attrit ion bias, select ive
report ing and select ion bias (-1 risk of bias)
bDowngraded once for inconsistency between study results (-1 inconsistency)
cConf idence intervals include no dif ference and potent ial important harm and benef it of the intervent ion (-1 imprecision)2
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dConf idence intervals fall within the MCID for this scale (no downgrade for imprecision)
eDowngraded once owing to risk of performance and detect ion bias (-1 risk of bias)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Simplified compared with usual regimens for asthma
Patient or population: asthma
Setting: community
Intervention: simplif ied regimens
Comparison: usual regimens
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with usual regi-
mens
Risk with simplified
regimens
% Adherence (objec-
tive measures)
WMD of follow-up 12.9
weeks
Mean adherence in the
control group was 86.
73%
Mean
adherence with simpli-
f ied regimens was 4.
02% higher
(1.88 higher to 6.16
higher)
- 1310
(3 RCTs)
⊕⊕⊕©
M ODERATEa
Only studies in which
adherence was mea-
sured with an electronic
monitor
Exacerbations requir-
ing OCS
People with 1 or more
Follow-up 12 weeks
125 per 1000 250 per 1000
(24 to 823)
OR 2.33
(0.17 to 32.58)
16
(1 RCT)
⊕⊕©©
LOWb
Asthma control (ACQ)
Follow-up 24 weeks
Mean ACQ score in the
control group was 0.89
Mean score with simpli-
f ied regimens was 0.03
better (0.34 better to 0.
28 worse)
- 103
(1 RCT)
⊕⊕⊕©
M ODERATEc
Lower score indicates
better control. Scale 0
to 6. MCID 0.5
Unscheduled visits
Follow-up 12 weeks
63 per 1000 72 per 1000
(46 to 113)
OR 1.17
(0.72 to 1.90)
1037
(1 RCT)
⊕⊕©©
LOWa,d
Absence from work/
school
Follow-up 12 weeks
19 per 1000 18 per 1000
(7 to 43)
OR 0.93
(0.37 to 2.30)
1037
(1 RCT)
⊕⊕©©
LOWa,d
2
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Change in quality of life
(ITG-ASF)
Follow-up 12 weeks
Mean change in qual-
ity of lif e in the control
group was 14
Mean change with sim-
plif ied regimens was 6
points better
(0.76 worse to 12.76
better)
- 1037
(1 RCT)
⊕⊕©©
LOWa,e
Higher score indicates
better QOL. Range 0 to
100. MCID not known
All adverse events
Follow-up 12 weeks
175 per 1000 139 per 1000
(106 to 181)
OR 0.76
(0.56 to 1.04)
1233
(1 RCT)
⊕⊕©©
LOWa,f
* The risk in the intervention group (and its 95% conf idence interval) is based on assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%
CI)
ACQ: Asthma Control Quest ionnaire; CI: conf idence interval; ITG-ASF: Integrated Therapeut ics Group - Asthma Short Form; MCID: minimal clinically important dif f erence; OCS:
oral cort icosteroid; OR: odds rat io; QOL: quality of lif e; RCT: randomised controlled trial; WMD: weighted mean durat ion
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to the est imate of ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of ef fect but may be substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded once primarily owing to lack of blinding and some concerns regarding attrit ion bias, select ive report ing and
select ion bias (-1 risk of bias)
bOne very small t rial result ing in very wide conf idence intervals (-2 imprecision)
cAlthough conf idence intervals fall within the MCID, only one study contributed to this outcome (-1 imprecision)
dConf idence intervals include both important potent ial harm and benef it of the intervent ion (-1 imprecision)
eConf idence intervals do not exclude no dif ference (-1 imprecision)
f Conf idence intervals range f rom no dif ference to an important benef it of simplif ied regimens (-1 imprecision)
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School-based ICS therapy compared with home therapy for asthma
Patient or population: children with asthma
Settings: school
Intervention: ICS given at school
Comparison: ICS given at home
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control School-based ICS ther-
apy
Unscheduled visits
1 or more hospitalisa-
t ions for any cause
WMD of follow-up 35.8
weeks
49 per 1000 29 per 1000
(8 to 96)
OR 0.58 (0.16 to 2.05) 279
(2 RCTs)
⊕⊕©©
LOWa,b
Quality of life (PAC-
QLQ)
1 to 7; higher is better
WMD of follow-up 35.8
weeks
Mean PAQLQ score in
the control group was
6.31
Mean score in the inter-
vent ion groups was
0.25 higher (0.01 to 0.
49 higher)
- 279
(2 RCTs)
⊕⊕⊕©
M ODERATEa
Adverse events
Follow-up 30 weeks
No events observed in either arm - 99
(1 RCT)
Not graded
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI)
CI: conf idence interval; ICS: inhaled cort icosteroid; OR: odds rat io; PAQLQ: Paediatric Asthma Quality of Life Quest ionnaire; RCT: randomised controlled trial; WMD: weighted
mean dif ference
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
No data could be meta-analysed for adherence, exacerbat ions requiring OCS, asthma control or absenteeism. Some data are
presented narrat ively in the review
aBoth contribut ing studies considered at high risk for performance and detect ion bias
bConf idence intervals include both potent ial harm and benef it of the intervent ion
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
This review found 39 eligible parallel randomised controlled tri-
als (RCTs), 28 of which (n = 16,303) contributed data to at least
one meta-analysis. Eighteen studies included only children, 20
included adults and/or adolescents and one recruited individuals
of all ages; all participants had asthma and a vast majority were
using an inhaled corticosteroid (ICS) at baseline. Follow-up of
analysed studies ranged from two months to two years (median
six months). Trials were conducted mainly in high-income coun-
tries. Outcomes reported were not consistent across reviews, and
investigators did not always use validated scales. Almost all in-
cluded studies reported some measure of adherence, usually as a
percentage, but the way in which this information was captured
and calculated varied between studies. Studies were generally at
low or unclear risk of selection bias and at high risk of bias asso-
ciated with blinding (although this varied by outcome). Review
authors considered around half of these studies to be at high risk
for attrition bias and selective outcome reporting.
Studies were classified into four comparisons by consensus: ad-
herence education versus control (20 studies); electronic trackers
or reminders versus control (11 studies); simplified drug regimens
versus usual drug regimens (four studies); and school-based di-
rectly observed therapy (three studies). Two multi-arm studies ap-
peared in two comparisons (Foster 2014; NCT00233181), and
two studies were described separately (Burgess 2007; Koufopoulos
2016).
All pooled results for adherence education, electronic trackers or
reminders and simplified regimens led to better adherence than
for controls, both when adherence was measured objectively and
when all measures were considered. However, our confidence in
the evidence was reduced by risk of bias and inconsistency. When
measured objectively (e.g. using a dose counter), adherence educa-
tion showed 20% benefit over controls (95% confidence interval
(CI) 7.52 to 32.74; five studies; low-quality evidence), and the
effect was attenuated to 12% when all measures were considered.
Electronic trackers or reminders led to 20% (18% if all measures
were included) better adherence than for controls (95% CI 14.47
to 25.26; six studies; low-quality evidence). Simplified regimens
led to 4% better adherence than usual care (95% CI 1.88 to 6.16;
three studies; moderate-quality evidence), but the effect is diffi-
cult to interpret, as two studies compared combined versus sep-
arate inhalers (ACTRN12606000508572; Bosley 1994) and one
study compared once-daily versus twice-daily dosing (Price 2010).
When we were able to conduct subgroup analyses, we found that
’complex’ or multi-faceted educational interventions were not sta-
tistically better than simpler interventions, but weak evidence sug-
gested that complex interventions involving adherence reminders
and feedback may be more effective than simpler interventions
within this comparison. Similarly, weak evidence from subgroup
analysis suggested that combining reminderswith feedback ismore
effective than using reminders alone. Overall, results for adults
and children were similar.
Improvements in adherencewere inconsistently translated into ob-
servable benefit for clinical outcomes, with some studies reporting
a reduction in usage of healthcare services or courses of oral steroids
favouring the intervention, and other studies reporting the oppo-
site, or no difference. None of the pooled analyses showed clear
benefit for exacerbations requiring an oral corticosteroid (OCS)
(evidence of low quality), unscheduled visits (evidence of very low
to moderate quality), asthma control or quality of life (evidence
for both of low to moderate quality). School or work absence data
were mostly skewed and were difficult to interpret (evidence of
low quality, when graded), and most studies did not report adverse
events.
Studies investigating the possible benefit of administering an ICS
at school did not measure adherence, exacerbations requiring
OCS, asthma control or adverse events. One study showed fewer
unscheduled visits, and another found no difference; data could
not be combined.
Overall completeness and applicability of
evidence
The findings of this review appear to support the premise that
interventions specifically intended to improve adherence to ICS
are effective in improving percent adherence in both adults and
children.However, a wide range of interventions have been used in
the included studies, and even within the four comparisons, inter-
ventions are variable. We cannot be sure to what extent improve-
ment in adherence was a result of the intervention itself, rather
than a result of participation in a trial in which the stated aim was
to improve adherence (the ”Hawthorne effect“ (McCambridge
2014)). Indeed, in many trials all participants showed improve-
ment in several outcomes, irrespective of the group to which they
were assigned. In some included trials, participants’ adherence was
covertly monitored to minimise the impact of performance bias,
but participants would likely have been aware of the overall aims
of the trial nonetheless. In addition, many of the interventions, es-
pecially in Comparison 1, would require considerable investment
of resources and in a budget-constrained healthcare system would
be unlikely to be widely adopted. All three considerations limit
the applicability of review findings to a real-world setting.
Although all three of the comparisons that measured percentage
adherence demonstrated improvement (albeit with low to mod-
erate confidence), it is not always clear whether this was a clini-
cally meaningful improvement, with no established minimal clin-
ically important difference for this outcome. Studies have sug-
gested that median ICS adherence to maintain asthma control is
in excess of 80% (Lasmar 2009). It may have been helpful for
interpretation if more trialists had prespecified what they consid-
ered to be ’acceptable’ adherence, for example, greater than 80%,
and had dichotomised participants into those achieving this level
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of adherence and those not achieving it. The clinical applicabil-
ity and usefulness of observed improvements in percent adher-
ence could be further disputed by observation of an inconsistent
impact on clinical outcomes such as asthma control, quality of
life or exacerbations. Most participants, despite improvements in
percent adherence, may not have reached the ’threshold’ neces-
sary for discernible clinical improvement (Comparisons 1 and 2),
or baseline/control group adherence was already at a high level
(Comparison 3), thus allowing little room for discernible improve-
ment (Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3). It must be noted that very
few studies specifically measured or reported adverse events be-
yond asthma-related events such as exacerbations. Therefore, we
cannot comment on the safety of the interventions studied.
Objectvely measured adherence would generally be considered
more reliable than patient-reported measures or pharmacy data.
In a post hoc decision, we presented objectively measured adher-
ence as our main adherence analysis. It came as a surprise that in
Comparison 1, limiting the analysis to objectively measured ad-
herence resulted in a greater effect size. One possible explanation
for this is that when participants were asked to self-report and had
received an educational intervention, they were able to make a
more realistic assessment of their adherence than were participants
in the control group, who may have consciously or unconsciously
inflated their adherences rates. This could have resulted in an un-
derestimation of the effect of the intervention.
Our protocol clearly stated that we would include only studies
for which adherence to ICS was the main aim of the trial. This
resulted in the exclusion of many studies for which adherence ed-
ucation was just one component of a broader asthma education
or self-management education intervention. This may have led to
the exclusion of potentially informative studies; however, their in-
clusion would have further hampered interpretation, as it would
be almost impossible to be sure which element of the intervention
had led to observed clinical benefit. Mann 1992 included a com-
parison (four-times-daily dosing) that is not relevant in current
practice, but we did not state that we would exclude ’historical’
comparisons, and this study was not combined with any other
study in a meta-analysis.
Some included studies specifically targeted people with poorly
controlled asthma, those known to have suboptimal adherence
levels or those in especially high-risk groups, such as adolescents.
We did not plan to analyse such trials separately from those that
recruited a more general asthma population. It may have been
illuminating to do so, as it is conceivable that these groups would
benefit most from a potentially resource-consuming intervention
and could be therefore be targeted in a real-world setting.
We were not able to carry out all of our planned subgroup analy-
ses, and our subgrouping by complexity may have imposed some
limitations. This was inevitably a subjective judgement, although
we involved all three review authors in the assessment and revised
three of our classifications after peer review. Some of the included
studies provided only a brief description of the intervention, which
also hampered our confidence in our classification. Although sub-
group analysis did not provide strong evidence that more complex
interventions are more effective than less complex interventions,
a different classification process may have led to different conclu-
sions.
Quality of the evidence
Studies were generally at low or unclear risk of selection bias, but
we downgraded many of the analyses for inherent risk of bias as-
sociated with studies of behavioural interventions that cannot be
blinded. To some extent, performance and detection biases varied
by outcome, and by the nature of interventions within a given
comparison, but we agreed that performance biases can be present
even for more objective outcomes (such as unscheduled visits or
exacerbations) because people who know they are receiving the
intervention, or know they are not, might be more or less likely to
visit their doctor or report a negative outcome. Lack of blinding
was a problem especially for self-rated outcomes such as asthma
control and quality of life and may have affected how participants,
study investigators and healthcare professionals behaved in each
group, producing a more indirect effect on other, more objec-
tive outcomes, including adherence itself. Thus, our confidence
in many of the outcomes was reduced by risk of bias, especially
when we had additional concerns about attrition or uncertainties
about the selection process.
Inconsistency between study results tended to be more of an is-
sue for adherence, and this may be explained at least in part by
methodological differences such as measurements used and length
of the study, or by differences in the underlying populations. Sub-
group analyses generally did not help to explain observed hetero-
geneity. Most studies showed better adherence in the intervention
group, but some outliers showed an effect close to no difference
or in the opposite direction, which reduced our confidence in the
findings.
Dichotomous analyses of fairly rare events such as exacerbations
and unscheduled visits tended to be limited by imprecision. For
these outcomes, confidence intervals stretched from an important
benefit of the intervention to a possible benefit of controls, which
prevented firm conclusions.
Indirectness of evidence was less of an issue in this evidence base,
as we applied eligibility criteria stringently. In only a couple of
instances, indirectness in themeasurement of an outcome reduced
our confidence in the effect (absences and unscheduled visits in
Comparison 1). Similarly, we did not detect or strongly suspect
publication bias for any outcomes.
Potential biases in the review process
34Interventions to improve adherence to inhaled steroids for asthma (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
As much as possible, we carried out this review as presented in
the published protocol (Kew 2016) and recorded deviations from
it under Differences between protocol and review. We could not
perform planned subgroup or sensitivity analyses on some out-
comes because studies were too few or fell into a single subgroup.
We did not attempt to contact study authors for additional out-
come data or risk of bias clarification owing to the number of stud-
ies identified. Therefore, we may have overstated the uncertainty
in risk of bias, particularly as related to allocation concealment.
Published reports may not have provided unpublished data that
were not included in the meta-analyses. However, it is unlikely
that eligible studies weremissed by the searches conducted because
they covered multiple sources and were sifted in duplicate.
We could not anticipate all the ways in which intervention groups
and control groups would differ across studies; as a result, our post
hoc classification of studies into four comparisons could have in-
troduced bias. It is conceivable that a different classification system
may have yielded different results.
Agreements and disagreements with other
studies or reviews
Several recent reviews have investigated adherence interventions
in people with chronic diseases, such as asthma. Both Ershad 2016
and Yasmin 2016 examined the effectiveness of text messaging in-
terventions for peoplewith chronic disease. Ershad 2016 presented
a narrative review that included six asthma studies. In keeping with
our review, these review authors found that text messaging was
effective in promoting adherence among different patient popula-
tions, although three of the asthma studies showed no differences
between groups in adherence to treatment. Yasmin 2016 included
two asthma studies of text message and voice call interactions.
These review authors concluded that people with chronic disease
showed improvement in adherence, but review authors did not see
a significant impact on clinical outcomes, which is consistent with
our findings. In addition, these review authors found variation
in types of interventions provided and outcome measurements
assessed, which made it difficult to draw firm conclusions, and
cost-effectiveness remains questionable. Anglada-Martinez 2014
reviewed m-health interventions proposed to increase medication
adherence and concluded that studies provided mixed evidence of
the benefits of these interventions, probably because of variation
in study methods. We also encountered problems with between-
study heterogeneity.
Hall 2014 considered effects of medical device dose memory func-
tions on medication adherence and included one study on asthma
medication adherence. These review authors found evidence of
benefit for these device functions in terms ofmedication adherence
and patient confidence in managing their condition. We did not
attempt to extract outcomes related to participant confidence or
self-efficacy.Wu 2014 reviewed adherence interventions delivered
by healthcare providers and included 23 studies of people with
asthma, most of whom were children. Review authors found that
interventions delivered by a healthcare provider improved adher-
ence and recommended that future reviews should focus on partic-
ular patient populations and adherence behaviours. They planned
to perform subgroup analyses based on the identified recipient of
the intervention but were unable to do so, as all interventions were
delivered directly to study participants.
Recent reviews of adherence interventions among asthma popula-
tions show a similar picture. Dibello 2014 brought together trials
of text messaging services aimed at adults 18 to 45 years of age.
Review authors found that adherence improved and noted some
impact on control and lung function. However, they were not able
to perform ameta-analysis because of heterogeneity. Tran 2014 re-
viewed studies of patient reminder systems. These review authors
were not able to pool the data but concluded, ”All studies in our
analysis suggest that reminder systems increase patient medication
adherence, but none documented improved clinical outcomes“.
Bårnes 2015 provides a wide-ranging review of adherence in
asthma and includes studies on adherence levels and effects of poor
adherence, as well as studies of interventions aimed at improv-
ing adherence. In the intervention studies, review authors found
mixed results, with most studies showing improved adherence,
although this did not always translate to improvement in other
outcomes.
The results of our review of interventions to improve adherence in
asthma are consistent with the findings of other reviews examining
asthma populations and the broader category of chronic disease,
as described. We found that adherence rates increased, but that
the impact on clinical outcomes was unclear, and our conclusions
must be considered in the light of variation across studies. Our
reviewdiffers in thatwe have drawndifferent types of interventions
together into a single review that focuses on people with asthma
rather than on a broader category of chronic disease, and, when
appropriate, we have been able to pool study results.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our findings suggest that interventions to improve ICS adher-
ence in adults and children with asthma can increase adherence,
whether objectively or subjectively measured. This finding was
consistent across the three comparisons performed tomeasure this.
The clinical relevance of this improvement, highlighted by uncer-
tain and inconsistent impact on clinical outcomes such as quality
of life and asthma control, is less clear. Overall, we have low to
moderate confidence in these findings owing to concerns about
risk of bias and inconsistency.
Implications for research
Guidelines for asthma management consistently call for routine
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discussion of adherence with patients, and evidence suggests that
poor adherence may contribute to unfavourable outcomes. This
fact emphasises the importance of research conducted to investi-
gate interventions that may be recommended to practitioners and
their patients. Future studies would benefit from ensuring that
investigators use validated tools for outcome measurement, such
as the Asthma Control Test (ACT), the Asthma Control Ques-
tionnaire (ACQ) and the Asthma Quality of Life Questionnaire
(AQLQ), and provide adequate details regarding baseline asthma
severity amongparticipants.Given that our confidence in our find-
ings was reduced by concerns about performance and detection
biases, we suggest that some form of blinding or active control is
important to include, when possible. This would help to elucidate
the contribution of the intervention itself to improved adherence,
beyond the potential benefit of inclusion in an adherence trial. It
may be helpful for trialists to prespecify a threshold for ’acceptable’
adherence and to perform a dichotomous analysis of those achiev-
ing this level and those not achieving it. The inconsistent impact
observed in terms of clinical outcomes may have occurred because
most participants did not achieve this threshold (Comparisons 1
and 2), or because baseline/control group adherence was already at
a high level (Comparison 3). Targeting those at high risk or known
to have poor adherence may provide evidence that is more ’useful’
in the real world, which may be affected by budget constraints.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ACTRN12606000508572
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 24 weeks
Setting:Medical Research Institute of New Zealand and the P3 Research Clinical Trials
Unit at Bowen Hospital, Wellington, New Zealand
Trial registration: ACTRN12606000508572
Participants Population: 111 adolescents and adults with asthma randomised to intervention (com-
bination inhaler) (n = 57) or control (separate inhaler) (n = 54)
Age: 16 to 65 years; mean (SD) age in the adherence group 45.5 (13.8) years and in the
control group 49.2 (11.2) years
Baseline asthma severity: Those with a significant exacerbation in the last month were
excluded
Inclusion criteria: adults in the Wellington region 16 to 65 years of age; diagnosis of
asthma; and currently taking ICS at a stable dose with or without a separate LABA
inhaler
Exclusion criteria: diagnosis of chronic obstructive pulmonary disease, current use of a
combination ICS/LABA inhaler, pregnant or lactating women, history of other clinically
significant disease, significant exacerbation of asthma in the previous month requiring
clinic or hospital attendance
Percentage withdrawn: 5.3% from the adherence group and 9.3% from the control
group
Other allowed medication: not reported
Interventions Intervention summary: 125 mg FP and 25 mg salmeterol in a combination Smartin-
haler, 2 actuations twice daily. The Smartinhaler casing recorded the date and time of
each actuation. Participants were not told that adherence would be monitored
Control summary: 125 mg FP and 25 mg salmeterol in separate Smartinhalers, 2
actuations twice daily. The Smartinhaler casing recorded the date and time of each
actuation. Participants were not told that adherence would be monitored
Complex intervention: no
Outcomes Outcomes measured: FEV1, ACQ, Asthma Exacerbation Questionnaire, need for oral
steroids or doctor visits over previous 6 weeks. Primary adherence measure was percent-
age of doses taken over last 6 weeks of the study; secondary adherence measures were
adherence during the other 6-week periods of the study, percentage of fully adherent
days, proportion who were > 50%, > 80% or > 90% adherent over each 6-week period,
overuse defined as > 2 doses taken within a 6-hour period or > 4 doses within a 24-hour
period (% of days when this occurred)
Adherence calculation: electronic Smartinhaler data - number of doses taken as a per-
centage of those prescribed. All calculations were made after exclusion of dose dumping,
defined as 6 or more actuations within a 5-minute period
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ACTRN12606000508572 (Continued)
Notes Type of publication: single peer-reviewed journal article
Funding: GlaxoSmithKline (GSK)
GSK ID number: SAM106689
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Randomization was by computer-gener-
ated random code supplied by a statisti-
cian. The sequence was imbedded in a Mi-
crosoft Access Database (Microsoft Corp,
Redmond, Wash) by a third party and con-
cealed from the researchers until the time
the subject was enrolled and entered into
the database“
Allocation concealment (selection bias) Low risk ”The sequence was imbedded in a Mi-
crosoft Access Database (Microsoft Corp,
Redmond, Wash) by a third party and con-
cealed from the researchers until the time
the subject was enrolled and entered into
the database“
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Although participants were aware that they
were taking combined or separate inhalers,
adherence was measured covertly with a
SmartInhaler; this was the main outcome
measured. However, ACQ may be at risk
of performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Although blinding of outcome assessors
was not described, adherence was mea-
sured objectively with a SmartInhaler; this
was the only outcome measured. However,
ACQ is participant reported and may be at
risk of detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 8 participants withdrew (3 from the
combined inhaler group and 5 from the
separate inhaler group). All are accounted
for in the flow diagram, and drop-out oc-
curred for similar reasons
Selective reporting (reporting bias) High risk Prospectively regis-
tered trial (ACTRN12606000508572). All
outcomes listed in trial registration have
been clearly reported, but the study men-
tions the Asthma Exacerbation Question-
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ACTRN12606000508572 (Continued)
naire and the need for oral steroids and doc-
tor visits over the previous 6 weeks, which
are not reported in the paper
Other bias Low risk None noted
ACTRN12607000489493
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 4 months
Setting: 1 paediatric asthma clinic within an outer metropolitan general hospital in
Australia
Trial registration: not reported
Participants Population: 26 children with asthma randomised to receive adherence feedback (n =
14) or usual care (n = 12)
Age: 6 to 14 years; mean age in the adherence feedback group 9.1 years and in the control
group 9.3 years
Baseline asthma severity: intervention group: FEV1 % predicted = 72.9, mean fluti-
casone dose (mcg/d) 300; number with symptoms or reliever use 3 or more times per
week = 10. Control group: FEV1 % predicted = 77.5, mean fluticasone dose (mcg/d)
250, number with symptoms or reliever use 3 or more times per week = 8
Inclusion criteria: Children given a diagnosis of asthma at between 6 and 14 years of
age (inclusive) were eligible for enrolment if their asthma was not well controlled despite
prescribed preventive medication. Suboptimal control was based on reported history of
asthma symptoms (wheeze or limitation of activity) occurring more than twice a week
and requiring reliever medication and/or reduced lung function (reproducible FEV1 <
80% predicted)
Exclusion criteria: not reported
Percentage withdrawn: no withdrawal from trial
Other allowed medication: not reported
Interventions Intervention summary: Adherence data collected via Smartinhaler were shared with the
child, parent and physician during consultation for those allocated to the intervention
group. These data were incorporated in the management plan for the coming month.
Reviews were performed monthly with the child’s usual physician
Control summary: Children in the control group had their Smartinhaler collected
and were given a new device. Their adherence remained unknown to parent, child and
respiratory physician. Reviews were performed monthly with the child’s usual physician
Complex intervention: yes
Outcomes Outcomes measured: adherence, symptoms (via questionnaire), lung function
Adherence calculation: Adherence was calculated as a percentage of prescribed doses
registered by the Smartinhaler, between midnight and midday or between midday and
midnight for morning and evening doses, respectively, or at any time during the day for
once-daily dosing
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ACTRN12607000489493 (Continued)
Notes Type of publication: single peer-reviewed full-text journal article
Funding: not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”After providing informedwritten consent,
children were randomly allocated to either
the intervention or control group through
the use of sealed opaque envelopes“
Not clear how the order of sealed envelopes
was generated
Allocation concealment (selection bias) Low risk ”After providing informedwritten consent,
children were randomly allocated to either
the intervention or control group through
the use of sealed opaque envelopes“
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel
described. Although primary outcome - ad-
herence - was measured by an electronic
counter, other outcomes (such as SABA
use) may be subject to performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessors de-
scribed.Main outcome - adherence - objec-
tively measured, but other outcomes (such
as reported SABA use) subject to detection
bias as the unblinded parent is the outcome
assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Selective reporting (reporting bias) Unclear risk No prospective trial registration identified;
symptoms measured but not reported so
could not be included in meta-analysis. No
measure of variance is given for the adher-
ence outcome, nor for the secondary out-
comes of FEV1 and controller medication
use. P values are not exact (1 decimal place)
. Other outcomes reported appropriately
Other bias Low risk None noted
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ADERE PEDIATRIC 1
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 90 weeks
Setting: 1 site. Brazil
Trial registration: ADERE PEDIATRIC 1 (GSK trial register)
Participants Population: 298 childrenwith asthma randomised to a telephone follow-up intervention
(n = 149) or to usual care (n = 149)
Age: 6 to 14 years; mean age (SD) in the intervention group 8.9 (2.4) years and in the
control group 9.0 (2.5) years
Baseline asthma severity: Of those who completed the trial in the intervention group,
67 had moderate and 41 severe asthma, and in the control group, 74 had moderate and
37 severe asthma
Inclusion criteria: moderate or severe asthma defined by SPT II Brazillian Consensus
on Asthma Management
Exclusion criteria: comorbidities that may interfere with study evaluation, systemic
steroids required for more than 7 days; patients treated with allergen immunotherapy
Percentage withdrawn: 28% from the intervention group and 27% from the usual care
group
Other allowed medication: not reported
Interventions Intervention summary: medical guidance and follow-up telephone call from a health-
care professional every 15 days
Control summary: medical guidance; no telephone follow-up
Complex intervention: no
Outcomes Outcomes measured: level of compliance, disease control evaluated by 5-point ques-
tionnaire, quality of life (SF-36)
Adherence calculation: percentage of actual number of doses of salmeterol/fluticasone
propionate divided by number of expected doses
Notes Type of publication: pharmaceutical company report
Funding: GlaxoSmithKline
NB: participants from non-intervention group not followed up, no conclusions drawn
from protocol. No peer-reviewed publication
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Subjects were randomized to intervention
or non-intervention“ - no further details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel;
described as open-label
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ADERE PEDIATRIC 1 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessors; de-
scribed as open-label
Incomplete outcome data (attrition bias)
All outcomes
High risk > 25% drop-out in both groups. Control
group not followed up as planned, so miss-
ing data for entire outcomes for this group.
Study protocol was violated
Selective reporting (reporting bias) High risk Multiple planned outcomes, including pri-
mary outcome (adherence ’not available’),
or available only for the intervention group
Other bias Low risk None noted
Bender 2010
Methods Design: single-blind, parallel-group randomised controlled trial
Duration: 10 weeks
Setting: single site; participants recruited through newspaper adverts; in association with
community allergy practices. USA
Trial registration: not reported
Participants Population: 50 adults with asthma randomised to an interactive voice response (IVR)
intervention (n = 25) or usual care (UC) (n = 25)
Age: 18 to 65 years; mean age (SD) in IVR group 39.6 (12.8) years and in UC group
43.5 (14.3) years
Baseline asthma severity: physician-diagnosed asthma for which they were prescribed
daily inhaled corticosteroid treatment; no other severity information given
Inclusion criteria: adults 18 to 65 years old who had physician-diagnosed asthma for
which they were prescribed daily inhaled corticosteroid treatment. Participants were
recruited through newspaper advertising and in co-operation with community allergy
practices and received $25 for each completed study visit
Exclusion criteria: significant disease or disorder that, in the opinion of the investigator,
might influence results of the study or the patient’s ability to participate in the study
(this included other chronic health disorders, current substance abuse or dependence,
mental retardation or psychiatric disorder); current participation in another asthma-
related research or clinical trial
Percentage withdrawn: no withdrawal
Other allowed medication: not specifically reported
Interventions Intervention summary: 2 automated IVR telephone calls separated by 1 month, with 1
additional call if recently reported symptoms of poorly controlled disease or failure to fill a
prescription. Calls were completed in less than 5 minutes and included content designed
to inquire about asthma symptoms, deliver core educationalmessages, encourage refilling
of inhaled corticosteroid prescriptions and increase communication with providers
Control summary: usual care
Complex intervention: no
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Bender 2010 (Continued)
Outcomes Outcomes measured: AQLQ, ACT, BMQ, adherence with use of an electronic monitor
Adherence calculation: electronic adherence device or canister weight to give a mean
% adherence (exact details of calculation not provided)
Notes Type of publication: single peer-reviewed full-text journal article
Funding: supported by the Investigator-Sponsored Study Program of AstraZeneca
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomization table generated before
study initiation determined group assign-
ment by order of entry into the study
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants described.
Main outcome - adherence - objectively
measured, but other outcomes such as
ACQ and AQLQ subject to performance
bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Investigators remained blind to treatment
until final data set was completed. How-
ever, for participant-reported outcomes
such a AQLQ and ACQ, the participant is
the outcome assessor; therefore these out-
comes are at high risk of detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Although attrition not specifically re-
ported, end of study data given for all 50
randomised participants
Selective reporting (reporting bias) Unclear risk No prospective trial registration identified,
but all outcomes stated in methods clearly
reported
Other bias Low risk None noted
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Black 2008
Methods Design: parallel-group randomised controlled trial; blinding not stated
Duration: 2 months
Setting: set in New Zealand; no other details reported
Trial registration: not reported
Participants Population: 40 children with asthma randomised to an inhaler alarm intervention (n =
20) or usual care (n = 20)
Age: 7 to 17 years; no further details reported
Baseline asthma severity: ’symptomatic asthma despite being on inhaled corticosteroids’
Inclusion criteria: children aged 7 to 17 years with symptomatic asthma despite taking
inhaled corticosteroids
Exclusion criteria: not reported
Percentage withdrawn: withdrawal not reported
Other allowed medication: not reported
Interventions Intervention summary: inhaler alarm with 14 different tones, 1 for each morning and
evening of the week
Control summary: usual care (inhaler alarm turned off )
Complex intervention: no
Outcomes Outcomes measured: AQLQ, prebronchodilator FEV1, use of salbutamol, adherence
to inhaled steroid
Adherence calculation: Adherence was expressed as a percentage; exact calculation not
reported
Notes Type of publication: conference abstract
Funding: not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel
described. Some outcomes (e.g. AQLQ)
may be influenced by knowledge of group
allocation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Noblinding of outcome assessor described,
and not clear how adherence data were col-
lected and calculated. Self-report outcomes
(e.g. AQLQ) may be subject to detection
bias
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Black 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition not reported
Selective reporting (reporting bias) High risk Conference abstract; no trial registration
identified. Study reported only as a confer-
ence abstract from 2008 and does not ap-
pear to have been published in full. There-
fore, limited details about methods and
outcomes, in particular, nomeasure of vari-
ance for the AQLQ
Other bias Low risk None noted
Bosley 1994
Methods Design: open-label, multi-centre, parallel-group randomised controlled trial
Duration: 12 weeks
Setting: 4 general practices and a hospital outpatient clinic. UK
Trial registration: not reported
Participants Population: 102 adults with asthma randomised to receive a combined inhaler (n = 51)
or separate inhalers (n = 51)
Age: 18 to 70 years; mean age of all trial completers (36 in each group) 44 years (range
20 to 69 years)
Baseline asthma severity: mean duration of illness 13.9 years (range 0.25 to 54 years).
No details of baseline asthma severity given
Inclusion criteria: patients with asthma, 18 to 70 years of age, who required treatment
with regular inhaled steroids and beta-agonists (as assessed by their own doctor)
Exclusion criteria: not reported
Percentage withdrawn: 30% from each trial arm
Other allowed medication: not reported
Interventions Intervention summary: Treatment group was given 1 Turbuhaler inhaler containing a
fixed combination of terbutaline (250 µg per dose) and budesonide (100 µg per dose)
Control summary:Control group was given 2 Turbuhaler inhalers - 1 containing terbu-
taline (250 µg per dose) and 1 containing budesonide (100 µg per dose)
Complex intervention: no
Outcomes Outcomes measured: adherence, lung function measures (FVC and FEV1)
Adherence calculation: percent adherence = number of doses taken × 100/number of
doses prescribed - measured using Turbuhaler Inhalation Computer
Notes Type of publication: single peer-reviewed full-text journal article
Funding: study funded by the Astra Clinical Research Unit, which also provided the
Turbuhaler Inhalation Computer
Risk of bias Risk of bias
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Bosley 1994 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”They were randomly divided into treat-
ment and control groups“ - no further de-
tails
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Open-label design; although outcomes (ad-
herence with an electronic monitor and
lung function) are unlikely to be highly sus-
ceptible to influence according to partici-
pants’ and personnel’s knowledge of group
allocation. ”In order to obtain as accurate
a picture of “normal” behaviour as possi-
ble, patients were not told that the Tur-
buhalers contained TICs [Turbuhaler In-
halation Computer] or that their compli-
ance was being monitored“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Open-label design, although outcomes (ad-
herence with a covert electronic monitor
and lung function) are unlikely to be highly
susceptible to influence according to out-
come assessors’ knowledge of group alloca-
tion
Incomplete outcome data (attrition bias)
All outcomes
High risk Approximately 30% drop-out in both arms
of the trial. Participants who dropped out
were younger but otherwise did not dif-
fer from those who completed according to
trial report. However, no flow diagram pre-
sented, so unclear if reasons for drop-out
were balanced
Selective reporting (reporting bias) Unclear risk No prospective trial registration identified,
but all outcomes stated in methods clearly
reported
Other bias Low risk None noted
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Burgess 2007
Methods Design: parallel-group randomised controlled trial; blinding not stated
Duration: 13 weeks
Setting: private and public paediatric respiratory clinics. Australia
Trial registration: not reported
Participants Population: 47 children with asthma randomised to receive a ’Funhaler’ (n = 26) or a
control spacer (n = 21)
Age: 18 months to 7 years; mean age in the Funhaler group 3.4 years and in the control
group 3.8 years
Baseline asthma severity: intervention group: mean frequency of wheeze (5-point scale)
= 1.9; number with exacerbation in previous month = 8; mean fluticasone dose (mg/d)
= 166. Control group: mean frequency of wheeze (5-point scale) = 1.9; number with
exacerbation in previous month = 3; mean fluticasone dose (mg/d) = 193
Inclusion criteria: children with diagnosis of asthma, 18months to 7 years of age, taking
preventive asthma medication on a daily basis
Exclusion criteria: not reported
Percentage withdrawn: 8% from the intervention arm and 5% from the control arm
Other allowed medication: not reported
Interventions Intervention summary: small-volume spacer that incorporates an incentive toy (spin-
ning disk and whistle) that is driven by the child’s expired breath (the ’Funhaler’)
Control summary: a control spacer (Aerochamber Plus)
Complex intervention: no
Outcomes Outcomes measured: adherence, symptoms (from a ’symptoms questionnaire’), exac-
erbations (defined as the child having received a course of prednisolone initiated by the
parent in response to an escalation of symptoms requiring regular reliever medication
more than 4th-hourly for 24 hours as per asthma management plan or prescription of
prednisolone by the child’s primary care physician)
Adherence calculation: Adherence was evaluated as a percentage of prescribed doses
registered by the Smartinhaler between midnight and midday and between midday and
midnight for morning and evening doses, respectively, or at any time during the day for
once-daily dosing
Notes Type of publication: single peer-reviewed full-text journal article
Funding: not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”All subjects were then randomized to ei-
ther the FunHaler or a control spacer
using a minimization computer program
(Minim) with equal weighting for age, sex
and level of maternal education“
Allocation concealment (selection bias) Unclear risk No details
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Burgess 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel
described. Although primary outcome - ad-
herence - was measured by an electronic
counter, other outcomes (such as symp-
toms) may be subject to performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessors de-
scribed.Main outcome - adherence - objec-
tively measured, but other outcomes (such
as symptoms) subject to detection bias, as
the unblinded parent is the outcome asses-
sor
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition low and balanced (< 10% in both
arms) and all drop-outs accounted for
Selective reporting (reporting bias) Unclear risk No prospective trial registration identified;
symptoms measured but not reported nu-
merically so could not be included inmeta-
analysis. Other outcomes reported appro-
priately
Other bias Low risk None noted
Chan 2015
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 6 months
Setting: participants recruited from emergency departments, followed up in community.
New Zealand
Trial registration: ACTRN12613001353785
Participants Population: 220 children with asthma randomised to receive an audiovisual inhaler
reminder (n = 110) or usual care (n = 110)
Age: 5 to 15 years; mean age (SD) in audiovisual reminder group was 8.9 (2.5) years
and in control group was 8.9 (2.6) years
Baseline asthma severity: intervention group: mean (SD) asthma morbidity score 9.3
(2.2); mean (SD) Childhood Asthma Control Test score 18.8 (4.4); mean (SD) FEV1
(% predicted) 92 (17). Control group: mean (SD) asthma morbidity score 9.2 (2.5)
; mean (SD) Childhood Asthma Control Test score 18.8 (4.2); mean (SD) FEV1 (%
predicted) 90 (17)
Inclusion criteria: children and adolescents 6 to 15 years of agewho attended the regional
emergency department in Auckland, New Zealand, with a suspected diagnosis of asthma
exacerbation and were screened for eligibility; patients with a diagnosis of acute asthma
who were on treatment or needed treatment with twice-daily inhaled corticosteroids
Exclusion criteria: diagnosis of a chronic lung disease other than asthma, congenital
heart disease; living outside the Auckland catchment area; diagnosis of a severe chronic
medical disorder that causes impaired immunity or increased morbidity
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Chan 2015 (Continued)
Percentage withdrawn: 2% from the intervention arm and 5% from the control arm
Other allowed medication: other asthma drugs, including LABAs and theophylline
Interventions Intervention summary: covert electronic monitoring device for use with preventive
inhalers (SmartTrack) with the audiovisual function enabled
Control summary: covert electronic monitoring device for use with preventive inhalers
(SmartTrack) with the audiovisual function disabled
Complex intervention: no
Outcomes Outcomes measured: adherence to preventive inhaled corticosteroids; number of days
absent from school and whether or not parents or carers were absent from work for 1
day or longer; asthma control (cACT); asthma symptoms (Asthma Morbidity Score)
; exacerbations since previous visit; unscheduled doctor, emergency clinic or hospital
visits; rescue medication use; lung function
Adherence calculation: Adherence was defined as the proportion of preventer doses
taken relative to the number of doses prescribed. This proportion was calculated by
measuring the degree of deviation from the prescribed dose up to the prescribed dose (i.
e. non-adherence, up to a maximum of 0% non-adherence) and subtracting from 1 (i.
e. 100% adherence)
Notes Type of publication: single peer-reviewed full-text journal article
Funding: Health Research Council of New Zealand and Cure Kids
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Using a simple, unrestricted block ran-
domisation with block sizes of 200, we ran-
domly assigned patients“
Allocation concealment (selection bias) Low risk ”The study statistician provided the ran-
domisation group to investigators in
opaque, sealed envelopes, which were
opened by investigators and research assis-
tants in consecutive order to allocate par-
ticipants to their randomisation group. En-
velopes were sealed to investigators, and re-
search assistants did not know the next al-
location group“
Blinding of participants and personnel
(performance bias)
All outcomes
High risk ”Participants were unaware of the adher-
ence monitoring function of either device,
but were informed that the reliever mon-
itoring device was to be used with their
reliever inhaler to enable investigators to
know when the drug was running out“
Primary outcome - adherence - was moni-
tored covertly and objectively with an elec-
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Chan 2015 (Continued)
tronic device. However, other outcomes
such as cACT are subject to risk of perfor-
mance bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessors de-
scribed. Primary outcome - adherence - was
monitored covertly and objectively with
an electronic device. However, other out-
comes such as cACT and parent-reported
exacerbations are subject to risk of detec-
tion bias, as participant or parent is the out-
come assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low drop-out (< 5%) in both arms; all par-
ticipants accounted for and ITT analysis
performed
Selective reporting (reporting bias) Low risk Retrospectively registered trial. All planned
outcome measures in trial registration and
methods reported
Other bias Low risk None noted
Charles 2007
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 24 weeks
Setting: participants recruited from research volunteer databases, newspaper advertise-
ments and informal contacts. New Zealand
Trial registration: not reported
Participants Population: 110 people with asthma randomised to receive an audiovisual inhaler re-
minder (n = 55) or usual care (n = 55)
Age: 12 to 65 years; median age (range) in audiovisual reminder group was 39 (13 to
65) years and in control group was 35 (15 to 64) years
Baseline asthma severity: intervention group: baseline ICS dose: median (range) 500
(100 to 2000); PEF: mean (SD) 434 (99). Control group: baseline ICS dose: median
(range) 500 (100 to 4000); PEF: mean (SD) 444 (128)
Inclusion criteria: requirement to take regular ICS at a fixed dose, no exacerbation in
previous month or run-in period, not pregnant or lactating;if of child-bearing potential,
using contraception
Exclusion criteria: diagnosis of chronic obstructive pulmonary disease, use of a long-
acting beta-agonist, history of other clinically significant disease. Individuals were re-
quired to not be taking a long-acting beta-agonist to avoid the potential influence of
such treatment on adherence to ICS therapy
Percentage withdrawn: 20% from the intervention arm and 16% from the control arm
Other allowed medication: not reported, apart from the criterion that participants
could NOT be taking a long-acting beta-agonist
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Charles 2007 (Continued)
Interventions Intervention summary: covert electronic monitoring device for use with preventive
inhalers (SmartInhaler) with the audiovisual function enabled
Control summary: covert electronic monitoring device for use with preventive inhalers
(SmartInhaler) with the audiovisual function disabled
Complex intervention: no
Outcomes Outcomes measured: adherence to ICS, Asthma Control Questionnaire (ACQ), peak
expiratory flow (PEF)
Adherence calculation: adherence defined as the proportion of medication taken as
prescribed over the latter half of the trial (expressed as a percentage)
Notes Type of publication: single peer-reviewed full-text journal article
Funding: supported by a research grant from GlaxoSmithKline, UK. The sponsor had
no involvement in study design; collection, analysis or interpretation of data; writing of
the report; or the decision to submit for publication
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”The randomization was by reference to a
computer-generated random code“
Allocation concealment (selection bias) Low risk ”The randomization was by reference to
a computer-generated random code con-
cealed from the researcher who opened an
envelope at the time of randomization“
Blinding of participants and personnel
(performance bias)
All outcomes
High risk ”Subjects were informed that the purpose
of the study was to determine the out-
come when patients with asthma on a wide
range of ICS doses and inhaler devices were
changed to standard treatment via the novel
Smartinhaler MDI device. Subjects were
not informed of the electronic adherence
monitor placed within their FP MDI“
Primary outcome - adherence - was moni-
tored covertly and objectively with an elec-
tronic device. However, other outcomes
such as ACQ are subject to risk of perfor-
mance bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessors de-
scribed. Primary outcome - adherence - was
monitored covertly and objectively with
an electronic device. However, other out-
comes such as ACQ are subject to the risk
of detection bias, as the participant is the
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outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Drop-out moderately high (16% to 20%)
, although quite balanced. All participants
accounted for in flow diagram. 11 partici-
pants in the intervention group and 9 par-
ticipants in the control group ”did not pro-
vide data“ in the final 12-week period of
the study. It is not clear whether these par-
ticipants were included in the analysis
Selective reporting (reporting bias) Unclear risk No prospective trial registration identified,
but all outcomes stated in methods clearly
reported
Other bias Low risk None noted
Chatkin 2006
Methods Design: open-label, parallel-group, multi-centre randomised controlled trial
Duration: 13 weeks
Setting: ’15 states of the country’. Brazil
Trial registration: not reported
Participants Population: 271 people with asthma randomised to receive telephone calls to promote
adherence (n = 140) or usual care (n = 131)
Age: 12 years of age and older; mean age (SD) in the telephone call group was 43.3 (15)
years and in the control group was 44.4 (16.6) years
Baseline asthma severity: intervention group: proportion with severe persistent asthma
47.1%; proportionwith history of asthma emergencies 30.7%; proportionwith history of
asthma hospitalisations 48.6%. Control group: proportion with severe persistent asthma
47.3%; proportion with history of asthma emergencies 38.9%; proportion with history
of asthma hospitalisations 53.4%
Inclusion criteria: 12 years of age or older with moderate to severe persistent asthma
according to GINA criteria and the Third Brazilian Consensus on AsthmaManagement;
residential phone number; ability to comprehend study procedures and to sign the
relevant consent form
Exclusion criteria: mild persistent asthma, pregnancy or breast feeding, intention to
move during the study, regular use or recent past abuse of alcohol or illicit drugs, clinically
significant active general medical conditions
Percentage withdrawn: Report states that 293 participants were ’screened’; 4 were ex-
cluded for not fulfilling inclusion criteria, 8 for not responding to telephone calls and
10 for not returning the monitoring disk to the office. It is not clear whether these par-
ticipants were excluded before or after randomisation, and if after randomisation, from
which arm they were excluded. Baseline characteristics and results are given for only 271
participants
Other allowed medication: not reported
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Interventions Intervention summary: telephone calls every 2 weeks to reinforce asthma management
and to promote adherence, delivered by a specially trained nursing student
Control summary: usual care
Complex intervention: no
Outcomes Outcomes measured: adherence
Adherence calculation: percentage of patients taking 85% or more of prescribed doses
as measured by electronic monitor
Notes Type of publication: single peer-reviewed full-text journal article
Funding: funded by GSK-Brazil
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Subjects were randomized“ - no further
details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding of participants or person-
nel described. However, the only outcome
measured - adherence - was monitored ob-
jectively with an electronic device
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding of participants or person-
nel described. However, the only outcome
measured - adherence - was monitored ob-
jectively with an electronic device
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Drop-out not reported for each arm (22
dropped out in total); total numbers ran-
domised at start of intervention not clear
Selective reporting (reporting bias) High risk No prospective trial registration identified.
Adherence not reported in a way that can
be included in a meta-analysis (percentages
per groupwith nomeasure of variance, only
an inexact P value
Other bias Unclear risk None noted
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Foster 2014
Methods Design: open-label, 4-arm cluster randomised trial
Duration: 6 months
Setting: 60 GPs. To minimise cross-contamination between intervention groups, only
1 GP from a practice could participate. Australia
Trial registration: ACTRN12610000854033
Participants Population: 60 GPs (of which 55 attended training, and 43 were available to enrol
patients)were randomised to be trained in 1 of the following 4 interventions: personalised
adherence discussion (PAD); inhaler reminders and feedback (IRF); PAD + IRF; or usual
care. GP participants then enrolled 143 patient participants between them; PAD n = 24;
IRF n = 35; PAD + IRF n = 41; usual care n = 43
Age: enrolled patients 14 to 65 years of age; mean age (SD) in PAD group 42.3 (15.6)
years; in IRF group 40 (30.7) years; in PAD + IRF group 39.7 (17.1) years; in usual care
group 40 (14.1) years
Baseline asthma severity: FEV1 % predicted mean (SD) in the PAD group 67.3 (21.
3); in the IRF group 84.4 (19.4); in the PAD + IRF group 78.0 (15.2); in the usual
care group 75.7 (22.0); percentage prescribed high-dose (> 500 mcg/d) inhaled steroids:
PAD group 54%, IRF group 40%, PAD + IRF group 66%, usual care group 44%
Inclusion criteria: 14 to 65 years of age; suboptimal asthma control; twice-daily ICS/
LABA for at least 1 month
Exclusion criteria: asthma exacerbation in the last month; use of combined inhaler
as maintenance/reliever; major respiratory disease (e.g. COPD); serious uncontrolled
medical conditions; clinically important visual or auditory impairment; shift workers
with a variable roster; pregnant or lactating women
Percentage withdrawn: 13% from the PAD arm, 0% from the IRF arm, 22% from the
PAD + IRF arm, 5% from the usual care arm
Other allowed medication: not reported
Interventions Intervention summary (1): PAD:GPs asked participants to complete a short question-
naire about barriers to controller inhaler use. GPs were trained to carry out a personalised
discussion about the participant’s key barrier(s) to adherence and to help the participant
set goals and goal-achievement strategies around an asthma issue that the participant
wished to resolve, using patient-centered materials
Intervention summary (2): IRF: Participants received twice-daily SmartTrack re-
minders for missed ICS/LABA doses. They could customise ringtones/ring times, cancel
individual reminders or switch reminders off completely. Each month, GPs received an
automated e-mail to view a website graph of their patients’ daily ICS/LABA use; the
participant could log in to view his or her own graph at any time. GPs were asked to
discuss the ICS/LABA use graph with the participant at the study follow-up visit or at
any subsequent appointments, at the GP’s discretion. Only GPs in PAD groups were
trained in specific communication strategies for discussing adherence
Intervention summary (3): PAD + IRF: both PAD and IRF components as outlined
above
Control summary: All GPs in all groups received usual care training. This included
advice on writing an asthma action plan (10 minutes), demonstration and review of
inhaler technique (10 minutes) and recent changes to asthma guidelines (15 minutes)
Complex intervention: yes
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Outcomes Outcomes measured: ACT score;Mini-AQLQ;HADS;MARS-A; FEV1; exacerbations
Adherence calculation: monitored with SmartTrack device on inhaler. Calculation of
adherence not described
Notes Type of publication: single peer-reviewed full-text journal article
Funding: National Health and Medical Research Council of Australia (ID571053)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Each GP’s patients represented 1 cluster.
GPs were randomized separately 1:1 to ac-
tive and control groups for the 2 inter-
ventions, using a 2 × 2 factorial design,
allowing the effect of the 2 interventions
(given in addition to UC) to be tested sep-
arately and together, in comparison with
UC alone. Randomization of GPs was by a
computer-generated program prepared by
an independent statistician before study
start, with an automated minimization al-
gorithm to ensure a balance of randomiza-
tion across 3 stratification factors“
Allocation concealment (selection bias) Unclear risk ”Allocation concealment for GPs was
maintained before study start, and revealed
to each GP only during the training work-
shop“
However, it is unclear whether allocation
was concealed from investigators until ran-
domisation had occurred
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants (GPs or their
patients) described. Most of the outcomes
measured are subjective and are susceptible
to influence from knowledge of group al-
location
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Primary outcome - ACT - was collected via
telephone by a researcher blinded to group
allocation. However, for many outcomes,
measures are subject to risk of detection
bias, as the participant is the outcome as-
sessor
Incomplete outcome data (attrition bias)
All outcomes
High risk Primary analysis was by intention to treat.
However, drop-out was somewhat unbal-
anced, with 5% dropping out from the
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usual care group, 13% from the PAD
group, 0% from IRF group and 21% from
the IRF + PAD group
Selective reporting (reporting bias) Unclear risk No prospective trial registration identified,
but all outcomes stated in methods clearly
reported
Other bias Low risk None noted
Gallefoss 1999
Methods Design: single-blind, parallel-group randomised controlled trial
Duration: 1 year
Setting: recruited at outpatient chest clinic and followed up by GPs. Norway
Trial registration: not reported
Participants Population: 78 adults with asthma randomised to an asthma education intervention (n
= 39) or usual care (n = 39)
Age: 18 to 70 years; mean age (SD) in the intervention group 41 (12) years and in the
control group 44 (12) years
Baseline asthma severity: FEV1 % predicted (SD) in the intervention group 93 (13)
and in the control group 95 (17). 95% were using an ICS at baseline in the intervention
group and 97% in the control group
Inclusion criteria: asthma, defined as prebronchodilator FEV1 ≥ 80% of predicted
value; positive reversibility test;documented 20% spontaneous variability (PEF or FEV1)
; positive methacholine test
Exclusion criteria: unstable coronary heart disease, heart failure, serious hypertension,
diabetes mellitus, kidney or liver failure
Percentage withdrawn: 18% from the intervention group and 0% from the usual care
group
Other allowed medication: not reported
Interventions Intervention summary: patient brochure; 2 × 2 hour group sessions (separate groups
for asthma and COPDpatients). First session delivered by doctor, second by pharmacist;
1 or 2 individual sessions with nurse or physiotherapist; individual treatment plan
Control summary: standard treatment plan; GP follow-up for 1 year
Complex intervention: yes
Outcomes Outcomes measured: patient compliance, GP visits, absenteeism, days in hospital
Adherence calculation: Medication compliance was coded to Daily Defined Doses
(DDD). Dispensed medication reported from local pharmacies on monthly basis. Com-
pliance calculated as prescribed DDD/dispensed DDD × 100. Defined a priori patients
as compliant at 75%
Notes Type of publication: 2 peer-reviewed full-text journal articles reporting different out-
comes
Funding: Norwegian Medical Association Fund for Quality Improvement
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”At inclusion they signed a written consent
and were then randomized to an interven-
tion group or a control group using ran-
dom number tables“
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel
described. Outcomes measured were rel-
atively objective (e.g. exacerbations, hos-
pitalisations, GP visits, absenteeism), but
participant knowledge of group allocation
may have affected health care-seeking be-
haviour
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessors de-
scribed; although some outcomesmeasured
were relatively objective and unlikely to be
affected by assessors’ knowledge of group
allocation, patient-reported outcomes such
as QOL may be at risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unbalanced drop-out: 0% in control group
but 18% in intervention group
Selective reporting (reporting bias) High risk No prospective trial registration found;
multiple publications, each including a dif-
ferent set of outcomes. Not clear if all mea-
sured outcomes have been reported
Other bias Low risk None noted
Gerald 2009
Methods Design: open-label, parallel-group randomised controlled trial
Duration: intervention delivered over 65 weeks
Setting: school setting. USA
Trial registration: NCT00110383
Participants Population: 290 children with asthma randomised to supervised ICS therapy at school
(n = 145) or usual care (n = 145)
Age: 5 to 18 years; mean age (SD) in the intervention group 11.1 (2) years and in the
control group 10.8 (2.1) years
Baseline asthma severity: intervention group: 22 had mild asthma, 113 moderate
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asthma and 9 severe asthma; control group: 24 had mild asthma, 115 moderate asthma
and 14 severe asthma
Inclusion criteria: physician-diagnosed asthma, requiring daily controller medication
Exclusion criteria: children not able to switch medications to budesonide
Percentage withdrawn: 14% from the intervention group and 21% from the usual care
group
Other allowed medication: Children could take additional medications if their physi-
cian considered this necessary
Interventions Intervention summary: Child took inhaler medication at a set time each schoolday
under the supervision of staff members. Child was provided education in using the
inhaler if he or she was observed to use the inhaler incorrectly. Daily monitoring
Control summary: continued usual parent or self-supervised daily ICS treatment. Daily
monitoring
Complex intervention: no
Outcomes Outcomes measured: episode of poor asthma control (EPAC); rescue medications;
school absences; peak flow; rescue medication use at school
Adherence calculation: not applicable
Notes Type of publication: single peer-reviewed full-text journal article
Funding: National Institutes of Health Grant R01HL075043; AstraZeneca provided
the medications (Pulmicort Turbuhaler)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”A random sequence of treatment codes,
stratified according to school system, was
generated“
Allocation concealment (selection bias) Low risk ”Allocation was concealed“, although no
details given regarding how this was
achieved
Blinding of participants and personnel
(performance bias)
All outcomes
High risk ”Patients, their parents, and study staff
were not blinded to intervention condition;
however, physicians were blinded to their
patient’s
intervention condition“
Main outcome (EPAC) measuredmight be
subject to performance bias, as participant
knowledge of group allocation may have
affected behaviour
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessors de-
scribed. Main outcome (EPAC) measured
might be subject to detection bias, as par-
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ticipant knowledge of group allocationmay
have affected behaviour, such as decision to
use rescue medication or absenteeism from
school
Incomplete outcome data (attrition bias)
All outcomes
High risk Drop-out was somewhat higher in the con-
trol group (20.7%) than in the interven-
tion group (13.8%), and data do not ap-
pear to have been imputed for those who
did not complete the study. The length of
the study explains the extent of drop-out,
although the quantity of missing data and
imbalance between groups may still have
affected endpoint scores
Selective reporting (reporting bias) High risk Prospectively published protocol and main
outcome measure - EPAC - clearly re-
ported. However, some data not reported
in a way that would allow inclusion in a
meta-analysis (e.g. QOL)
Other bias Low risk None noted
Halterman 2004
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 9 weeks
Setting: schools in the Rochester City School District. USA
Trial registration: not reported
Participants Population: 184 children with asthma randomised to school-based care (n = 93) or usual
care (n = 91)
Age: 3 to 7 years; mean age in each group not reported
Baseline asthma severity: not reported
Inclusion criteria: symptoms consistent with mild persistent or more severe asthma; 3
to 7 years of age; enrolled in the Rochester City School District; family had access to a
working telephone for monthly follow-up telephone calls
Exclusion criteria: children scheduled tomove from the school district within 6months;
Spanish-speaking families enrolled in study year 2 only
Percentage withdrawn: 4% from the intervention group and 0% from the usual care
group
Other allowed medication: Children using more than 1 preventive medication were
instructed to continue with their other medications (in addition to the fluticasone given
through school) at the discretion of their primary care provider
Interventions Intervention summary: School nurse administered fluticasone once each day the child
was in school
Control summary: carers and parents notified of their child’s asthma severity. No med-
ications received in school through the programme
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Complex intervention: no
Outcomes Outcomes measured: number of symptom-free days during the 2 weeks before the
follow-up interview; asthma symptoms; night-time asthma symptoms; need for rescue
inhaler use; absenteeism
Adherence calculation: not applicable
Notes Type of publication: peer-reviewed journal article
Funding: Halcyon Hill Foundation, Webster, NY; Robert Wood Johnson Foundation’s
Generalist Physician Faculty Scholars Program. GlaxoSmithKline, Research Triangle
Park, NC, donated fluticasone propionate and spacers used in this study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Randomization was stratified by current
use of preventive medications and was
blocked in groups of 6. Pairs of siblingswere
assigned randomly to the same group. Ran-
domization cards were made from a table
of random numbers“
Allocation concealment (selection bias) Low risk ”Randomization cards were made from a
table of random numbers and were kept in
sealed, opaque, sequentially numbered en-
velopes until after the baseline assessment
was completed. Following randomization,
families and primary care providers were
notified of the child’s group allocation“
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel
described. Some outcomes (e.g. PAQLQ,
health care-seeking behaviour) may be sub-
ject to risk of performance bias fromknowl-
edge of group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ”To ensure an unbiased assessment, an in-
dependent research group, blinded to each
child’s group allocation, conducted the fol-
low-up interviews“
However, for participant-reported out-
comes, such as symptoms and PAQLQ, the
unblinded participant is the outcome asses-
sor; therefore, these outcomes are at risk of
detection bias
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Incomplete outcome data (attrition bias)
All outcomes
Low risk All but 4 participants (for whom no data
were available - all from the intervention
group) were included in the primary anal-
ysis
Selective reporting (reporting bias) Unclear risk No prospective trial registration identified,
although all outcomes listed inmethods re-
ported
Other bias Low risk None noted
Hart 2002
Methods Design: parallel-group randomised controlled trial; blinding not stated
Duration: 13 weeks
Setting: not reported. UK
Trial registration: not reported
Participants Population: 83 ’pre-school’ children with asthma randomised to an asthma education
intervention or usual care (n for each group not given)
Age: ’pre-school children’; no further details reported
Baseline asthma severity: not reported
Inclusion criteria: ’asthmatic pre-school children’; no further details reported
Exclusion criteria: not reported
Percentage withdrawn: not reported
Other allowed medication: not reported
Interventions Intervention summary: educational booklet about asthma and its treatment, and clinic
consultation based on contents of booklet
Control summary: usual care
Complex intervention: yes
Outcomes Outcomes measured: adherence; beliefs and anxieties about adherence
Adherence calculation: medication electronically monitored; details of adherence cal-
culation not given
Notes Type of publication: conference abstract
Funding: National Asthma Campaign, UK
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Children were ”randomly allocated“ - no
further details
Allocation concealment (selection bias) Unclear risk No details
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk No description of procedures to blind par-
ticipants or personnel
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No description of procedures to blind out-
come assessors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Drop-out not reported, so unclear how
many participants completed the study
Selective reporting (reporting bias) High risk Conference abstract, so minimal details
given. No prospective trial registration
identified
Other bias Low risk None noted
Kamps 2008
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 6 weeks, with follow-up to 52 weeks
Setting: family home. USA
Trial registration: not reported
Participants Population: 15 children with asthma randomised to adherence improvement strategies
(n = 7) or usual care plus education (n = 8)
Age: 7 to 12 years; mean age (SD) in the intervention group 9 (1.16) years and in the
control group 8.8 (1.67) years
Baseline asthma severity: not reported
Inclusion criteria: children 7 to 12 years of age with diagnosis of asthma
Exclusion criteria: not reported
Percentage withdrawn: 0% from the intervention group and 0% from the usual care
group
Other allowed medication: not reported
Interventions Intervention summary: focused education, monitoring, contingency management, dis-
cipline techniques
Control summary: comprehensive asthma education covering topics from the ”Air
Wise“ programme
Complex intervention: yes
Outcomes Outcomes measured: adherence (MDILog); pulmonary function; PedsQL Asthma
module; healthcare costs
Adherence calculation: (number of actuations per day/number of actuations prescribed)
× 100 (mean % dose per day per child)
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Notes Type of publication: single peer-reviewed journal article
Funding: National Institute of Child Health & Human Development Grant number
HD34784
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomisation table was developed by a
statistics consultant before participant re-
cruitment to assign children to a group; we
assigned children to groups on the basis of
this table
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No description of procedures to blind par-
ticipants or personnel
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No description of procedures to blind out-
come assessors; in the case of VAS results
and QOL results, the participant/career,
who was aware of group allocation, is the
outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
High risk Very small study; less than 50% in each arm
completed the study
Selective reporting (reporting bias) High risk No prospective trial registration identified.
Such small numbers make results difficult
to interpret and combine in a meta-anal-
ysis; SDs small despite small sample sizes
so will be falsely highly weighted in meta-
analysis. Unable to extract adherence data
owing to statistical method (pooled series
time analysis) used to analyse and no raw
data presented
Other bias Low risk None noted
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Methods Design: open-label, parallel-group, proof-of-concept randomised controlled trial
Duration: 9 weeks
Setting: recruited through emails sent to 40 largest universities in the UK requesting that
those with individuals managing their asthma with an ICS preventer should consider
enrolling
Trial registration: ISRCTN29399269
Participants Population: 216 adults with asthma randomised to an online community intervention
(”AsthmaVillage“) (n = 99) or no online community intervention (”AsthmaDiary“) (n
= 117)
Age:mean (SD) in the intervention group 27.2 (9.2) years and in the control group 28.
8 (10.1) years
Baseline asthma severity: not reported
Inclusion criteria: individuals managing their asthma with an ICS preventer
Exclusion criteria: failed to complete the eligibility questionnaire (n = 256) or baseline
measures (n = 228), did not have asthma (n = 105), were not prescribed an ICS preventer
inhaler for a weekly regimen of at least 1 dose per week (n = 87), failed to complete
informed consent (n = 35), had previously participated in the pilot study (n = 9)
Percentage withdrawn: 60.6% from the intervention group and 45.3% from the usual
care group (’withdrawn’ defined as insufficiently engaging in the intended intervention)
Other allowed medication: not reported
Interventions Intervention summary: an online community in which participants could report their
preventer use and write posts, comments or questions. Questions and comments needed
to be answered by community members themselves because no experimenter interven-
tion was provided once the trial had begun. The only feedback participants could receive
during the trial was that received from other participants because this intervention was
optimised for implementation at scale and at low cost. This trial attempted to determine
the value of an online community, implemented without the added support of a com-
munity manager to engage members
Control summary: Control condition comprised an online diary, AsthmaDiary. This
online diary was created with the use of Google Forms. A single-item survey was created:
“How many times did you take your preventer?” Participants randomised to the control
condition could report the number of puffs and, after entering their unique PIN, hit
“submit”. Because participants did not need to log in with a username to fill out the
form, participants used a PIN that allowed their posts to be identified by the researcher.
Participants in the control condition could not see the posts of other participants and
could not otherwise know whether other participants were posting on their condition
Complex intervention: no
Outcomes Outcomes measured: medication adherence (SMAQ), website activity/’adherence’
Adherence calculation: SMAQ was recalculated with dichotomous scoring of all vari-
ables (more than 2 missed uses was treated as non-adherent) and reverse scoring of item
4 of the SMAQ (“Thinking about the last week, how often have you not taken your
asthma preventer medicine as prescribed?”)
Notes Type of publication: single peer-reviewed journal article
Funding: funded by a pilot grant from the University of Leeds School of Psychology. A
Fulbright Scholarship from the US-UK Fulbright Commission supported the first study
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author
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Randomization occurred through a ran-
dom number generator, yielding two un-
equal groups“
Allocation concealment (selection bias) Unclear risk ”The experimenters then manually sepa-
rated the two lists and emailed both groups
log-in instructions“
It seems unlikely that allocation was not
concealed given the nature of the study de-
sign (i.e. the participant is ’remote’), but
this is not a standard description of an al-
location procedure, so we cannot be sure
exactly what the process entailed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not blinded to group al-
location and knowledge of group alloca-
tion, and adherence monitoring may have
affected their self-reported adherence (e.g.
those in the intervention arm systematically
over-estimating adherence)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The participant is the outcome assessor for
themain outcome - self-reported adherence
- and as participants were aware of group
allocation, we consider this outcome to be
at high risk of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Very high and unbalanced drop-out (60%
in intervention arm and 45% in control
arm). Although an ITT analysis was per-
formed for the primary outcome - self-re-
ported adherence - it is unclear how this
high level of drop-out may have impacted
the results
Selective reporting (reporting bias) High risk Trial retrospectively registered (ISRCTN
29399269), but not all outcomes reported
in trial report, including AQLQ
Other bias Low risk None noted
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Methods Design: open-label, parallel-group randomised controlled trial
Duration: 6 weeks, with follow-up to 6 weeks
Setting: clinic and private practice. USA
Trial registration: not reported.
Participants Population: 16 adults with asthma randomised to twice-daily (bid) dosing (n = 8) or 4-
times-daily (qid) dosing (n = 8)
Age: over 18 years of age; mean age (SD) in the intervention group 46.9 (10) years and
in the control group 42.3 (12.1) years
Baseline asthma severity: intervention group: 2 on maintenance oral steroids; control
group: 4 on maintenance oral steroids
Inclusion criteria: clinical stable asthma, requiring regular ICS
Exclusion criteria: not reported
Percentage withdrawn: 0% from the intervention group and 0% from the usual care
group
Other allowed medication: ”other asthma therapy continued throughout the study“
Interventions Intervention summary: 4 inhalations flunisolide twice daily
Control summary: 2 inhalations flunisolide, 4 times daily
Complex intervention: no
Notes: Participants changed to flunisolide at beginning of study if necessary. Both groups
used bid dosing for a run-in period to establish a baseline
Outcomes Outcomes measured: compliance; PEFR; symptom score
Adherence calculation: % days with more or less than prescribed 8 inhalations; mean
inhalations per day; frequency distribution of total daily inhalation; number inhaler
responses per day
Notes Type of publication: single peer-reviewed journal article
Funding: not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”After informed consent was obtained, pa-
tients were randomized into two groups of
eight each. Randomization was stratified so
each group contained four clinic and four
private practice patients“ - no further de-
tails given about how stratified random se-
quence was generated
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No description of procedures to blind par-
ticipants or personnel. However, primary
outcome measure - adherence - objectively
measured and unlikely to be prone to per-
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formance or detection bias. Participants
were unaware that the primary aim of the
study was to assess compliance. Subjec-
tive nature of secondary outcomes, such as
asthma symptoms,may result in higher risk
of bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No description of procedures to blind out-
come assessors.However, primary outcome
measure - adherence - objectively measured
and unlikely to be prone to performance
or detection bias. Subjective nature of sec-
ondary outcomes, such as asthma symp-
toms, may result in higher risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk ”One patient did not use the NC at all for
39of the 42 study days, but actuated the de-
vice 109 times on the day of the three-week
visit, and 56 times on the day of the six-
week visit. This patient was dropped and
replaced in the study.“
No other withdrawals reported
Selective reporting (reporting bias) Unclear risk No prospective trial registration identified,
although all outcomes listed inmethods re-
ported in text
Other bias Low risk None noted
Mehuys 2008
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 6 months
Setting: 66 community pharmacies in Belgium
Trial registration: not reported
Participants Population: 201 adults with asthma randomised to adherence education (n = 107) or
control (n = 94)
Age: 18 to 50 years of age; mean age (range) in the intervention group 32.5 (19 to 51)
years and in the control group 36.3 (17 to 51) years
Baseline asthma severity: intervention group: mean (range) ACT score: 19.3 (10 to 25)
; 89.5% on ICS at baseline; control group: 19.7 (11 to 25); 93.9% on ICS at baseline
Inclusion criteria: required to carry a prescription for asthma medication; under treat-
ment for asthma for at least 12 months; “using” controller medication; making regular
visits to the pharmacy
Exclusion criteria: smokinghistory ofmore than10 pack-years, another severe disease (e.
g. cancer) and an ACT score at screening < 15 (indicating seriously uncontrolled asthma;
for ethical reasons, these patients were immediately referred to their GP or respiratory
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specialist) or = 25 (indicating complete asthma control; no room for improvement)
Percentage withdrawn: 25% from the intervention group and 26% from the usual care
group
Other allowed medication: not reported
Interventions Intervention summary: At the first visit, pharmacist delivered personal education about
using an inhaler correctly; understanding asthma symptoms, triggers and early warnings;
understanding asthma controller and reliever therapy; facilitating adherence to use of
controller; and stopping smoking. At visits 2 and 3 (1 and 3 months), pharmacist gave
advice based on participant’s ACT score
Control summary: usual pharmacy care. All participants filled in an asthma diary in the
2-week run-in period but had no further contact outside of usual pharmacy visits
Complex intervention: yes
Outcomes Outcomes measured: AsthmaControl Test (Dutch), diary card data (nocturnal awaken-
ings, rescue medication use, PEF), asthma-related ED visits and hospitalisations, AQLQ,
Knowledge of Asthma and Asthma Medicine questionnaire (KAAM), inhalation tech-
nique checklist
Adherence calculation: Adherence was measured using refill rates and self-reporting via
an adherence scale
Notes Type of publication: single peer-reviewed journal article
Funding: not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”The sequence of allocation to either con-
trol or intervention group was predeter-
mined by the investigators based on a ran-
domisation
table“
Allocation concealment (selection bias) Low risk ”Serially numbered, closed envelopes were
made for each participating pharmacy. The
envelope with the lowest number was
opened by the pharmacist upon inclusion
of a new patient“
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It was not possible to blind participants,
so although adherence is measured objec-
tively using pharmacy data, many other
outcomes such as ACT and AQLQ are sub-
ject to potential performance bias, as par-
ticipants know to which group they were
assigned
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding of outcome assessors is not de-
scribed, and although the primary outcome
(adherencemeasured using pharmacy data)
is not prone to detection bias, other pa-
tient-reported outcomes (such as ACT and
AQLQ) are at risk because the participant
is the outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
High risk Approx-
imately 25% of participants dropped out
of each arm of the trial. Although reasons
were similar and baseline characteristics of
those completing and not completing did
not differ significantly, rate of drop-out is
high, and we cannot be sure that this did
not affect the results. Secondary outcomes
were analysed per protocol rather than by
ITT
Selective reporting (reporting bias) Unclear risk No prospective trial registration identified,
although all outcomes listed inmethods re-
ported in text/tables
Other bias Low risk None noted
NCT00115323
Methods Design: open-label, parallel-group randomised controlled trial
Duration: intervention delivered over 13 weeks; follow-up continued to 26 weeks
Setting:primary care and asthma specialty practices serving low-income inner-city neigh-
bourhoods with high prevalence of asthma morbidity. USA
Trial registration: NCT00115323
Participants Population: 333 adults with asthma randomised to a problem-solving (PS) intervention
(n = 165) or an asthma education (AE) intervention (n = 168)
Age: minimum age 18; mean age (SD) in PS group 49 years (13) and in AE group 49
(14) years
Baseline asthma severity: sufficiently severe to require treatment with ICS. FEV1%
predicted (SD) in PS group 66 (19) and in AE group 64 (19)
Inclusion criteria: English- or Spanish-speaking adults with moderate or severe persis-
tent asthma according to National Heart, Lung, and Blood Institute Expert Panel Report
3 guidelines. Inclusion criteria were designed to identify patients with sufficiently severe
and reversible asthma who were likely to benefit from ICS therapy. Specific criteria in-
cluded the following: age≥ 18 years; physician’s diagnosis of asthma; prescription for an
ICS-containing medication for asthma; and evidence of reversible airflow obstruction,
that is, an increase≥ 15% and 200mL in FEV1 with asthma treatment over the previous
3 years, or an increase in FEV1 or FVC≥ 12% and 200 mL in FEV1 within 30 minutes
of inhaled albuterol. Smokers were included
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Exclusion criteria: severe psychiatric problems such as obvious mania or schizophrenia
that would make it impossible for individuals to understand or carry out problem solving
Percentage withdrawn: not specifically reported
Other allowed medication: not specifically reported
Interventions Intervention summary: four 30-minute sessions. Individualised intervention involved
4 interactive steps, usually 1 per research session, aimed at improving or maintaining
adherence. Step 1: breaking problems into small achievable pieces; Step 2: brainstorming
for alternative solutions; Step 3: choosing the best solution byweighing the consequences,
both desirable and undesirable, of each candidate solution (between third and fourth
meetings, the solution was tried); Step 4: evaluating and revising chosen solution. Inter-
vention delivered to participants by a research co-ordinator (college graduates interested
in health-related or education carers or further schooling, committed to working with
patients and having a research experience. Co-ordinators were diverse in race/ethnicity,
as were participants)
Control summary: four 30-minute sessions, each focused on an asthma patient edu-
cation topic unrelated to self-management, adherence or ICS therapy. Topics covered
included proper technique for using an albuterol-rescue metered dose inhaler and a
dry powder inhaler or spacer, depending on the patient’s medications; use of peak flow
meters; common asthma triggers; and pathophysiology of asthma. These sessions did
not involve discussion of problem solving or adherence, only a didactic presentation of
health information. Delivered to participants by a research co-ordinator (college gradu-
ates interested in health-related or education carers or further schooling, committed to
working with patients and having a research experience. Co-ordinators were diverse in
race/ethnicity, as were participants)
Complex intervention: yes
Outcomes Outcomes measured: adherence to ICS regimen prescribed by participant’s physician
assessed by an electronic monitor; Mini-AQLQ; ACQ; spirometry (FEV1 and FVC);
hospitalisations and ED visits for asthma or any cause; patient satisfaction
Adherence calculation: Daily ICS adherence was calculated as (# actuations down-
loaded/# prescribed) × 100 (using an electronic adherence monitor attached to the in-
haler)
Notes Type of publication: single peer-reviewed full-text journal article
Funding: supported by grants from the National Institutes of Health (HL070392,
HL088469)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Subjects were randomized according to a
computer-generated algorithm in 1:1 ra-
tio“
Allocation concealment (selection bias) Unclear risk No details
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel
described. Main outcome - adherence -
objectively measured, but other outcomes
such as ACQ and AQLQare subject to per-
formance bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessors de-
scribed.Main outcome - adherence - objec-
tively measured, but other outcomes such
as ACQ and AQLQ are subject to detec-
tion bias as the unblinded participant is the
outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition not reported
Selective reporting (reporting bias) Low risk Prospectively registered trial
(NCT00115323). All outcomes reported
Other bias Low risk None noted
NCT00149487
Methods Design: open-label, parallel-group, multi-centre randomised controlled trial
Duration: 17 weeks, with follow-up continuing to 1 year
Setting: recruitment from primary and subspecialty care, inpatient and emergency de-
partment settings at 1 large paediatric tertiary care centre. USA
Trial registration: NCT00149487
Participants Population: 141 children with asthma randomised to a problem-solving intervention
or family-based education (n for each group not reported)
Age: 5 to 17 years; mean age not reported
Baseline asthma severity: not reported
Inclusion criteria: African American, family income below the poverty line, physician-
based diagnosis of asthma of at least 12 months, moderate to severe asthma (moder-
ate asthma includes daily symptoms, daily use of inhaled short-acting beta-agonist, ex-
acerbations more than 2 times per week that affect activity and night-time symptoms
more often than once a week, FEV1 or PEF between 60% and 80% predicted and PEF
variability > 30%; severe asthma includes continual symptoms, limited physical activity,
frequent exacerbations together with frequent night-time symptoms, FEV1 or PEF <
60% predicted and PEF variability > 30%). Likely to be on a stable and daily medica-
tion (inhaled steroid) that can be modified electronically for the time period required to
participate in the study
Exclusion criteria: serious comorbid chronic condition, serious developmental disabil-
ity, income exceeding poverty level
Percentage withdrawn: not reported
Other allowed medication: not reported
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Interventions Intervention summary: intervention tailored to observed adherence behaviours and
identified barriers to increasing adherence in African American children and adolescents
with asthma and their families
Control summary: family education
Complex intervention: yes
Outcomes Outcomes measured: adherence, frequency of asthma symptoms, utilisation of health-
care services, use of reliever medication
Adherence calculation: adherence defined as correspondence betweenmedication doses
taken each day and prescribed dose, tracked by electronic monitoring device during
months 9 to 12 of the study
Notes Type of publication: single peer-reviewed full-text journal article and NCT record with
no study results provided. Full-text publication of RCT findings not found; above data
extracted from a paper describing observational data related to trial participants
Funding: National Heart, Lung, and Blood Institute (NHLBI)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Randomized“ but no further details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel
described
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Noblinding of outcome assessors described
Incomplete outcome data (attrition bias)
All outcomes
High risk Drop-out not reported for each arm; 49/
141 dropped out overall (35%)
Selective reporting (reporting bias) High risk Unable to identify full-text report of the
RCT. Observational study on same cohort
reported. No study results posted on clin-
icalrials.gov. Not able to include any out-
comes in meta-analysis
Other bias Low risk None noted
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Methods Design: open-label, 3-arm, parallel-group randomised controlled trial
Duration: 2 months
Setting: recruited from asthma clinics at a rural, university-based hospital in northeastern
United States and an urban-based children’s hospital in the Midwest
Trial registration: NCT00166582
Participants Population: 55 children with asthma randomised to receive a team work intervention
(n = 19), an asthma education intervention (n = 19) or usual care (n = 17)
Age: 9 to 15 years; mean age (SD) 11.1 (1.9) years across the 3 groups (mean age not
given for each group)
Baseline asthma severity: team work intervention group: mild persistent asthma = 37.
5%, moderate persistent asthma = 50.0%, severe persistent asthma = 12.5%; asthma
education group: mild persistent asthma = 25.0%, moderate persistent asthma = 56.2%,
severe persistent asthma = 18.8%; usual care group: mild persistent asthma = 18.8%,
moderate persistent asthma = 62.5%, severe persistent asthma = 18.8%
Inclusion criteria: child with diagnosis of persistent asthma for at least 6 months;
fluticasone MDI taken daily; and no evidence of neurological or significant cognitive
impairment (per parent report). Suspected history of medication non-adherence not
required
Exclusion criteria: not reported
Percentage withdrawn: 16% from both teamwork intervention and asthma education
intervention groups and 6% from usual care group
Other allowed medication: not reported
Interventions Intervention summary (1): teamwork: emphasised the importance of parents and youth
sharing responsibility for the patient’s asthma management and learning methods for
addressing conflicts associated with increased responsibility of youth. Involved handouts
on adolescent development, promoting youth independence, appropriate parental med-
ication supervision and problem solving around asthma management conflicts. MDI
Log-II served as the primary source of adherence information for families. ICS adherence
goals were set in consultation with physician (lowest 70%). Four sessions 2 to 3 weeks
apart delivered by a ’therapist’
Intervention summary (2): asthma education: similar to the teamwork group, families
in this group received and reviewed written materials with the researcher during sessions.
Thesematerials covered topics often found in asthma education programmes. Time spent
with families generally was equivalent to that of its parallel teamwork session, thereby
creating an attention control condition. Four sessions 2 to 3 weeks apart delivered by a
’therapist’
Control summary: Youth in the usual care group completed all assessments at the same
time interval as other participants but did not receive guidance beyond usual care. On
completion of follow-up, these families were provided feedback on their child’s medica-
tion adherence and were offered an opportunity to receive either of the 2 interventions
Complex intervention: yes
Outcomes Outcomes measured: adherence to ICS using MDI Log-II; parent-adolescent conflict
(CBQ-20); health outcomes (FSI); lung function; consumer satisfaction (CSQ)
Adherence calculation: Mean daily adherence was defined as follows: total number of
puffs inhaled divided by total number of puffs prescribed, multiplied by 100
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Notes Type of publication: single peer-reviewed full-text journal article
Funding: supported by theNational Institute of ChildHealth andHumanDevelopment
(R03-HD039767-02)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Initially, youth were randomly
assigned (via computer-generated number
sequence) to one of three parallel groups…
subsequent participants were assigned us-
ing a randomized block design to maintain
group balance across variables“
Allocation concealment (selection bias) High risk The sequence was available to the research
assistant who recruited participants into
the study, as participants were immedi-
ately randomised; thus, the research assis-
tant might have been aware of group allo-
cation before participants were randomised
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel
described. The main outcome measured -
adherence - wasmonitored objectively with
an electronic device, but other outcomes
such as functional severity index and satis-
faction may have been affected by knowl-
edge of group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessors de-
scribed. The main outcome - adherence
- was monitored objectively with an elec-
tronic device. However, other outcomes
such as functional severity index are subject
to risk of detection bias, as the participant
is the outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-out lower in the standard care group
(6%) than in the 2 active groups (both
16%); all participants accounted for in the
flow diagram, but uneven drop-out may
have skewed results because these people
were not included in the analyses
Selective reporting (reporting bias) Unclear risk Prospec-
tively registered trial (NCT00166582), al-
though details minimal in trial registration
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and outcomes not specified. However, all
outcome measures listed in methods of the
paper are reported clearly
Other bias Low risk None noted
NCT00233181
Methods Design: single-blind, parallel-group randomised controlled trial
Duration: 78 weeks
Setting: Paediatric ED in Baltimore. USA
Trial registration: NCT00233181
Participants Population: 250 children with asthma randomised to adherence monitoring and edu-
cation (n = 83), education (n = 84) or usual care (n = 83)
Age: 2 to 12 years of age; mean (SD) age in the adherence group 6.5 (3.43) years, in the
education group 7.1 (3.37) years and in the control group 7.4 (3.3) years
Baseline asthma severity: not reported
Inclusion criteria: eligible for randomisation when between 2 and 12 years of age,
physician-diagnosed asthma, 2 ED visits or 1 hospitalisation for asthma in the preceding
year, resided in Baltimore City, prescribed an asthma controller medication
Exclusion criteria: not reported
Percentage withdrawn: 8.4% from the adherence group, 3.5% from the education
group and 8.4% from the control group
Other allowed medication: not reported
Interventions Intervention summary (1): Educational content in the education group PLUS elec-
tronic adherence monitoring with feedback, asthma control and adherence goal setting,
reinforcement (praise and low-cost rewards), and strategies for self-monitoring medica-
tion use
Intervention summary (2): five 30- to 45-minute home visits by trained asthma educa-
tors (AEs) 1, 2, 3, 4 and 8 weeks after randomization. ABC intervention is a home-based
asthma education programme with 5 core components: review of prescribed asthma
regimen and training in medication, spacer and peak flow technique; development of
an asthma action plan; identification of barriers to accessing healthcare services and
problem solving to reduce barriers; discussion of beliefs and concerns about asthma and
medications; and provision of written asthma education materials
Control summary: asthma education booklet and resource guide that provided infor-
mation about low-cost asthma care providers, social services, legal services and other
resources. Regardless of group assignment, participants were regularly encouraged to
receive care from their primary care provider
Complex intervention: yes
Outcomes Outcomes measured: self-reported adherence; pharmacy-based adherence; career re-
ports of symptoms, night-time awakenings, ED visits, hospitalisations and courses of
OCS in the previous 6 months
Adherence calculation: Pharmacy-based adherence was calculated as number of ICS
refills per quarter, converted into equivalent values; rates were defined as number of ICS
canisters dispensed quarterly (where 3 = 100% adherence). Self-reported adherence was
85Interventions to improve adherence to inhaled steroids for asthma (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT00233181 (Continued)
% use/prescribed dose × 100
Notes Type of publication: single peer-reviewed journal article
Funding: National Heart, Lung, and Blood Institute grant HL063333
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”To mask staff to group assignment during
recruitment, the statistician created block
randomization schema and placed the ran-
domization assignments into sealed en-
velopes, which were opened after families
completed baseline surveys“
Allocation concealment (selection bias) Low risk ”To mask staff to group assignment during
recruitment, the statistician created block
randomization schema and placed the ran-
domization assignments into sealed en-
velopes, which were opened after families
completed baseline surveys“
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not blinded to group al-
location, and knowledge of group alloca-
tion and adherence monitoring may have
affected healthcare utilisation behaviour, as
well as adherence behaviour, beyond the ef-
fect intended by trialists
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ”Trained research assistants who were
blinded to study assignments conducted
surveys by telephone“
However, all asthma morbidity measures
were career reported, and therefore were
at risk of detection bias, as the career is
the outcome assessor for these self-reported
outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk More than 80%of participants in all 3 arms
completed all questionnaires and follow-
up. Results analysed as ITT, and all ran-
domised participants included in the ITT
analysis
Selective reporting (reporting bias) High risk Prospectively registered trial
(NCT00233181), but not all outcomes (e.
g. QOL) reported in the published paper
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Other bias Low risk None noted
NCT00414817
Methods Design: open-label, pragmatic, parallel-group randomised controlled trial
Duration: 78 weeks
Setting: conducted through 2 Kaiser Permanente research centres in Hawaii and Balti-
more. USA
Trial registration: NCT00414817
Participants Population: 14,064 adults with asthma randomised to receive interactive voice response
calls or usual care. Not all participants were previous ICS users. 3171 of the intervention
group and 3260 of the usual care group described as the primary analysis sample -
previous ICS users
Age: 18 years of age and older; ages reported in categories rather than as mean (SD)
Baseline asthma severity: 33.3% had comorbid COPD; other characteristics included
recent ED visit, hospitalisation or OCS burst for asthma; current SABA usage; and
number of medications used
Inclusion criteria: Target population consisted of KPNW and KPH members 18 years
of age and older who were members for the 12 months before randomisation, had been
seen for asthma and received at least 1 dispensing of a respiratory medication during that
time frame. For study of both primary and secondary ICS adherence, target population
included individuals without evidence of prior ICS use. Present analysis focuses on the
subset of 6903 individuals with ICS dispensing during baseline year
Exclusion criteria: Individuals meeting the above criteria were included in the final
analysis sample only if they had ever received (or for usual care participants would have
qualified for) an intervention call
Percentage withdrawn: of 6903 previous users qualifying for analysis, 3171 were in-
cluded in the intervention analysis sample and 3260 in the usual care analysis sample
Other allowed medication: not reported
Interventions Intervention summary: interactive voice recognition (IVR) intervention including 3
basic IVR call types, each typically lasting 2 to 3 minutes: refill reminder call, for people
whose last ICS dispensing was at least amonth ago and who should have < 30 days supply
left, reminded participants that they were due for a refill and offered a transfer to the
automated pharmacy refill line and/or information about KP’s online refill service; tardy
refill call, for people > 1month past refill date, reminded participants theywere due for an
ICS refill, assessed asthma control, explored ICS adherence barriers and provided tailored
educational messages; and initiator/restart call, for participants who were starting ICS
for the first time or were lapsed users, included probes for asthma control and adherence
barriers and offered tailored educational messages
Control summary: usual care
Complex intervention: no
Outcomes Outcomes measured: 8 alternative measures of pharmacy-based adherence, described as
continuous multiple-interval measures of medication availability and gaps. Clinicaltrials.
gov lists the primary outcome as days’ supply of ICS available as documented in partic-
ipants’ pharmacy records at 19 months, and secondary outcomes as health status from
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survey responses (subset), utilisation of acute healthcare services from medical record
data and an economic analysis. Multiple post hoc analyses provided in published reports
Adherence calculation: 8 alternative measures of pharmacy-based adherence (one of
the resulting publications is a comparison of pharmacy-based measures of medication
adherence)
Notes Type of publication: multiple peer-reviewed journal articles
Funding: NHLBI
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Randomization stratified by region and
the clinic facility to which each patient was
paneled“ - but no further details about how
the random sequence was generated
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Although it was not possible to blind par-
ticipants to group allocation, the primary
outcome (adherence) was measured objec-
tively using pharmacy data. However, as
participants would have been aware that
they were taking part in a trial of adherence
and were being monitored, this may have
affected their adherence behaviour beyond
the effect intended by the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessors is not de-
scribed; however, the nature of the primary
outcomes (adherencemeasured using phar-
macy data) makes them not prone to de-
tection bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Owing to the trial design, it was not possi-
ble to measure attrition in the usual way
Selective reporting (reporting bias) High risk Prospec-
tively registered trial (NCT00414817), but
many outcomes of interest not presented
numerically, so unable to include it in the
meta-analysis (”We also observed no signif-
icant intervention effects on reliever med-
ication (SABA) use, quality of life, asthma
control, or the rate of acute asthma health
care utilization“)
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Other bias Low risk None noted
NCT00459368
Methods Design: single-blind, parallel-group, stratified cluster randomised trial
Duration: 52 weeks
Setting: primary care: 34 clusters (’practices’ comprising 193 providers). USA
Trial registration: NCT00459368
Participants Population: 2698 adults and children with asthma from 34 clusters (’practices’ com-
prising 193 providers) randomised to adherence education and individualised patient
adherence information (17 practices, 88 providers, 1335 participants) or adherence ed-
ucation alone (17 practices, 105 providers, 1363 participants)
Age: 5 to 56 years of age; mean age (SD) in the adherence education and individualised
patient adherence information group 26.8 (17.4) years and in the adherence education
alone group 28.8 (17.4) years
Baseline asthma severity: physician diagnosis of asthma and prescription for ICS in the
preceding 2 years; no other severity information given
Inclusion criteria: Eligible primary care practices had to have access to electronic pre-
scription writing. Eligible patients had to fulfil the following criteria: recent previous
electronic prescription for an ICS; 5 to 56 years of age as of 30 April 2007; continuous
enrolment in the affiliated health maintenance organisation (HMO) for at least 1 year
before 30 April 2007; prescription drug coverage as of 30 April 2007; at least 1 physician
diagnosis of asthma and no diagnosis of chronic obstructive pulmonary disease or con-
gestive heart failure after 19 January 2005; and at least 1 visit to a primary care provider
in the year before 30 April 2007
Exclusion criteria: ICS medication stopped and not restarted, left the HMO before
start of the intervention
Percentage withdrawn: 22% from the adherence education and individualised patient
adherence information arm and 24% from the adherence education alone arm
Other allowed medication: Participants continued their normal medication
Interventions Intervention summary: Physicians assigned to both groups received an audio compact
disc, a digital video disc and a booklet that contained information on the most recent
national asthma guidelines and methods for discussing medication non-adherence with
patients. Physicians in the intervention arm could also view their patients’ individual
adherence data generated by ePrescribing
Control summary: as above, but physicians were not able to view their patients’ indi-
vidual adherence data
Complex intervention: yes
Outcomes Outcomes measured: patient adherence to ICS in last 3 months of intervention (i.e. an
individual-level outcome accounting for practice clusters), time to and number of the
following events during the intervention period: asthma-related emergency department
visit, asthma-related hospitalisation and oral steroid use. Post hoc analysis revealed that
the change in adherence between baseline and study end differed between participants
in intervention and control arms
Adherence calculation: Based on data from electronic prescribing, calculated days of
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supply was calculated to estimate adherence as a continuous measure of medication
availability equal to the cumulative days of supply divided by the number of days of
observation.This estimates the proportionof time that participants took theirmedication
Notes Type of publication: multiple peer-reviewed full-text journal articles
Funding: supported by grants from the National Heart, Lung, and Blood Insti-
tute (HL79055), the National Institute of Allergy and Infectious Diseases (AI61774,
AI79139), the National Institute of Diabetes and Digestive and Kidney Diseases
(DK64695), National Institutes of Health; the Fund for Henry Ford Hospital; and the
Strategic Program for Asthma Research of the American Asthma Foundation
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Practices were randomised with stratifica-
tion for whether the practice was a pae-
diatric practice (i.e. paediatrics vs family
medicine and internal medicine) to achieve
approximately equal partitioning of chil-
dren and adults in both study arms. One
researcher (E.L.P.) generated the random
allocation sequence within strata, and the
identities of the practices were concealed at
the time of randomisation
Allocation concealment (selection bias) Low risk The identities of practices were concealed
at the time of randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Healthcare providers (rather than individ-
ual participants) were randomised andwere
aware of group allocation. It is unclear how
their knowledge of group allocation may
have impacted the adherence of their pa-
tients in ways unintended by the interven-
tion itself
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study staff was masked to the individual
practice treatment assignment, and the pri-
mary outcome - adherence as calculated
from pharmacy data - is objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Although > 20% of participants did not
complete the trial (22% in the intervention
arm and 24% in the control arm), we car-
ried forward their last 3 months of adher-
ence and analysed data in the primary anal-
ysis
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Selective reporting (reporting bias) Low risk Prospectively regis-
tered trial (NCT00459368). All outcomes
reported in at least 1 of several associated
publications
Other bias Low risk None noted
NCT00516633
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 26 weeks, with follow-up to 78 weeks
Setting: children ’in our region’ given diagnosis of asthma in previous 1 to 2 months.
Sweden
Trial registration: not reported
Participants Population: 60 children with asthma and their parents randomised to group discussions
plus basic education (n = 32) or basic education (n = 28)
Age: 3 months to 6 years of age; mean age (SD) in the intervention group 28.1 months
and in the control group 26.1 months
Baseline asthma severity: not reported
Inclusion criteria: moderate or severe asthma defined by SPT II Brazillian Consensus
on Asthma Management
Exclusion criteria: not reported
Percentage withdrawn: 9% from the intervention group and 14% from the usual care
group
Other allowed medication: not reported
Interventions Intervention summary: meetings in a group setting with both parents. Afternoon ses-
sions of 1.5 hours’ duration; 3 weekly meetings soon after asthma diagnosis and a follow-
up meeting at 6 months. Session involved 3 paediatricians, 3 nurses and 2 psychologists.
One nurse was present on all occasions. The method applied was based on the concept
of concordance, meaning that we tried to “speak the same language” as the parents and
to reach an alliance with them on how to look upon asthma and its management. Our
goal was to reach their “main worry” and, apart from teaching about asthma, we asked
the key question: “What is asthma to you?” Our intention was to use dialogue and peer
education, whereby the group was encouraged to share personal experiences. In each
group session, leaders had a list of subjects that were to be covered during the discussion.
Attendees also received basic education
Control summary: basic education about asthma and its treatment, including how to
use the Nebunette, and information on environmental control at first visit to the clinic.
Participants received a written treatment plan for which the principle was high dose
initially, then, in association with URTI, stepping down therapy to the lowest possible
dose according to the status of the child. Treatment was stopped if the child had no
asthma symptoms for 6 months
Complex intervention: yes
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Outcomes Outcomesmeasured: presence of parents at groupmeetings; personal view on adherence
at inclusion and after 6 and 18 months; how many days the child was hospitalised;
how many times participants had to seek emergency help for asthma; exacerbations, as
defined by the need for parents to stay at home to take care of their child because of
asthma symptoms; objective measures of adherence; adherence according to parents
Adherence calculation: diaries and weighing of MDIs used between 12 and 18 months
after inclusion
Notes Type of publication: single peer-reviewed journal article
Funding: Primary Care Unit in the county of Varmland. AstraZeneca provided the
medicines
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”The parents of the 60 children were ran-
domized consecutively in groups of four
to either the intervention or the control
group“ - but no further details about how
this was achieved
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk ”The nurses carried out the randomization
and the three doctors that were involved in
the group sessions also performed the fol-
low-up visits. Therefore, a complete blind-
ing procedure could not be established“
Blinding of outcome assessment (detection
bias)
All outcomes
High risk ”The nurses carried out the randomization
and the three doctors that were involved in
the group sessions also performed the fol-
low-up visits. Therefore, a complete blind-
ing procedure could not be established“
Incomplete outcome data (attrition bias)
All outcomes
Low risk High levels of follow-up in both arms
(86% in control group, 91% in interven-
tion group); all withdrawals accounted for
in the publication
Selective reporting (reporting bias) High risk No prospective trial registration identi-
fied. Many outcomes reported narratively
in text but with insufficient numerical
detail for inclusion in the meta-analyses.
Within-group or whole study population
results sometimes presented rather than be-
tween-group differences. ’N.S.’ frequently
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reported rather than exact CIs, SDs or P
values
Other bias Low risk None noted
NCT00958932
Methods Design: open-label, pragmatic, parallel-group randomised controlled trial
Duration: 2 years
Setting: 18 primary care and 2 specialty care medical offices, 2 contract hospitals and
more than 800 physicians. USA
Trial registration: NCT00958932
Participants Population: 1187 children with asthma randomised to speech recognition (SR) inter-
vention (n = 590) or usual care (UC) (n = 597)
Age: 3 to 12 years of age; mean age (SE) in SR group 8.2 (0.13) years and in the UC
group 8.1 (0.13) years
Baseline asthma severity: diagnosed persistent asthma for which daily inhaled corticos-
teroid treatment was prescribed. Children in the SR group had inpatient visits/person-
year, mean (SE), number 0.04 (0.01); ED visits/person-year, mean (SE), number 0.09
(0.02); oral steroid bursts/person-year mean (SE), number 0.469 (0.04); primary care
visits/person-year, mean (SE), number 2.3 (0.08); and children in the UC group had in-
patient visits/person-year, mean (SE), number 0.04 (0.01); ED visits/person-year, mean
(SE), number 0.09 (0.02); oral steroid bursts/person-year, mean (SE), number 0.383 (0.
04); primary care visits/person-year, mean (SE), number 2.4 (0.10)
Inclusion criteria: 3 to 12 years of age, diagnosis of persistent asthma, 1 or more ICS
prescriptions filled in the prior 6 months. Participants were limited to those enrolled in
KPCO (Kaiser Permanente Colorado; a group-model health maintenance organisation)
for at least 1 year to ensure that patients were consistently given a diagnosis of persistent
asthma and to establish a baseline ICS adherence rate
Exclusion criteria: identified by physician as having a life-threatening comorbid condi-
tion; sibling already included in the study; parent who declined to participate; instructed
to take an ICS only intermittently or as needed; obtained medication from a non-KPCO
pharmacy
Percentage withdrawn: 23% from the SR arm and 25% from the UC arm
Other allowed medication: Participants continued their normal medication
Interventions Intervention summary: Speech recognition telephone calls to parents in the interven-
tion condition were triggered when an inhaled corticosteroid refill was due or overdue.
Calls were automatically tailored with medical and demographic information from the
electronic health record and from parent answers to questions during the call regarding
recent refills or a desire to receive help refilling, to learn more about asthma control or to
speak with an asthma nurse or a pharmacy staff member. All standard asthma resources
remained available to both intervention groups throughout the duration of the study
Control summary: All standard asthma resources remained available to the usual care
group throughout the duration of the study
Complex intervention: no
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Outcomes Outcomes measured: adherence to ICS, beta2-agonist use, oral steroid use; asthma-
related visits for primary healthcare services, ED visits, hospitalisations and after-hours
visits on weekends or weekdays after 6 PM; participant satisfaction
Adherence calculation: Adherence was expressed as proportion of days covered (PDC)
over 24 months. PDC was calculated as total number of ICS days supplied divided by
period for which medication was prescribed
Notes Type of publication: single peer-reviewed full-text journal article
Funding: supported by grant 1R01HL084067-01A2 from the National Institutes of
Health. The National Institutes of Health had no role in design and conduct of the
study; collection, management, analysis and interpretation of data; preparation, review
or approval of the manuscript; and decision to submit the manuscript for publication
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Randomization will be at the level of in-
dividual patients“ - but no further detail
given in the study report or protocol
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel
described.Main outcomes are related to us-
age of healthcare services and may be influ-
enced by participants’ knowledge of group
allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Noblinding of outcome assessor described.
However, main outcomes are related to us-
age of healthcare services, which was ob-
tained frommedical records and is unlikely
to be influenced by knowledge of group al-
location
Incomplete outcome data (attrition bias)
All outcomes
Low risk Although drop-out was relatively high (>
20%) owing to loss of insurance, it was bal-
anced and trialists performed an intention-
to-treat analysis; participants who lost in-
surance coverage during the 2-year study
period were included in a secondary analy-
sis for evaluation of potential sample attri-
tion bias
Selective reporting (reporting bias) Low risk Prospectively
registered trial (NCT00958932) and pro-
tocol available online. All main outcomes
of interest reported; trialists state they will
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report rescue medication use in the proto-
col, but this information does not appear
in the main report
Other bias Low risk None noted
NCT01064869
Methods Design: single-blind, parallel-group randomised controlled trial
Duration: intervention delivered over 12 weeks. Follow-up continued to 1 year
Setting: Regional Difficult Asthma Service. Northern Ireland
Trial registration: not reported
Participants Population: 20 people with asthma attending a difficult asthma service facility ran-
domised to individualised psychoeducational nurse-led intervention (n = 9) or usual care
(n = 11)
Age: age range not reported, but mean age (SD) in the intervention group was 50 (9.1)
years and in the control group 45.2 (10) years
Baseline asthma severity: All participants had ’difficult asthma’ - defined as persistent
symptoms, despite treatment at BTS/SIGN step 4/5. Baseline mean (SD) % predicted
FEV1 74.4 (20.5)
Inclusion criteria: difficult asthma, defined as persistent symptoms, despite treatment
at BTS/SIGN step 4/5; attendance at the Northern Ireland Regional Difficult Asthma
Service; non-adherence after phase 1 of the study (received a patient concordance dis-
cussion); age over 18 years
Exclusion criteria: current tobacco smoking or significant other comorbidity that con-
tributed to persistent respiratory symptoms
Percentage withdrawn: 22% from the intervention group and 0% from the usual care
group
Other allowed medication: ICS/LABA; prednisolone
Interventions Intervention summary: individualised psychoeducational nurse-led intervention com-
prising 8 visits to a respiratory nurse, plus usual care
Control summary: usual care
Complex intervention: yes
Outcomes Outcomes measured: change in adherence to inhaled combination therapy; daily pre-
scribed dose of ICS; courses of rescue oral corticosteroids; total inhaled and nebulised
beta-agonist doses; hospital admissions and lung function; ACQ; AQLQ; HADS; State
Trait Anxiety Scale
Adherence calculation: % of inhaled combination therapy prescriptions refilled and
change in number of participants in each group filling ≤ 50% of prescription refills
Notes Type of publication: single peer-reviewed full-text journal article
Funding: Research and Development Office, Northern Ireland
Risk of bias Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Patients were randomly allocated to either
the intervention or control group“ - no fur-
ther details
Allocation concealment (selection bias) Unclear risk None noted
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Trial described as ’single blind’ but blinding
not further described. Seems unlikely that
participants or personnel would have been
masked, and many outcomes (e.g. ACQ,
AQLQ)were subject to risk of performance
bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Trial described as ’single blind’ but blind-
ing not further described. Seems unlikely
that participants or personnel would have
been masked, so likely outcome assessors
were masked. However, many outcomes (e.
g. ACQ, AQLQ) subject to risk of detec-
tion bias, as the unblinded participant is
the outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
High risk Drop-out unbalanced, although small
numbers in both arms (0% drop-out in
control group, 22% in intervention group)
Selective reporting (reporting bias) Unclear risk No prospective trial registration identified,
although all outcomes listed inmethods re-
ported
Other bias Low risk None noted
NCT01132430
Methods Design: single-blind, parallel-group randomised controlled trial
Duration: 6 weeks, with follow-up to 52 weeks
Setting: Outpatient clinic. Single site. Canada
Trial registration: not reported.
Participants Population: 54 adults with asthma randomised to motivational interviewing (MI) (n =
26) or usual care (n = 28)
Age: over 18 years of age; mean age (SD) in the intervention group was 52 (15) years
and in the control group 49 (16) years
Baseline asthma severity: intervention group: ACT score 17 (4); ACQ1.7 (0.9); control
group: ACT score 17 (4); ACQ score 2.1 (1.1)
Inclusion criteria: age 18 years; primary diagnosis of moderate to severe persistent
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asthma; prescribed stable dose of ICS for at least 12 months before enrolment; uncon-
trolled asthma according to ACQ; non-adherence (filling < 50% prescribed ICS in the
past 12 months)
Exclusion criteria: comorbid condition with greater risk than asthma (COPD, CVD,
etc.), severe psychopathology; current substance abuse; cognitive or language difficulties;
plan to become pregnant; plan to leave Quebec over course of the study
Percentage withdrawn: 30.77% from the intervention group and 21.43% from the
usual care group
Other allowed medication: not reported
Interventions Intervention summary: individual session based on anMImanual, with the overall goal
of enhancing participant motivation to take ICS
Control summary: Participants received whichever treatments were prescribed by their
physician, whichmay include an action plan or referral to asthma education. Participants
were given the opportunity to receive MI after study completion
Complex intervention: yes
Outcomes Outcomes measured: ICS adherence; self-reported adherence; asthma control; asthma-
related quality of life; asthma-related self-efficacy
Adherence calculation: number of treatment days/total number of days (6 months and
12 months)
Notes Type of publication: single peer-reviewed journal article
Funding: unrestricted investigator-initiated grant from GSK, salary awards from Fonds
del laRechercheQuebec (FRQS) andCanadian Institute ofHealthResearch. Scholarship
support from FRQS
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Following the completion of all baseline
assessments, patients were randomized to
MI or UC using a computer algorithm that
generated a random code“
Allocation concealment (selection bias) Low risk ”Patients were randomized to MI or UC
using a computer algorithm that generated
a random code that was kept in a concealed
envelope until opened by the study coordi-
nator at the time of randomization as per
the CONSORT guidelines“
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No description of procedures to blind par-
ticipants or personnel. Subjective nature of
many secondary outcomes results in high
risk of bias
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk ”With the exception of the visual analog
scales assessing patients’ impressions on the
MI intervention (which were completed
at baseline and immediately postinterven-
tion only), all postintervention assessments
were completed in-hospital at 6 and 12
months postintervention by a research as-
sistant who was blinded to patient group.
To increase the success of blinding, patients
were instructed not to disclose their group
assignment to the research assistant“
However, for some outcomes (such as
AQLQ and ACT), participants the out-
come assessor were unblinded; therefore,
these outcomes are at risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Over 20%drop-out in both arms; however,
ITT and per-protocol analyses were per-
formed, and results were very similar over-
all
Selective reporting (reporting bias) Unclear risk No prospective trial registration identified,
although all outcomes listed in methods
clearly reported
Other bias Low risk None noted
NCT01169883
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 10 weeks
Setting: 3 primary care practices at Rush University Medical Center in Chicago, Illinois.
USA
Trial registration: not reported
Participants Population: 68 adolescents with asthma randomised to adherence messaging and group
sessions (n = 34) or an ”attention control“ (n = 34)
Age: 11 to 16 years of age; mean age (range) in the intervention group was 13.3 (11 to
16) years and in the control group 13.6 (11 to 16) years
Baseline asthma severity: intervention group: 85.3% of participants had uncontrolled
asthma at baseline; control group: 76.5% had uncontrolled asthma at baseline
Inclusion criteria: self-identified as African American or Hispanic, given diagnosis of
persistent asthma, possessing an active prescription for a daily ICS for asthma. Persistent
asthma was defined as asthma symptoms (e.g. cough, wheeze, shortness of breath, chest
tightness) more than 2 days per week or night-time awakenings more often than twice
a month; or taking a prescribed daily ICS for asthma
Exclusion criteria: career or child unable to speak English, comorbidities that could
interfere with study participation, ≥ 48% adherence over 2 weeks during the run-in
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period. Participants with ≥ 48% adherence were excluded, as the aim of the study was
to target children with poor adherence
Percentage withdrawn: 15% from both intervention and control groups
Other allowed medication: not reported
Interventions Intervention summary: All participants received medical supervision, peak flow meters
and an iPod during the run-in. Those in the intervention group received music tracks
and attended coping peer group sessions led by social workers during weeks 1 to 4 and
6 to 9. Session leaders were trained to use a motivational interviewing approach and to
follow the study guide. During the session, participants developed and recorded 2 to
4 messages from the discussion to encourage daily use of ICS, to be played at random
between music tracks
Control summary: All participants received medical supervision, peak flow meters and
an iPod during the run-in. Those in the attention control group attended weekly indi-
vidual sessions with a research assistant who did not promote adherence. They received
the same number of iPodmessages as those in the active intervention group, with content
promoting adherence to ICS; also played at random between music tracks but recorded
by an asthma doctor rather than by peers
Complex intervention: yes
Outcomes Outcomes measured: ICS adherence (measured at baseline and at 5 and 10 weeks),
asthma knowledge (ZAP Caregiver Asthma Knowledge Instrument), ICS knowledge,
ICS self-efficacy, social support, asthma exacerbations
Adherence calculation: average daily adherence over previous 14 days, measured with
the electronic medication monitor for ICS
Notes Type of publication: single peer-reviewed journal article
Funding: National Heart, Lung, and Blood Institute grants K23 HL092292 and R21
HL098812. Support in the form of study drug was provided by a grant from Glaxo-
SmithKline (FLV114794)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Blocked group randomization, using a
computer-generated allocation schedule“
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It was not possible to blind participants, al-
though adherence, the only reported out-
come of interest for this review, was mea-
sured objectively. However, awareness of
intervention group and monitoring may
have affected adherence behaviour beyond
the effect intended by the intervention
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”Outcomes data were collected at baseline
and at 5 and 10 weeks post-randomization
(during the active treatment phase) by re-
search assistants blinded to the participants’
group assignment“
Incomplete outcome data (attrition bias)
All outcomes
Low risk More than 80% in both arms attended at
least 1 follow-up visit (at 5 or 10 weeks)
and were included in the analysis; reasons
for dropping out were similar between the
2 groups
Selective reporting (reporting bias) Unclear risk Prospectively registered trial
(NCT01169883); outcomes listed on trial
register clearly reported (although medians
and IQR used, so unable to include it in
the meta-analysis). Several outcomes of in-
terest in this review were listed as measured
in the methods section of the published re-
port but were not reported in the results (e.
g. unscheduled visits, exacerbations)
Other bias Low risk None noted
NCT01175434
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 6 to 8 months
Setting: schools in the Rochester City School District. USA
Trial registration: NCT01175434
Participants Population: 100 children with asthma randomised to school-based care (n = 49) or usual
care (n = 51)
Age: 3 to 10 years of age; mean age (SD) in each intervention group 7.5 (1.7) years and
in usual care group 7.0 (1.8) years
Baseline asthma severity: baseline PAQLQ in the intervention group 6.25 (0.8) and
baseline QOL 5.82 (1.2)
Inclusion criteria: children with physician-diagnosed asthma with persistent symptoms
based on NHLBI guidelines
Exclusion criteria: career unable to speak and understandEnglish, no access to aworking
phone for follow-up surveys, plan to leave the school district within 6 months;any other
significant medical conditions, including congenital heart disease, cystic fibrosis or other
chronic lung disease, that could interfere with assessment of asthma-related measures
Percentage withdrawn: 2% from the intervention group and 0% from the usual care
group
Other allowed medication: not specifically reported; assumed children continued with
usual medication
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Interventions Intervention summary: systematic Web-based screening to assess children’s asthma us-
ing guideline-based symptom questions along with an algorithm to compute NHLBI
severity or control classification; report of generation and electronic communication
with primary care provider for authorisation of directly observed therapy with preventive
asthma medications through school; prescription of guideline-based preventive medica-
tions purchased through the child’s health insurance and delivered to schools and chil-
dren’s homes by a local pharmacy; directly observed administration of medications at
school by a school nurse or health aide; and systematic reassessment of symptoms using
the same system, with guideline-based adjustments to therapy as needed
Control summary: Similar to children receiving the intervention, children in the usual
care group were screened for eligibility with the online screening tool at the beginning
of the school year, but reports were not sent to their primary care provider and directly
observed therapy was not implemented at school
Complex intervention: yes
Outcomes Outcomes measured: feasibility; mean symptom-free days over 2 weeks, averaged over
the study period; numbers of days and nights with symptoms; activity limitations; rescue
medication use; school absenteeism; parent sleep interruption; change in family plans
due to the child’s asthma over the prior 2 weeks; Pediatric Asthma Caregiver’s Quality
of Life Questionnaire (PACQLQ); utilisation of healthcare services (office, ED visits,
hospitalisations and non-urgent visits for asthma care); fractional exhaled nitric oxide
Adherence calculation: recorded as part of feasibility assessment only in children ran-
domised to the intervention arm
Notes Type of publication: peer-reviewed journal article
Funding: funded by the National Heart, Lung, and Blood Institute of the National
Institutes of Health (RC1HL099432)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was stratified by use of
a preventive asthma medication at base-
line. A permutated block design was used
to ensure an equal balance of children in
each group over time. The randomisation
scheme was independently developed by
the Biostatistics Center
Allocation concealment (selection bias) Low risk The randomisation scheme was indepen-
dently developed by the Biostatistics Cen-
ter; the interviewer called the Study Co-or-
dinator, who provided the participant’s ID
number and treatment assignment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It was not possible to blind participants and
personnel to group allocation. Although
some outcomes may be more objective
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(such as hospitalisations), other outcomes
such as unscheduled visits and patient-re-
ported outcomes (e.g. quality of life) may
have been affected by participant (or career)
knowledge of group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Although the trial reports that ”all follow
up data were collected by a research group
blinded to the child’s group allocation“ for
outcomes such as quality of life, the un-
blindedparticipant or career is the outcome
assessor; therefore, these outcomes are still
at risk of detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 participant from the intervention
group was lost to follow-up before starting
the intervention. The remainder were anal-
ysed in the groups to which they were ran-
domised
Selective reporting (reporting bias) High risk Prospectively registered trial
(NCT01175434); however, peer-reviewed
publication reports outcomes not prespec-
ified (e.g. quality of life). Unclear if other
outcomes of interest (such as asthma con-
trol) may have been measured but not re-
ported
Other bias Low risk None noted
NCT01714141
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 13 weeks
Setting: an urban university and an affiliated medical centre, Detroit. USA
Trial registration: not reported
Participants Population: 49 young adults with asthma randomised tomulti-component, technology-
based intervention (n = 25) or asthma education (n = 24)
Age: 18 to 29 years; mean age (SD) in the intervention group 21.8 (4) years and in the
control group 23.1 (3.4) years
Baseline asthma severity: intervention group: asthma exacerbations in last month mean
(SD) 1.8 (2.0), ACT mean (SD) 14.0 (3.1), FEV1 mean (SD) 80.0% (21.6). Control
group: asthma exacerbations in last month mean (SD) 2.4 (4.6), ACT mean (SD) 14.4
(3.1), FEV1 mean (SD) 80.4% (15.7)
Inclusion criteria: 18 to 29 years old, African American with diagnosis of persistent
asthma, prescribed a controller medication. Individuals also had to have access to a cell
phone with texting capability and to report < 80% adherence in the past 30 days and
score ≤ 19 on the ACT
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Exclusion criteria:pregnancy, inability to understandwritten or spokenEnglish, another
serious medical condition requiring regular medication, active psychiatric disorder that
would interfere with study participation
Percentage withdrawn: 8% from the intervention group and 4% from the usual care
group
Other allowed medication: not reported
Interventions Intervention summary: Intervention consisted of 2 ”Computerized Intervention Au-
thoring Software“ (CIAS)-delivered sessions with personalised, daily text messaged re-
minders to takemedication delivered between these sessions. ”EcologicalMomentary As-
sessment“ (EMA) via text messaging was conducted before the first intervention session
to gather real-time data on participants’ medication adherence and asthma symptoms.
These data were used to tailor the intervention session for each participant
Control summary: Control participants completed CIAS-delivered asthma education
matched for length, location and method of delivery of the intervention session. Control
session was delivered by the avatar “Peedy the parrot” and included interactive features
such as quizzes and responses to poll questions. Content focused on facts andmyths about
asthma, control of environmental factors and pharmacological management. Control
participants received text messages between sessions via CareSpeak, but message content
was the same for all participants and contained general facts about asthma. Control
participants also received 7 days of EMA before the first session, but data were not used
to tailor the session
Complex intervention: no
Outcomes Outcomes measured: adherence, asthma control (ACT), lung function (FEV1), partic-
ipant satisfaction
Adherence calculation: calculated from self-reported number of doses missed compared
with prescribed doses
Notes Type of publication: single peer-reviewed journal article
Funding: supported by a grant from the National Institutes of Health (NHLBI,
1R34HL107664-01A1 (K.K.M.))
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”After completing the questionnaires, the
computer automatically randomized them
to receive either the intervention (n =25)
or control (n =24)“
Of note is a baseline imbalance in males
and females with fewermales in the control
arm, but this is more likely to be the result
of small numbers in the trial than failure of
randomisation
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Allocation concealment (selection bias) Low risk ”After completing the questionnaires, the
computer automatically randomized them
to receive either the intervention (n = 25)
or control (n = 24)“
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded to group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding of outcome assessors is not de-
scribed. In addition, for many outcomes
in this trial (self-reported adherence, ACT,
etc.), the participant is the outcome asses-
sor; therefore, we judge this study to be at
high risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low and balanced drop-out (< 10%) in
both arms
Selective reporting (reporting bias) Unclear risk No prospective trial registration identified,
but all planned outcomes clearly reported
Other bias Low risk None noted
NCT02413528
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 12 weeks
Setting: 1 university centre in New York. USA
Trial registration: NCT02413528
Participants Population: 12 adolescents with asthma planned to be randomised to adherence mon-
itoring app and sensor or standard care with monitoring via sensor
Age: 11 to 19 years
Baseline asthma severity: not reported
Inclusion criteria: asthma diagnosis, currently on a daily controller HFA medication
for asthma, English-speaking, access to a smartphone or tablet
Exclusion criteria: pregnancy, foster care, emancipated minor
Percentage withdrawn: not applicable
Other allowed medication: not reported
Interventions Intervention summary:Participants would have been given an inhaler sensor tomonitor
medication use and a mobile phone application that would send them reminders and
provide an opportunity to see their own medication use and win incentives for adherence
Control summary: Participants would have been given an inhaler sensor to monitor
medication use and a sham version of the mobile app that would not include reminders
or incentives
Complex intervention: no
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Outcomes Outcomes measured: real-time medication adherence; asthma control (ACT)
Adherence calculation: not reported
Notes Type of publication: trial registration only
Funding: CoheroHealth
NB: Study terminated owing to ”wireless connectivity challenges with device and mobile
app“
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as ”randomised“ onNCT record
- but no further details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Described as open-label but minimal de-
tails given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Described as open-label but minimal de-
tails given
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unable to assess as no study results posted;
terminated owing to ”wireless connectivity
challenges with device and mobile app“
Selective reporting (reporting bias) Unclear risk Unable to assess as no study results posted
Other bias Low risk None noted
NCT02451709
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 1 year
Setting: hospital clinics in Sheffield or Rotherham
Trial registration: NCT02451709
Participants Population: 90 children with asthma randomised to electronic adherence monitoring
with reminders and feedback (n = 47) or monitoring with no reminders or feedback (n
= 43)
Age: 6 to16 years of age; mean age (SD) in the intervention group 10.4 (2.9) years and
in the control group 10.2 (2.9) years
Baseline asthma severity: poorly controlled asthma; BTS level 3 or above
Inclusion criteria: Participants had to be taking regular inhaled steroids, with no change
in their medication in the last month and an ACQ score ≥ 1.5, indicating poorly
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controlled asthma. Electronic monitoring devices available for this trial were compatible
only with Seretide or Symbicort inhalers. Therefore, all participants were at BTS level 3
at the start of the trial
Exclusion criteria: could not speak English, had another significant chronic condition
Percentage withdrawn: 15% from the intervention group and 9% from the control
group, but all randomised participants were included in the primary ITT analysis, with
the exception of 1 control group participant who was withdrawn after randomisation
for not meeting eligibility criteria
Other allowed medication: not reported
Interventions Intervention summary: Adherence was electronically monitored with regular feedback
provided at clinic visits, during which the importance of adherence was emphasised and
personalised strategies for improvement were devised. Devices also played medication
reminder alarms. Alarms sounded for 5 seconds, every minute for 15 minutes (or until
actuation), if the inhaler had not been actuated within the previous 6 hours of the
specified time. Devices were locked to prevent tampering
Control summary: Control participants had the same EMDs attached to their regular
inhaler and were told that the devices monitored how often inhalers were taken, but that
these data would not be reviewed. Participants were seen in their standard asthma clinic,
and data were downloaded but were not reviewed. Alarms were disabled, and the devices
locked
Complex intervention: yes
Outcomes Outcomes measured: adherence, change in ACQ, FEV1%, number of unplanned at-
tendances at general practitioner (GP)/emergency department (ED) for asthma since last
visit (as reported by parents), number of courses of oral steroids
required, number of days off school due to asthma, use of beta-agonists in the past week,
BTS level of asthma therapy, mini PAQLQ
Adherence calculation: calculated for each 3-month period, both morning and after-
noon doses, and recorded as a percentage. This was calculated as number of doses actually
taken/number of doses prescribed × 100
Notes Type of publication: peer-reviewed journal article
Funding: Sheffield Children’s Hospital Charity
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised via permuted
block randomisation, with allocation of 1:
1 created from a computer-generated ran-
dom number sequence
Allocation concealment (selection bias) Low risk Allocation of participants involved phon-
ing the independent holder of the randomi-
sation code
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
neither participants nor study team mem-
bers were blinded. Although adherence,
lung function and oral steroid use might
be considered objective outcomes, poten-
tial for performance bias remains for out-
comes such as AQLQ and ACQ
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding of outcome assessors is not de-
scribed; although some outcomes are rela-
tively objective and are not prone to detec-
tionbias (adherence, lung function andoral
corticosteroid use), others such asACQand
AQLQ involve the unblinded participant
as the outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk Less than 15% drop-out in both arms; all
but 1 participant included in the intention-
to-treat primary analysis
Selective reporting (reporting bias) High risk Prospectively registered
trial (NCT02451709); all outcomes spec-
ified in the methods are mentioned in the
paper, although some non-numerically (e.
g. mini-PAQLQ, BMQ, SABA use, IPQ),
so could not be included in the meta-anal-
ysis
Other bias Low risk None noted
Onyirimba 2003
Methods Design: single-blind, parallel-group randomised controlled trial
Duration: 10 weeks
Setting: 1 asthma centre at Saint Francis Hospital, Connecticut. USA
Trial registration: not reported
Participants Population: 30 adults with asthma randomised to adherence monitoring and education
or monitoring without feedback (n randomised to each arm not reported)
Age: over 18 years of age; mean (SD) age in the intervention group 45 (11) years and in
the control group 53 (14) years
Baseline asthma severity: intervention group: mean FEV1 78% predicted; mean (SD)
ED visits in the past year 2.3 (2.4); 80% on LABA; mean (SD) AQLQ score 4.34 (1.
62). Control group: mean FEV1 63% predicted; mean (SD) ED visits in the past year
1.0 (0.8); 100% on LABA; mean (SD) AQLQ score 3.75 (1.39)
Inclusion criteria: Adults with moderate to severe asthma were considered for the study
if they met all of the following inclusion criteria: referral to the Asthma Center at Saint
Francis Hospital and Medical Center; 1 or more markers of low socioeconomic status
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(Medicaid or no insurance, family income < $20,000, less than a high school education)
; prebronchodilator FEV1 < 80% of predicted and 15% predicted greater reversibility
after bronchodilator administration; and regular use of inhaled steroids and willingness
to change the schedule, if necessary, to twice-daily dosing
Exclusion criteria: not reported
Percentage withdrawn: 10 participants in the intervention group and 9 in the control
groups completed the trial. Numbers randomised to each arm not reported
Other allowed medication: Use of long-acting oral or inhaled bronchodilators, theo-
phylline and oral corticosteroid was permissible
Interventions Intervention summary: Intensive asthma education and management was provided by
a nurse and/or respiratory therapist over approximately a 3-week period, with follow-
up for 7 additional weeks. Content was based on NAEPP guidelines covering goals of
therapy, signs of worsening asthma, types of medications, importance of prophylactic
medication, properMDI technique, use of PEFmeter, patient satisfaction and QOL and
environmental evaluation and education. Data fromMDI Chronologs were downloaded
at each visit andwere reviewedwith the clinician,who emphasised techniques or strategies
to improve adherence when necessary, according to type and timing of non-adherence
Control summary:Control group visited to complete outcome measures, and data were
downloaded from Chronologs, but no education or adherence advice was given
Complex intervention: yes
Outcomes Outcomes measured: adherence to ICS, albuterol use (mean actuations per 24 hours
for each week), AQLQ, FEV1
Adherence calculation: overall mean weekly adherence and percentage of days with
overuse
Notes Type of publication: single peer-reviewed journal article
Funding: in part by an award from theUniversity ofConnecticutHealthCenterResearch
Advisory Committee
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”patients were randomized into 1 of 2
groups“ - no further details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk ”Patients were told that these instruments
recorded the time and date of each MDI
actuation but were blinded to the study hy-
pothesis“
Although participants were blinded to the
study hypothesis, knowledge of group allo-
cation and the fact that adherence was be-
ing monitored may have altered adherence
behaviour beyond the effect intended by
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trialists
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Although trialists went to some lengths to
blind outcome assessors (”For the initial pe-
riod, patients met at the first visit and three
subsequent visits with a nurse and/or res-
piratory therapist blinded to the patients’
group“), for AQLQ the participant is the
outcome assessor; therefore, such outcomes
are presented at risk of detection bias
Incomplete outcome data (attrition bias)
All outcomes
High risk 10/30 participants did not complete the
study; it is not clear how many were ran-
domised to each group or whether rea-
sons for dropping out were similar between
groups
Selective reporting (reporting bias) Unclear risk No prospective trial registration identified,
although all outcomes listed in methods
were reported in text/tables
Other bias Low risk None noted
Price 2010
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 12 weeks
Setting: 143 sites in the UK
Trial registration: not reported
Participants Population: 1233 participants with asthma randomised to intervention (once-daily ICS)
(n = 611) or control (twice-daily ICS) (n = 622)
Age: 12 years of age and older; mean (SD not reported) age in the adherence group 50.
9 years and in the control group 50.9 years
Baseline asthma severity: intervention group: mean duration of asthma 16.4 years;
control group: mean duration of asthma 16.2 years
Inclusion criteria: treated with beclomethasone dipropionate (BDP) hydrofluoroalkane
(≤ 500 µg/d) or BDP chlorofluorocarbon (≤ 1000 µg/d) for ≥ 12 weeks, with sta-
ble BDP dosing regimen for ≥ 4 weeks immediately before study entry. Inclusion of
patients who used BDP as their prior ICS therapy was justified because BDP was the
ICS prescribed most commonly in the UK at the time the study was conducted, thereby
providing a patient population as large and as homogeneously treated as possible. Eligible
patients had no clinically significant disease that would interfere with study evaluation,
and female patients of childbearing potential were required to use medically accepted
birth control
Exclusion criteria: ventilator support required for respiratory failure due to asthma
within the previous 5 years, hospitalisation within the previous 3 months due to asthma
Percentage withdrawn: 16.5% from the adherence group and 15.3% from the control
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group
Other allowed medication: not reported
Interventions Intervention summary: mometasone furoate (MF) DPI 400 µg once daily in the
evening. Participants were instructed in inhaler use and peak flow measurement to
demonstrate proficiency and received salbutamol for rescue medication. They were also
given diary cards and were instructed to follow an asthma action plan formulated at their
first visit
Control summary: mometasone furoate DPI 200 µg twice daily. Participants were in-
structed in inhaler use and peak flow measurement to demonstrate proficiency and re-
ceived salbutamol for rescuemedication. Theywere given diary cards andwere instructed
to follow an asthma action plan formulated at their first visit
Complex intervention: no
Outcomes Outcomes measured: Primary outcome was adherence measured by the counter. Sec-
ondary outcomes included self-report adherence, physician’s assessment of response,
quality of life on the Integrated Therapeutics Group Asthma Short Form (ITG-ASF)
(week 12), utilisation of healthcare resources and number of days missed from work or
school. Adverse events were recorded at all visits, and an abbreviated physical exam was
performed at visits 1 and 4. Evaluation of asthma worsening was performed at all visits,
defined as increased use of rescue medication (> 12 inhalations on 2 consecutive days)
, a decrease in peak flow > 25% on 2 consecutive days or clinical asthma exacerbations
(unscheduled doctor’s visit, hospitalisation, ER visit and/or use of additional asthma
medications other than short-acting beta-agonists)
Adherence calculation: Adherence was calculated as the number of administered doses
(as determined by device counter number) times 100 divided by the number of scheduled
doses. Data were not included for analysis if invalid (e.g. gross misuse of device, missing
treatment end dates, device malfunction)
Notes Type of publication: single peer-reviewed journal article
Funding: Schering Corp., a division of Merck & Co.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Patients were randomized to receive either
MF-DPI 400 µg once-daily in the evening
or MF DPI 200 µg twice-daily from in-
halersmeasuring 220µg/actuation and de-
livering 200 µg/inhalation“
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Trial is described as open-label; although
adherence was measured objectively with a
device counter, knowledge of group allo-
cation and monitoring may have affected
adherence behaviour. In addition, patient-
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reported outcomes, such as HRQOL, are
susceptible to risk of performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Trial is described as open-label; although
adherence was measured objectively with a
device counter, knowledge of group allo-
cation may have affected patient-reported
outcomes, such as HRQOL, for which the
participant is the outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop-out < 20% in both groups, and rea-
sons for discontinuation appear similar be-
tween groups. All participants included in
the safety analysis
Selective reporting (reporting bias) Unclear risk No prospective trial registration identified,
although all outcomes listed in methods
were reported in text/tables. Asthma wors-
ening was not reported as planned
Other bias Low risk None noted
Strandbygaard 2010
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 12 weeks
Setting: 1 university hospital. Denmark
Trial registration: not reported
Participants Population: 26 adults with asthma randomised to SMS adherence reminders (n = 12)
or usual care (no reminders) (n = 14)
Age: 18 to 45 years of age; mean (SD not reported) age in the intervention group 34.4
years and in the control group 30.7 years
Baseline asthma severity: among the randomised participants: 8 (30.8%) were cate-
gorised as mild persistent (GINA 2), 16 (61.5%) as moderate persistent (GINA 3) and
2 (7.7%) as severe persistent (GINA 4). Before enrolment into the study, 9 participants
(34.6%) had used SABA as monotherapy, 9 (34.6%) had used ICS (alone or in combina-
tion with LABA and/or SABA) and the remaining 8 (30.8%) had not used any treatment
at all over the last 3 months
Inclusion criteria: diagnosis of asthma based on clinical history and daily symptoms,
age between 18 and 45 years, positive methacholine challenge test with PD20≤ 4 mmol
Exclusion criteria: other medical comorbidities, smoking history of more than 10 pack-
years
Percentage withdrawn: 17% from the intervention group and 14% from the control
group
Other allowed medication: not reported
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Interventions Intervention summary: 4-week run-in on LABA/ICS, then 12 weeks of daily SMS
reminders. SMS reminder was sent daily at 10 AM on cell phone over the following 8
weeks. All enrolled participants received a thorough education concerning the necessity
of ICS treatment in asthma, and all were provided with knowledge of disease mechanisms
and correct inhaler technique
Control summary: 4-week run-in on LABA/ICS and no reminders. All enrolled par-
ticipants received a thorough education concerning the necessity of ICS treatment in
asthma, and all were provided with knowledge of disease mechanisms and correct inhaler
technique
Complex intervention: no
Outcomes Outcomes measured: mean rate of adherence to asthma treatment, reimbursement
for asthma medication, change in exhaled nitric oxide levels, lung function, airway
responsiveness
Adherence calculation: Adherence rate was registered as the percentage of medicine ac-
tually taken by participants, calculated frommedicine dose count on the Discos Seretide
and number of days between clinical examinations: (60 dose-count)/2 × days × 100%
Notes Type of publication: single peer-reviewed journal article
Funding: GlaxoSmithKline provided a financial contribution to the service on the In-
ternet including the short message service provided by CIM mobility
NB:Only 34.6% of people had taken ICS in the last 3 months, and 30.8% no treatment
at all, but everyone was put on Seretide at the start of the study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Randomisation was done by means of au-
tomatic computer generation of randomi-
sation numbers in blocks of six“
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Trial is not described as blinded; although
adherence was measured objectively with
a device counter, knowledge of group al-
location and monitoring may have af-
fected adherence behaviour. In addition,
patient-reported outcomes, such as ACQ
and AQLQ, are susceptible to risk of per-
formance bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Trial is not described as blinded; although
adherence was measured objectively with a
device counter, knowledge of group allo-
cation affected patient-reported outcomes,
such as ACQ and AQLQ, for which the
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participant is the outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Drop-out < 20% in both groups, but rea-
sons for discontinuation not given and no
participant flow diagram presented. Also
unclear how many participants are in-
cluded in the primary analysis, as this is
presented in the text and not in a table
Selective reporting (reporting bias) Unclear risk No prospective trial registration identified,
although all outcomes listed inmethods re-
ported in text/tables
Other bias Low risk None noted
Ulrik 2009
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 12 weeks
Setting: 29 GSK investigational sites in Denmark and Switzerland
Trial registration: NCT00351143; EudraCT no. 2005-0003374-48; ACE104325
Participants Population: 274 adults with asthma randomised to adherence education and study
medication (n = 140) or study medication only (n = 134)
Age: over 18 years of age; mean (SD) age in the intervention group 40.5 (13.9) years
and in the control group 38.7 (14.6) years
Baseline asthma severity: Across the 2 groups, most randomised participants had mild
persistent (51%) or moderate persistent (34%) asthma
Inclusion criteria: ≥ 18 years of age; diagnosis of persistent asthma; treatment with at
least 250 mg fluticasone propionate bid (or equivalent for other ICS) 4 weeks before
the study and/or LABA bid or monotherapy with a short-acting beta2-agonist; ability
to comply with use of the Asthma Monitor 2 (AM2) and the Asthma Quality of Life
Questionnaire (AQLQ). Participants who had an exacerbation during the study period
were allowed to remain in the study
Exclusion criteria: known or suspected chronic obstructive pulmonary disease (COPD)
; pregnancy or lactation; smoking history > 10 pack-years; clinical or laboratory evidence
of serious uncontrolled systemic disease; microbiologically verified upper or lower respi-
ratory tract infection within 1 month before screening visit; acute asthma exacerbation
requiring hospitalisation/emergency department treatment/treatment with systemic cor-
ticosteroids within 3months before screening visit; furthermore, for entry into treatment
period 1 and treatment period 2: changes in asthma medication, including treatment
with systemic corticosteroid, during the preceding period; more than 1 week of guide-
line-defined asthma control before baseline visit/during treatment period 1; achieving
total control in treatment period 1 (participants randomised at end of treatment period
1 and before entry into treatment period 2)
Percentage withdrawn: not reported
Other allowed medication: Those who had been treated with oral corticosteroids in
the preceding 3 months were excluded from enrolling, and those who needed a change
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in asthma medication during period 1 were excluded from period 2
Interventions Intervention summary: given salmeterol/fluticasone propionate 50/250 mg (Diskus®)
bid and salbutamol prn for 12 weeks before randomisation (period 1). Then for 12
weeks (period 2), those who did not achieve total control were randomised and were
given 5 patient-centred teaching modules that included education about asthma, risk
factors, prognosis, expectations of treatment, correct ways of taking controller and rescue
medication and mnemonics as an aid for optimal dosing/timing of medication. Based on
both written and oral information. Coaches were trained to use the standardised material
at all centres
Control summary: given salmeterol/fluticasone propionate 50/250 mg (Diskus®) bid
and salbutamol prn for 12 weeks before randomisation (period 1). Then for 12 weeks
(period 2), those who did not achieve total control were randomised and continued with
the same study medication
Complex intervention: yes
Outcomes Outcomes measured: total asthma control; PEF; symptom scores; rescue medication
use; number of nights awakenings due to asthma; adverse events; quality of life (AQLQ);
medication compliance; asthma severity; adverse events (including exacerbations, emer-
gency visits and hospitalisations); vital signs. The asthma monitor AM2 medical device
was used to collect the following data on a daily basis: FEV1; pre-dose morning PEF;
symptoms; use of rescue medication; night-time awakenings; exacerbations; change of
medication due to side effects and emergency doctor visits
Adherence calculation: Treatment compliance was assessed by counting the number of
doses in the returned investigational product
Notes Type of publication: single peer-reviewed journal article
Funding: GlaxoSmithKline
NB: Period 2 of interest. During study period 1, all participants were treated with salme-
terol/fluticasone 50/250. Those who did not achieve total asthma control in treatment
period 1 were randomised to continued treatment with or without adherence education
concomitantly for a further 12 weeks (period 2)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”subjects who did not achieve total asthma
control in treatment period 1 were ran-
domised to continued treatment with or
without compliance enhancement training
concomitantly for a further 12 weeks“ - no
further details
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Trial is described as open-label; although
adherence was measured objectively with a
device counter, knowledge of group allo-
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cation and monitoring may have affected
adherence behaviour. In addition, patient-
reported outcomes, such as quality of life,
are susceptible to risk of performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Trial is described as open-label; although
adherence was measured objectively with a
device counter, knowledge of group allo-
cation and monitoring may have affected
patient-reported outcomes, such as quality
of life, for which the participant is the out-
come assessor
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All efficacy analyses were performed by in-
tent-to-treat (ITT) analysis on all partici-
pants with data entered into the database,
who had received at least 1 single dose of
trial medication in treatment period 2 (ran-
domised portion of the trial); therefore, this
was the population for analysis of the pri-
mary endpoint. Sensitivity analyses were
performed
for the per-protocol population for treat-
ment period 2, which comprised all partici-
pants in the ITT-2 population who did not
have major protocol violations. The safety
population comprised all participants who
had received at least 1 single dose of study
medication. However, no flow diagramwas
presented and drop-out was not clearly re-
ported
Selective reporting (reporting bias) High risk Prospectively registered
trial (NCT00351143; EudraCT no. 2005-
0003374-48).However,many outcomes of
interest were not reported numerically, so
could not used in the meta-analysis
Other bias Low risk None noted
Vasbinder 2015 E-MATIC
Methods Design: open-label, parallel-group randomised controlled trial
Duration: 52 weeks
Setting: 5 outpatient clinics. The Netherlands
Trial registration: Netherlands Trial Register NTR2583
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Participants Population: 219 children with asthma randomised to receive SMS adherence reminders
(n = 108) or no reminders (n = 111)
Age: 4 to 11 years of age; mean (SD) age in the intervention group 7.8 (2.2) years and
in the control group 7.7 (2.1) years
Baseline asthma severity: intervention group: 39.8% had poorly controlled asthma
(ACT); control group: 36.5%
Inclusion criteria: 4 to 11 years of age at the start of the study; doctor-diagnosed asthma
for at least 6 months; ICS use for at least 3 months; use of a pMDI; use of fluticasone,
fluticasone/salmeterol or beclomethasone; at least 1 parent/career with a mobile phone
Exclusion criteria: refusal to participate in the study
Percentage withdrawn: not reported
Other allowed medication: not reported
Interventions Intervention summary: All children received an RTMM-device that registers time and
date of administered ICS doses. Children in the intervention group received “time-
tailored” text messages that were sent only when a dose was at risk of omission
Control summary: All children received an RTMM-device that registers time and date
of administered ICS doses. Those in the control group do not receive such text messages
Complex intervention: no
Outcomes Outcomes measured: adherence to ICS; asthma control (ACT); frequency of asthma
exacerbations and use of healthcare services (pharmacy data checked for OCS use and
health records); disease-specific quality of life; school/work absence; paediatric AQLQ;
acceptance of e-monitoring; economic evaluation
Adherence calculation: proportion of all prescribed dosages taken by the child within
a 6-hour time frame around planned time of inhalation (i.e. from 3 hours before until
3 hours after) calculated from RTMM data on ICS use, attached to the inhaler
Notes Type of publication: multiple peer-reviewed journal articles
Funding: supported by a non-conditional grant fromThe NetherlandsOrganisation for
Health Research and Development (ZonMw, grand registration number 171101005).
The study is also partially sponsored by the pharmaceutical company GlaxoSmithKline.
The manufacturer of the RTMM devices, Evalan BV, partially sponsors the study by
providing devices at cost price
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Computer-generated block randomisa-
tion was used per hospital with block size
of 16 patients“
Allocation concealment (selection bias) Low risk ”At registration at the RTMM software
interface, children were automatically as-
signed to the intervention or control
group“ - suggests that allocation was con-
cealed, as this was performed at an IT in-
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terface
Blinding of participants and personnel
(performance bias)
All outcomes
High risk ”Although physicians, researchers and pa-
tients were initially blinded for randomi-
sation, patients were generally unblinded
shortly after the start of the study period,
when they found out whether they received
SMS reminders or not“
Knowledge about group allocation may
have affected performance, especially in
subjective measures such as PAQLQ and
cACT
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessors de-
scribed. Primary outcome - adherence -
measured objectively and not likely to be
at risk of detection bias, but for other
outcomes (such as PAQLQ and cACT),
the unblinded participant/career is the out-
come assessor; therefore, these outcomes
are at risk of bias
Incomplete outcome data (attrition bias)
All outcomes
High risk ”Reasonswhy patients left the study prema-
turely were not systematically registered“,
and the total number of people who did
not complete the study and hence had to
have their data imputed is not reported.
The numbers in Figure 2 suggest very low
retention of around 50% in each arm
Selective reporting (reporting bias) Low risk Prospectively published protocol and all
outcomes clearly reported in main publica-
tion
Other bias Low risk None noted
ACQ: Asthma Control Questionnaire; ACT: Asthma Control Test; AE: asthma education; AQLQ: Asthma Quality of Life Question-
naire; BDP: beclomethasone dipropionate; BMQ: Beliefs about Medication Questionnaire; BTS/SIGN: British Thoracic Society/
Scottish Intercollegiate Guidelines Network; cACT: Childhood Asthma Control Test; CBQ-20: Conflict Behaviour Questionnaire-
20; CI: confidence interval; COPD: chronic obstructive pulmonary disease; CSQ: Consumer Satisfaction Questionnaire; CVD:
cardiovascular disease; DDD: Daily Defined Doses; DPI: dry powder inhaler; ED: emergency department; EMA: Ecological Mo-
mentary Assessment; EMD: electronic monitoring device; EPAC: episode of poor asthma control; FEV1: forced expiratory volume
in one second; FP: fluticasone propionate; FSI: Functional Severity Index; FVC: forced vital capacity; GINA: Global Initiative for
Asthma; GP: general practitioner; GSK: GlaxoSmithKline; HADS: Hospital Anxiety and Depression Scale; HFA inhaler: hydroflu-
oroalkane inhaler; HMO: health maintenance organisation; HRQOL: health-related quality of life; ICS: inhaled corticosteroids;
IPQ: Illness Perceptions Questionnaire; IQR: interquartile ratio; IRF: inhaler reminders and feedback; IT: information technology;
ITT: intention-to-treat; IVR: interactive voice response; KAAM: Knowledge of Asthma and Asthma Medicine Questionnaire; KP:
Kaiser Permanente; KPCO: Kaiser Permanente Colorado; KPH: Kaiser Permanente Hawaii; KPNW: Kaiser Permanente Northwest;
LABA: long-acting beta2-agonists; MARS-A: Medication Adherence Report Scale; MD: mean difference; MDI: metered dose in-
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haler;MI: motivational interviewing; NAEPP:National Asthma Education and Prevention Program;NHLBI: National Heart, Lung,
and Blood Institute; NS: not statistically significant; OCS: oral corticosteroid; PAD: personalised adherence discussion; PAQLQ:
Paediatric Asthma Quality of Life Questionnaire; PDC: proportion of days covered; PedsQL: Paediatric Quality of Life Inventory;
PEF: peak expiratory flow; pMDI: pressurised metered dose inhaler; PS: problem solving; QOL: quality of life; RTMM: real-time
medication monitoring; SABA: short-acting beta2-agonists; SD: standard deviation; SF-36: Short Form-36; SMAQ: Simplified
Medication Adherence Questionnaire; SMS: short message service/text message; SR: speech recognition; UC: usual care; URTI:
upper respiratory tract infection; VAS: visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Armour 2007 Adherence not primary focus
Canino 2016 Adherence not primary focus
Coté 1997 Adherence not primary focus
Dal Negro 2002 Drug trial observing adherence
Delaronde 2005 Adherence not primary focus
Demiralay 2002 Adherence not primary focus
Demiralay 2004 Adherence not primary focus
Fiks 2015 Adherence not primary focus
Fujita 2002 Drug trial observing adherence
Gallefoss 2002 Adherence not primary focus
Garcia-Cardenas 2013 Adherence not primary focus
Gerald 2012 Drug trial observing adherence
Goeman 2013 Trial of tailored asthma education in older adults; adherence not primary focus
Guenette 2015 Wrong study design
Holt 2004 Wrong study design
Iqbal 2004 Wrong study design
Janson 2003 Adherence not primary focus
Janson 2009 Adherence not primary focus
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(Continued)
Jonasson 1999 Drug trial observing adherence
Jonasson 2000 Drug trial observing adherence
Krishnan 2012 Drug trial observing adherence
Kuna 2006 Trial of once-daily vs twice-daily dosing designed to demonstrate equivalent efficacy. Simplification of
treatment regimen postulated to improve adherence in a real-life setting, but this was a double-blind, double-
dummy trial, and participants in the trial were not aware of which regimen they had been prescribed. Judged
not to be an intervention to improve adherence per se
Martin 2015 < 50% taking ICS at baseline
Mishra 2005 Wrong study design
Munks-Lederer 2001 Adherence not primary focus
NCT00181194 Wrong study design
NCT00201188 Adherence not primary focus
NCT00381355 Written action plan (WAP) vs unformatted prescription post exacerbation. WAP was multi-faceted and was
intended to modify physician ICS prescribing behaviour as well as participant adherence, follow-up and
asthma management more generally. Adherence to ICS not primary focus of the intervention
NCT01106326 Wrong study design
NCT01128348 Adherence not primary focus
NCT01644357 Adherence not primary focus
NCT02093013 Wrong study design
NCT02363192 Adherence not primary focus
NCT02426801 Wrong study design
Nikander 1998 Drug trial observing adherence
Nikander 2003 Drug trial observing adherence
Patel 2013 Drug trial observing adherence
Petitto 2012 Drug trial observing adherence
Pongchaidecha 2005 Not asthma, or mixed population
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(Continued)
Sajadi 2016 Intervention to improve adherence to asthma therapy generally. Number using ICS not reported, and ICS
not mentioned anywhere in trial report. Therefore assumed not to be an intervention aimed at improving
adherence to ICS
Schacher 2006 Adherence not primary focus
Schultz 2012 Drug trial observing adherence
Sovani 2008 SMART therapy (single LABA/ICS inhaler for maintenance and reliever) vs separate inhalers for ICS and
SABA, so groups received different medications. This means the effect on measures of asthma control might
be a result of LABA therapy, or of improved adherence to ICS, but it is not a clear enough comparison to
judge
Wilson 2010 Shared decisionmaking vs clinician decisionmaking and usual care. Interventions led to differentmedication
usage, which meant this is not a clear comparison by which to assess ICS adherence, and that and was
not primarily aimed at improving adherence to ICS. Adherence to ICS therefore not a primary focus of
intervention
Wolthers 2002 Wrong study design
ICS: inhaled corticosteroid; LABA: long-acting beta2-agonists; SABA: short-acting beta2-agonists; WAP: written action plan
Characteristics of studies awaiting assessment [ordered by study ID]
ISRCTN83334596
Methods Randomised controlled trial. Title: Is Compliance With Inhaled Therapy in Asthma Increased by the Use of Small-
Volume Spacers?
Participants Asthma. No other details
Interventions Patients are randomised to use:
• Small-volume spacer
• Large-volume spacer
Outcomes Not provided at time of registration
Notes Trial end date 01/10/2003. Listed as completed and no longer recruiting. No publications identified and no results
posted
120Interventions to improve adherence to inhaled steroids for asthma (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT00269282
Methods Open-label randomised controlled trial with parallel assignment. Title: Increasing Adherence to Asthma Medication
in Urban Teens
Participants Inclusion criteria: 10 to 15 years of age; resident of Baltimore City; diagnosis of asthma or reactive airway disease;
current emergency department visit or hospitalisation for asthma; prescribed a daily asthma controller medication
Exclusion criteria: plans to move outside of the Baltimore City area within 1 year from study entry; current partic-
ipation in another asthma education study; families unwilling or unable to participate; families who were enrolled
and participated in the pilot study
Interventions Self-management (standard care group) vs motivational interviewing plus self-management
Outcomes Adherence to controller therapy measured by electronic medication monitoring at baseline, 3 months and 6 months.
Number of symptom-free days, emergency department utilisation and hospitalisation, career/adolescent quality of
life - all measured at the same time points
Notes Planned enrolment 207. Primary completion date January 2012. Listed as completed, but no publications identified
and no results posted
NCT01253330
Methods Open-label randomised controlled trial with cross-over assignment. Title: Usage, Usability & Effect on Adherence
and Clinical Outcomes of Text Message Reminders for Adolescents With Asthma
Participants Inclusion criteria: between the ages of 12 and 22; diagnosis of persistent asthma; receiving care at Cincinnati Children’s
Hospital Medical Center or affiliate; prescription of a controller medication; must have a cell phone that receives text
messages; asthma not well controlled based on Asthma Control Test (ACT) score; English speaking
Exclusion criteria: no diagnosis of persistent asthma; receiving asthma care other than at a Cincinnati Children’s
Hospital Medical Center or affiliate; asthma well controlled based on ACT score; does not have a cell phone that
receives text messages or plans to change phones within the next 6 months; not taking a daily asthma controller
medication; currently receiving asthma appointment or medication reminder text messages from another source
Interventions Text message reminders vs no intervention
Outcomes Asthma Control Test (ACT), Pediatric Quality of Life Scale (PedsQL), adherence change from baseline
Notes Planned enrolment 61. Primary completion date December 2012. Listed as completed but no publications identified
and no results posted
NCT02045875
Methods Open-label randomised controlled trial with parallel assignment. Title: Improving AsthmaControl in the RealWorld:
A Systematic Approach to Improving Dulera Adherence
Participants Inclusion criteria: physician diagnosis of asthma ofmoderate severity;≥ 18 years of age; currently receiving an inhaled
corticosteroid medication and prescribed Dulera 100/5 as part of standard of care based on asthma severity and
dosing guidelines; Asthma Control Questionnaire (ACQ) result > 1.0 at entry; demonstration of correct inhalation
technique for use of meter dosed inhalers (MDIs); history of reversible airway obstruction documented by treating
physician
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NCT02045875 (Continued)
Exclusion criteria: Intermittent asthma (asthma exacerbations or symptoms < 3 days/wk); diagnosis of emphysema
in prior year; diagnosis at any time of chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic
fibrosis, bronchiectasis, Churg Strauss, Wegener’s, sarcoidosis, pulmonary hypertension or lung cancer; taking any
medication documented to have a drug interaction with Dulera
Interventions Dulera adherence monitoring with motivational interviewing vs standard asthma care
Outcomes ACQ, adherence to Dulera, validation of an adult asthma adherence questionnaire (AAAQ)
Notes Planned enrolment 40. Estimated study completion date December 2015. Note from clinicaltrials.gov: ”The recruit-
ment status of this study is unknown because the information has not been verified recently“
NCT02176694
Methods Open-label randomised controlled trial with parallel assignment. Title: Adolescent Controlled Text Messaging to
Improve Asthma Medication Adherence in Primary Care (ACT Me)
Participants Inclusion criteria: provider-diagnosed persistent asthma; prescription of an inhaled corticosteroid (ICS) in accordance
with National Heart, Lung, and Blood Institute (NHLBI) Expert Panel Report 3 guidelines for at least 30 days before
enrolment; Asthma Control Test (ACT) score < 20 (indicating lack of current control);
no provider-diagnosed exacerbation in the 30 days before enrolment; possession of a text-enabled cell phone and
plan to keep it throughout the study period; agreement by parents (or participants over 18 years old) to any charges
levied by their cell phone carrier for text messages associated with the study if they do not have an unlimited texting
plan; ability to speak and read English
Exclusion criteria: another chronic lung disease (which would complicate measurement of asthma control); cognitive
or psychiatric disorder that the treating clinician judges would impair study participation; use of Advair Diskus for
ICS (for which no reliable electronic monitor exists); current enrolment in another asthma intervention study
Interventions Technology-based system that allows adolescents to compose, schedule and send 1-time or recurring text messages
to their own cell phones. Control group receives usual care
Outcomes Adherence each month, feasibility, acceptability and useability of the website, asthma control (ACT), quality of life
(Pediatric Quality of Life Scale (PedsQL))
Notes Planned enrolment 29. Primary completion date December 2015. Listed as completed, but no publications identified
and no results posted
Characteristics of ongoing studies [ordered by study ID]
NCT01381159
Trial name or title Motivational Intervention for Asthma (MI-ACT)
Methods Double-blind, parallel-group randomised controlled trial
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NCT01381159 (Continued)
Participants • Patients 18 years of age and older
• Primary diagnosis of moderate to severe persistent asthma (as per GINA)
• Prescribed inhaled corticosteroid medication (minimum dose of 250 µg fluticasone equivalent per day)
for at least 12 consecutive months
• Uncontrolled asthma (≥ 1.25 on the Asthma Control Questionnaire)
• Coverage by a drug insurance plan
• Non-adherence to ICS medication (based on having filled < 50% of their prescriptions over the past
year)
• Ability to speak English or French
Interventions Motivational communication or control
Outcomes Primary outcome measure: inhaled corticosteroid adherence
Starting date January 2011
Contact information
Notes Link to study registration: https://clinicaltrials.gov/ct2/show/NCT01381159
NCT02170883
Trial name or title EmPhAsIS: Empowering Pharmacists in Asthma Management Through Interactive SMS
Methods Open-label, parallel-group randomised controlled trial
Participants • Filling a (incident or prevalent) prescription for inhaled corticosteroids (monotherapy or in
combination inhaler with long-acting beta-agonists) who have received a diagnosis of asthma from a doctor
• Possessing a cell phone with ability to send/receive text messages
• Residing in British Columbia (BC), Canada, and planning to reside in BC for the next 12 months
• Registered with the medical services plan (MSP, the provincial insure of medically required services) in
the past 12 months, and planning to remain registered for the next 12 months
• Designated pharmacy being main drugstore for patient
• Not participating in another interventional study
• Providing consent to participate in the study
Interventions Interactive SMS or usual care
Outcomes Adherence to inhaled corticosteroid medication
Starting date May 2015
Contact information
Notes https://clinicaltrials.gov/ct2/show/NCT02170883
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NCT02203266
Trial name or title Teaching Inhaler Use With the INCA Device in a Community Pharmacy Setting
Methods Open-label, parallel-group randomised controlled trial
Participants • 18 years old or above
• Capable of understanding and willing to provide voluntary informed consent before any protocol-
specific procedures are performed
• Capable of understanding and complying with requirements of the protocol, and demonstrating
willingness to attend for all required visits
• Capable of taking and willing to take inhaled medication
• Valid prescription for use of a Seretide Diskus inhaler or already using a Seretide Diskus inhaler
• History of regular attendance at the pharmacy in which they are recruited, which will be demonstrated
by patient having collected 3 prescriptions for any medication in that pharmacy in the 6 months preceding
their recruitment into the study
Interventions Feedback on inhaler use, education or control
Outcomes Rate of adherence
Starting date February 2014
Contact information
Notes https://clinicaltrials.gov/ct2/show/NCT02203266
NCT02307669
Trial name or title Inhaler Adherence in Severe Unstable Asthma (INCA-SUN)
Methods Double-blind, parallel-group randomised controlled trial
Participants • Willing to give voluntary informed consent
• Having a clinical diagnosis of asthma-
• Having a bronchodilator FEV1 > 40% and < 80% in the past 1 year
• Having current unstable asthma (i.e. ACT score < 19) at enrolment
• Taking 2 or more courses of oral corticosteroids in the prior year, or hospitalisation or ED attendance
with an asthma exacerbation in the past year
• 18 years of age or older at time of consent
• Capable of understanding and complying with requirements of the protocol, including ability to
attend for all required visits
• Ability and willingness to take inhaled medication via a Diskus
• In the opinion of the investigator, suitable for use of a salmeterol/fluticasone Diskus inhaler or already
using a salmeterol/fluticasone inhaler
Interventions Feedback on inhaler use or routine care
Outcomes Adherence to preventer medication; cost and effectiveness of medication
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NCT02307669 (Continued)
Starting date December 2015
Contact information
Notes https://clinicaltrials.gov/ct2/show/NCT02307669
NCT02386722
Trial name or title Intervention to Improve Inhalative Adherence
Methods Single-blind, parallel-group randomised controlled trial
Participants • Inpatients and outpatients older than 18 years with a clinical diagnosis of asthma or COPD
• At least 1 exacerbation in the past year
• Ability to give informed consent.
• Good knowledge of the German language by themselves
• Use of a metered dose Inhaler (e.g. Ventolin®), Diskus (e.g.Seretide®), Turbohaler (e.g.Symbicort®),
Aerolizer/Breezhaler (e.g. Onbrez®) or HandiHaler (e.g. Spiriva®)
Interventions Audio reminders and support calls or control
Outcomes Time to next asthma or COPD exacerbation; number of exacerbations; adherence
Starting date January 2014
Contact information
Notes https://clinicaltrials.gov/ct2/show/NCT02386722
NCT02426814
Trial name or title Assessment of a Mobile Intervention to Increase Adherence to Asthma Medication Among Adolescents
Methods Open-label, parallel-group randomised
Participants • Age 11 to 19 years
• Asthma diagnosis
• Current prescription for a hydrofluoroalkane (HFA) asthma controller medication
• Ability to speak English
• Having a smartphone or access to a smartphone or tablet
Interventions Medication Monitoring and Mobile App or sham comparator
Outcomes Real-time medication adherence
Starting date August 2015
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NCT02426814 (Continued)
Contact information
Notes https://clinicaltrials.gov/ct2/show/NCT02426814
NCT02556073
Trial name or title ICS/LABA Combination With Integrated Dose Counter and Smartphone App to Improve Asthma Control
Methods Open-label, parallel-group randomised
Participants • Symptomatic asthmatic individuals free of controller medication for at least 3 months
• 20 to 70 years of age
• Life-long smoking index < 10 pack-years
Interventions Smartphone self management or routine care
Outcomes Changes in airway inflammation profile; changes in scores of Asthma Control Questionnaire; changes in lung
function parameters; numbers of rescue medications used
Starting date August 2014
Contact information
Notes Link to study registration: https://clinicaltrials.gov/ct2/show/NCT02556073
NCT02615743
Trial name or title Asthma Controller Adherence After Hospitalization
Methods Open-label, parallel-group randomised
Participants • Unlimited text messaging plan
• Prescription for 1 of the following metered dose inhalers for daily use: Flovent (fluticasone), QVAR
(budesonide), Seretide (fluticasone-salmeterol), Advair MDI (fluticasone-salmeterol) or Dulera
(mometasone-formoterol)
• Primary care received at 1 of 3 urban CHOP primary care practices (Karabots, South Philadelphia or
Cobbs Creek)
Interventions Daily text message reminders or control
Outcomes Feasibility; acceptability; adherence
Starting date December 2015
Contact information
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NCT02615743 (Continued)
Notes https://clinicaltrials.gov/ct2/show/NCT02615743
NCT02715219
Trial name or title Effectiveness of an AEP on Patient’s Knowledge, Medication Adherence and Inhaler Technique
Methods Single-blind, parallel-group randomised controlled trial
Participants • Confirmed diagnosis of bronchial asthma in the medical record
• Use of inhaler medication for past 1 year
Interventions Asthma Education Programme (AEP) or routine care
Outcomes Participant knowledge status regarding asthma; participant medication adherence status; participant inhaler
technique
Starting date June 2015
Contact information
Notes https://clinicaltrials.gov/ct2/show/NCT02715219
NCT02768623
Trial name or title Evaluation of a Community Pharmacist Managed Asthma Consultation Service
Methods Open-label, parallel-group randomised controlled trial
Participants • Provided written consent
• Intended to refill all asthma-related prescriptions at the study pharmacy
• Given a diagnosis of asthma by a physician or a nurse practitioner
• Taking inhaled corticosteroids for which dose and/or medication has remained unchanged for at least 2
months
• 18 years of age or older
• Having uncontrolled asthma (defined as in the past 4 weeks, patient has used rescue medication 4 or
more times in a given week and/or patient has woken up in the night because of asthma during a given week)
Interventions Comprehensive disease management programme for asthma or control
Outcomes Peak expiratory flow rate; medication adherence; asthma control
Starting date May 2016
Contact information
Notes https://clinicaltrials.gov/ct2/show/NCT02768623
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NCT02787174
Trial name or title A Computer-Based ED Intervention to Improve Pediatric Asthma Medicine Adherence (ED-AMAP)
Methods Single-blind, parallel-group randomised controlled trial
Participants • Asthma diagnosis by physician or parent report
• Age 2 to 12
• Inhaled corticosteroid asthma controller medicine prescribed
Interventions Interactive tailored asthma medication adherence education on an iPad or routine care
Outcomes Asthma controller medication adherence
Starting date February 2016
Contact information
Notes https://www.clinicaltrials.gov/ct2/show/NCT02787174
NTR5061
Trial name or title Development and Testing of an Adolescent Adherence Patient Tool for Asthma
Methods Open-label, parallel-group randomised controlled trial
Participants Adolescent patients using ICS registered at 1 of the pharmacies in the UPPER-network
• Age between 12 and 18 years
• Use of ICS: filling of ≥ 2 prescriptions for ICS or ICS/LABA combination during previous 12 months
• Diagnosis of (persistent) asthma (verified by GP)
• Access to a smartphone
Interventions Smartphone application for patients combined with a computer management system for healthcare providers
(pharmacists)
Outcomes Adherence
Starting date April 2015
Contact information
Notes http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5061
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Sulaiman 2016
Trial name or title Prospective Study of the Feedback From an Adherence Monitor on Asthma Control (INCA)
Methods Single-blind, parallel-group randomised controlled trial
Participants • Patients prescribed therapy equivalent to step 3 or higher on the Asthma Management Guidelines for
at least 3 months
• At least 1 exacerbation in the previous year with systemic glucocorticoids
• Uncontrolled/Partially controlled asthma by GINA guidelines
Interventions Feedback from a computer log of inhaler use or control
Outcomes Adherence rate
Starting date February 2012
Contact information
Notes https://clinicaltrials.gov/ct2/show/NCT01529697
ACT: Asthma Control Test; COPD: chronic obstructive pulmonary disease; ED: emergency department; FEV1: forced expiratory
volume in one second; GINA: Global Initiative for Asthma; GP: general practitioner; HFA: hydrofluoroalkane; ICS: inhaled
corticosteroids; INCA: Inhaler Compliance Assessment device; LABA: long-acting beta2-agonist; MDI: metered dose inhaler; SMS:
short message service/text message
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D A T A A N D A N A L Y S E S
Comparison 1. Adherence education versus controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 % Adherence (objective
measures)
5 280 Mean Difference (IV, Random, 95% CI) 20.13 [7.52, 32.74]
1.1 Complex 4 230 Mean Difference (IV, Random, 95% CI) 21.55 [4.71, 38.39]
1.2 Simple education 1 50 Mean Difference (IV, Random, 95% CI) 15.40 [5.98, 24.82]
2 % Adherence (all measures) 10 1693 Mean Difference (IV, Random, 95% CI) 11.59 [3.72, 19.46]
2.1 Complex 8 744 Mean Difference (IV, Random, 95% CI) 12.21 [1.26, 23.17]
2.2 Simple education 2 949 Mean Difference (IV, Random, 95% CI) 10.60 [5.17, 16.03]
3 > 85% adherence 1 271 Odds Ratio (M-H, Random, 95% CI) 2.68 [1.61, 4.46]
4 Exacerbations requiring OCS
(people with 1 or more)
3 349 Odds Ratio (M-H, Random, 95% CI) 1.82 [0.99, 3.36]
5 Asthma control 6 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 ACQ 4 455 Mean Difference (IV, Random, 95% CI) -0.03 [-0.49, 0.43]
5.2 ACT 3 333 Mean Difference (IV, Random, 95% CI) 0.30 [-0.82, 1.43]
6 Unsheduled visits to a healthcare
provider (people with 1 or
more)
4 688 Odds Ratio (M-H, Random, 95% CI) 0.48 [0.19, 1.19]
6.1 Hospital 1 250 Odds Ratio (M-H, Random, 95% CI) 1.23 [0.56, 2.70]
6.2 ED 2 367 Odds Ratio (M-H, Random, 95% CI) 0.23 [0.06, 0.83]
6.3 GP 1 71 Odds Ratio (M-H, Random, 95% CI) 0.20 [0.07, 0.54]
7 Quality of life (AQLQ) 6 734 Mean Difference (IV, Random, 95% CI) 0.01 [-0.20, 0.23]
Comparison 2. Electronic trackers or reminders (± feedback) versus controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 % Adherence (objective
measures)
6 555 Mean Difference (IV, Random, 95% CI) 19.86 [14.47, 25.26]
1.1 Reminders/trackers 3 321 Mean Difference (IV, Random, 95% CI) 16.29 [9.53, 23.04]
1.2 With feedback 3 234 Mean Difference (IV, Random, 95% CI) 24.98 [17.53, 32.44]
2 % Adherence (all measures) 8 762 Mean Difference (IV, Random, 95% CI) 18.41 [11.82, 25.00]
2.1 Reminders/trackers 4 361 Mean Difference (IV, Random, 95% CI) 16.92 [10.82, 23.02]
2.2 With feedback 4 401 Mean Difference (IV, Random, 95% CI) 20.06 [7.27, 32.85]
3 Exacerbations requiring OCS
(people with at least 1)
4 3063 Odds Ratio (M-H, Random, 95% CI) 0.72 [0.37, 1.39]
4 Asthma control 6 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 ACQ 2 109 Mean Difference (IV, Random, 95% CI) 0.24 [-0.29, 0.78]
4.2 ACT 4 596 Mean Difference (IV, Random, 95% CI) 0.74 [-0.20, 1.69]
5 Unscheduled visits to a
healthcare provider
3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
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5.1 ED 2 2918 Odds Ratio (M-H, Random, 95% CI) 1.14 [0.88, 1.47]
5.2 Hospital 2 2865 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.53, 1.78]
6 Unscheduled visits to a
healthcare provider
1 Rate Ratio (Random, 95% CI) Totals not selected
6.1 GP/ED visits 1 Rate Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Hospitalisations 1 Rate Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
7 Absenteeism 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
8 Absenteeism 1 Rate Ratio (Fixed, 95% CI) Subtotals only
9 Quality of life (AQLQ) 4 369 Mean Difference (IV, Random, 95% CI) -0.03 [-0.20, 0.13]
Comparison 3. Simplified versus usual regimens
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 % Adherence 3 1310 Mean Difference (IV, Random, 95% CI) 4.02 [1.88, 6.16]
2 Exacerbations requiring OCS 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
3 Asthma control (ACQ) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
4 Unscheduled visits 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
5 Absence from work/school 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
6 Quality of life (ITG-ASF %
change from baseline)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
7 All adverse events 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 4. School-based ICS therapy versus controls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Unscheduled visits (1 or more
hospitalisations for any cause)
2 279 Odds Ratio (M-H, Random, 95% CI) 0.58 [0.16, 2.05]
2 Quality of life (PAQLQ) 2 279 Mean Difference (IV, Random, 95% CI) 0.25 [0.01, 0.49]
Comparison 5. Subgroup analyses for % adherence
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Comparison 1. Children vs
adults
10 1693 Mean Difference (IV, Random, 95% CI) 11.59 [3.72, 19.46]
1.1 Children 4 1241 Mean Difference (IV, Random, 95% CI) 8.01 [-4.77, 20.79]
1.2 Adults/adolescents and
adults
6 452 Mean Difference (IV, Random, 95% CI) 14.43 [5.49, 23.36]
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2 Comparison 2. Complex vs
simple interventions
6 555 Mean Difference (IV, Random, 95% CI) 19.86 [14.47, 25.26]
2.1 Complex 3 234 Mean Difference (IV, Random, 95% CI) 24.98 [17.53, 32.44]
2.2 Simple 3 321 Mean Difference (IV, Random, 95% CI) 16.29 [9.53, 23.04]
3 Comparison 2. Children vs
adults
6 555 Mean Difference (IV, Random, 95% CI) 19.86 [14.47, 25.26]
3.1 Children 3 314 Mean Difference (IV, Random, 95% CI) 17.29 [8.32, 26.26]
3.2 Adults/adolescents and
adults
3 241 Mean Difference (IV, Random, 95% CI) 22.84 [16.66, 29.02]
A D D I T I O N A L T A B L E S
Table 1. Comparison 1 study characteristics: adherence education
Study ID
(”first
received“
date for
clinical tri-
als
registries)
Total n Duration
of interven-
tion/
follow-up
Age Country Interven-
tion
Control Adherence
measure
Outcomes
NCT00115323
(2005)
333 13/26 weeks Adults USA Problem-
solving
intervention
Asthma edu-
cation
Electronic
inhaler
monitor
Adherence,
AQLQ,
ACQ, LFTs,
hospitalisa-
tion,
ED
visits, partic-
ipant satis-
faction
Bender
2010
50 10 weeks Adults USA Interac-
tive voice re-
sponse inter-
vention
Usual care Electronic
in-
haler moni-
tor or canis-
ter weight
Adherence,
AQLQ,
ACT, Beliefs
about
Medica-
tion Ques-
tionnaire
NCT00958932
(2009)
1187 2 years Children USA Telephone
speech
recognition
intervention
Usual care To-
tal ICS sup-
plied/total
prescribed
Adherence,
beta-agonist
use, OCS
use, primary
care,
ED and out
of hours vis-
its, hospital-
isations, par-
ticipant sat-
isfaction
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Table 1. Comparison 1 study characteristics: adherence education (Continued)
Chatkin
2006
271 13 weeks Adolescents
and adults
Brazil Telephone
counselling
Ususal care ”Number of
inhalations
recorded on
the disks“
Adherence
NCT00149487
(2005)
141 17 weeks/1
year
Children USA Problem-
solving
intervention
Fam-
ily-based in-
tervention
Electronic
inhaler
monitor
Adher-
ence, symp-
toms, use of
healthcare
services, re-
liever medi-
cation use
NCT00166582
(2009)
55 2 months Children USA Team work
intervention
Asthma edu-
cation
Electronic
inhaler
monitor
Adherence,
Parent-Ado-
lescent Con-
flict
Question-
naire, Func-
tional Sever-
ity Index,
LFTs, Con-
sumer Satis-
faction Sur-
vey
Foster 2014 60 GPs, 143
patients
6 months Adolescents
and adults
Australia Person-
alised adher-
ence discus-
sion (PAD)
PAD
+ inhaler re-
minder
feedback
(IRF)
Usual care Electronic
inhaler
monitor
ACT,
AQLQ,
Hos-
pital Anxiety
and Depres-
sion
Scale, Med-
ication Ad-
herence Re-
port Scale,
LFTs, exac-
erbations
Gallefoss
1999
78 1 year Adults Norway Asthma edu-
cation
Usual care Prescribed
doses/dis-
pensed doses
Ad-
herence, GP
visits, absen-
teeism, days
in hospital
NCT01064869
(2010)
20 12 weeks/1
year
Not re-
ported, but
mean
age suggests
Northern
Ireland
Nurse-
led psychoe-
ducation
Ususal care
(diffi-
cult asthma
service)
Percent
of prescrip-
tions refilled
Adherence,
OCS, beta-
agonist use,
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Table 1. Comparison 1 study characteristics: adherence education (Continued)
adults hospital ad-
missions,
LFTs, ACQ,
AQLQ,
Hospital
Anxiety and
Despression
Scale
ADERE
PEDI-
ATRIC
1
(2008)
298 90 weeks Children Brazil Telephone
follow-up
intervention
Usual care Percent-
age of actual
doses/num-
ber expected
Adherence,
disease con-
trol, quality
of life (SF-
36)
Hart 2002 83 13 weeks Children UK Asthma edu-
cation
Usual care Electronic
inhaler
monitor
Adher-
ence, beliefs
and anx-
ieties about
adherence
NCT00516633
(2007)
60 26 weeks/78
weeks
Children Sweden Group dis-
cussion plus
basic educa-
tion
Basic educa-
tion
Diaries
and canister
weight
Adherence,
views on ad-
herence,
days hospi-
talised, ED
visits, exac-
erbations
Kamps 2008 15 6 weeks/52
weeks
Children USA Specific ad-
herence im-
prove-
ment strate-
gies (educa-
tion, moni-
toring, etc.)
Usual
care plus ed-
ucation
Electronic
inhaler
monitor
Adherence,
LFTs, Ped-
sQL, health-
care costs
NCT01132430
(2010)
54 6 weeks/52
weeks
Adults Canada Motiva-
tional inter-
viewing
Usual care Prescribed
treatment
days/num-
ber of days
Adherence,
asthma con-
trol, quality
of
life, asthma-
related self-
efficacy
Mehuys
2008
201 6 months Adults Belgium Adherence
education
Usual care Prescription
refill
rates, self-re-
porting
ACT, di-
ary card, res-
cue medica-
tion use, ED
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Table 1. Comparison 1 study characteristics: adherence education (Continued)
visits, hospi-
talisations,
AQLQ,
Knowledge
of Asthma
and Asthma
Medicine
Question-
naire,
inhalation
technique
NCT01169883
(2010)
68 10 weeks Adolescents USA Adherence
messaging
and group
sessions
”Attention
control“
Electronic
inhaler
monitor
Adherence,
asthma
knowledge,
ICS knowl-
edge,
ICS self-ef-
ficacy, social
support, ex-
acerbations
NCT02413528
(2015)
12 12 weeks Adolescents USA Adherence
monitoring
and incen-
tivisation via
app and sen-
sor
Usual care Electronic
inhaler
monitor
Adherence,
ACT
NB: study
terminated
Onyirimba
2003
30 10 weeks Adults USA Adherence
monitor-
ing and edu-
cation
Mon-
itoring with-
out feedback
Electronic
inhaler
monitor
Adherence,
rescue medi-
cation
use, AQLQ,
LFTs
NCT00233181
(2005)
250 78 weeks Children USA Adherence
education
Usual care Prescription
refill
rates, self-re-
porting
Adher-
ence, symp-
toms, night-
time awak-
enings, ED
visits, hospi-
tali-
sation, OCS
courses
Ulrik 2009 274 12 weeks Adults Denmark
and Switzer-
land
Ad-
herence ed-
ucation and
study medi-
Study medi-
cation alone
Dose count-
ing in
returned in-
vestigational
Adherence,
asthma con-
trol,
LFTs, symp-
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Table 1. Comparison 1 study characteristics: adherence education (Continued)
cation product toms, rescue
medication
use, night-
time awak-
enings, ad-
verse events,
AQLQ,
asthma
severity, ad-
verse events,
vital signs
NCT00414817
(2006)
14,064
(6903 previ-
ous ICS
users)
78 weeks Adults USA Telephone
interactive
voice recog-
nition inter-
vention
Usual care Pharmacy-
based adher-
ence
measures
Ad-
herence, use
of health-
care services,
economic
evaluation
ACQ: Asthma Control Questionnaire; ACT: Asthma Control Test; AQLQ: Asthma Quality of Life Questionnaire; ED: emergency
department; GP: general practitioner; ICS: inhaled corticosteroid; IRF: inhaler reminder feedback; LFTs: lung function tests; OCS:
oral corticosteroid; PAD: personalised adherence discussion; PedsQL: Paediatric Quality of Life Inventory; SF-36: Short-Form
Health Survey
Table 2. Comparison 2 study characteristics: electronic trackers or reminders
Study ID Total n Duration
of interven-
tion/
follow-up
Age Country Interven-
tion
Control Adherence
measure
Outcomes
Black 2008 40 2 months Children New
Zealand
Inhaler
alarm
Usual care Electronic
inhaler
monitor
Adherence,
AQLQ,
LFTs, beta-
agonist use
AC-
TRN12607000489493
(2007)
26 4 months Children Australia Adherence
feedback
during con-
sultations
Usual care Electronic
inhaler
monitor
Adher-
ence, symp-
toms, LFTs
Chan 2015 220 6 months Children New
Zealand
Audiovi-
sual inhaler
reminder
Usual care Electronic
inhaler
monitor
Adherence,
school/work
absences,
ACT,
Asthma
Mor-
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Table 2. Comparison 2 study characteristics: electronic trackers or reminders (Continued)
bidity Score,
exacer-
bations, un-
scheduled
visits, beta-
agonist use,
LFTs
Charles
2007
110 24 weeks Adolescents
and adults
New
Zealand
Audiovi-
sual inhaler
reminder
Usual care Electronic
inhaler
monitor
Adherence,
ACQ, LFTs
Foster 2014 60 GPs, 143
patients
6 months Adolescents
and adults
Australia Inhaler re-
minder and
feedback
(IRF)
Usual care Electronic
inhaler
monitor
ACT,
AQLQ,
Hos-
pital Anxiety
and Depres-
sion
Scale, Med-
ication Ad-
herence Re-
port Scale,
LFTs, exac-
erbations
NCT01714141
(2012)
49 13 weeks Young
adults
USA Computer
sessions and
tailored text
reminders
Asthma edu-
cation
Self-
reported
missed doses
Adherence,
ACT, LFTs,
participant
satisfaction
NCT02451709
(2015)
90 1 year Children UK Adher-
ence moni-
toring with
feedback
Adherence
monitoring
but no feed-
back
Electronic
inhaler
monitor
”Clinical
outcomes“,
adherence,
LFTs, exac-
erbations
NCT00233181
(2005)
250 78 weeks Children USA Adherence
monitor-
ing and edu-
cation
Adherence
education
Prescription
refill
rates, self-re-
porting
Adher-
ence, symp-
toms, night-
time awak-
enings, ED
visits, hospi-
tali-
sation, OCS
courses
Strandby-
gaard
2010
26 12 weeks Adults Denmark SMS (text
message) ad-
herence re-
minders
Usual care ”Dose-
count“ on
the Seretide
was diskus
Adher-
ence, change
in FeNO,
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Table 2. Comparison 2 study characteristics: electronic trackers or reminders (Continued)
LFTs, air-
way respon-
siveness
Vasbinder
2015
E-MATIC
219 52 weeks Children The Nether-
lands
SMS (text
message) ad-
herence re-
minders
Usual care Electronic
inhaler
monitor
Adher-
ence, ACT,
exacerba-
tions, use of
health-
care services,
AQLQ,
school/work
absence, ac-
ceptance of
e-mon-
itoring, eco-
nomic eval-
uation
NCT00459368
(2007)
2698 (34
clusters)
52 weeks Children
and adults
USA Adher-
ence educa-
tionwith ad-
herence
feedback
Ad-
herence edu-
cation alone
Electronic
prescrib-
ing data/re-
fill rate
Ad-
herence, ED
visits, hospi-
talisation,
OCS use
ACQ: Asthma Control Questionnaire; ACT: Asthma Control Test; AQLQ: Asthma Quality of Life Questionnaire; ED: emergency
department; FeNO: fractional exhaled nitric oxide; ICS: inhaled corticosteroid; LFTs: lung function tests; OCS: oral corticosteroid
Table 3. Comparison 3 study characteristics: simplified regimens
Study ID Total n Du-
ration of in-
tervention/
follow-up
Age Country Interven-
tion
Control Adherence
measure
Outcomes
Bosley 1994 102 12 weeks Adults UK Combined
inhaler
Separate in-
halers
Electronic
inhaler mon-
itor
Adherence,
LFTs
Mann 1992 16 6 weeks/12
weeks
Adults USA Twice-daily
dosing
Four-times-
daily dosing
Electronic
inhaler mon-
itor
Adherence,
LFTs, symp-
toms
AC-
TRN12606000508572
(2007)
111 24 weeks Children NewZealand Combined
inhaler
Separate in-
halers
Electronic
inhaler mon-
itor
Adher-
ence, LFTs,
ACQ, OCS,
unscheduled
visits
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Table 3. Comparison 3 study characteristics: simplified regimens (Continued)
Price 2010 1233 12 weeks Adolescents
and adults
UK Once-daily
ICS
Twice-daily
ICS
”De-
vice counter
number“
Adherence,
physician as-
sess-
ment of re-
sponse, qual-
ity of life, use
of healthcare
services, days
of school/
work missed,
adverse
events, wors-
ening asthma
ACQ: Asthma Control Questionnaire; ICS: inhaled corticosteroid; LFTs: lung function tests; OCS: oral corticosteroid
Table 4. Comparison 4 study characteristics: school-based ICS therapy
Study ID Total n Du-
ration of in-
tervention/
follow-up
Age Country Intervention Control Adherence mea-
sure
Outcomes
Gerald 2009 290 65 weeks Children USA Supervised
ICS therapy at
school
Usual care N/A Episodes of poor
asthma control,
school absences,
rescue medica-
tion use at school
Halterman
2004
184 9 weeks Children USA Supervised
ICS therapy at
school
Usual care N/A Symptom-
free days, day-
time and night-
time symptoms,
rescue medica-
tion use, school
absences
NCT01175434
(2010)
100 6 to 8
months
Children USA Supervised
ICS therapy at
school
Usual care N/A Feasi-
bility, symptom-
free days,
numbers of days
and nights with
symptoms, activ-
ity limita-
tion, rescuemed-
ication
139Interventions to improve adherence to inhaled steroids for asthma (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 4. Comparison 4 study characteristics: school-based ICS therapy (Continued)
use, school ab-
senteeism, par-
ent sleep inter-
ruption, change
in family plans
due to the child’s
asthma,
PAQLQ, utilisa-
tion of healthcare
services, FeNO
FeNO: fractional exhaled nitric oxide; ICS: inhaled corticosteroid; PAQLQ: Pediatric Asthma Quality of Life Questionnaire
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We did not use Covidence to extract data from the included studies because we found the process too time consuming, and we were
unable to capture different types of data using the software. Instead, we used an Excel template commonly used by the Cochrane
Airways Group to capture study characteristics, outcome data and risk of bias information.
In the protocol, we listed various factors that may alter the treatment effect; we intended to present these factors in an additional table.
We anticipated that the factors listed (type, delivery, dose and schedule of ICS; whether treatment was given in a combination inhaler
with a long-acting beta-agonist (LABA), baseline severity of asthma) would document differences between studies, but in practice,
studies generally were not designed to assess adherence to a particular type of ICS, dose or regimen, with or without a LABA, so we did
not design the table in this way. We have described these factors in the description of studies, and we have presented important clinical
and intervention characteristics in Tables 1 to 3.
We had to define post hoc as what constituted an ’objective’ measure of adherence. Studies used a variety of measures including
self-report scales, pharmacy refill data, canister weight and electronic monitors. We decided that only electronic monitors could be
considered truly objective. In a post hoc change to our analysis plan, we presented studies using objective measures (i.e. electronic
inhaler monitors) as the primary analysis for % adherence, as we deemed this a more useful analysis. An analysis including studies that
used all measures then follows.
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